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CHAPTER I 
GENERAL INTRODUCTION 

1. Anatomy of the prostatic gland 
The normal prostate surrounds the proximal part of the 
human male urethra, and is traversed by the ejaculatory ducts, 
which open into the prostatic urethra. These structures 
divide the gland into localised areas, known as the prostatic 
lobes-anterior, middle, posterior and two lateral. These 
lobes, however, are purely anatomical and have no functional 
implications. 
Functionally, the prostate is divided into inner and outer 
gland groups. The inner gland group is made up of short 
periurethral glands and somewhat larger submucosal glands. 
The main ducts of the submucosal glands are lined by 
transitional epithelium. The inner group is separated from 
the main mass of the prostatic glands -the outer prostate- by 
an indefinite fibrous capsule. 
Excretory duct and tubule-alveolar glands (exocrine acini) 
arranged within lobuli form the functional entity of the 
prostatic gland. Acini of inner and outer glands are 
microscopically indistinguishable and are both lined by a 
double layer of epithelium: the inner cylindric cell-layer 
(with secretory activity) and the outer basal or myoepithelial 
cell-layer. 
The inner glands are relatively inconspicuous in the young 
but become increasingly prominent with age (see I-3.4). 
Benign Prostatic Hyperplasia (BPH) develops from this inner 
gland group. A series of changes also occurs in the outer 
group of glands with age: atrophy of epithelium and stroma has 
been described in addition to hyperplasia and neoplasia 
(Franks et al., 1956). 
2. Epidemiology of prostatic cancer 
In those Western countries with a high socio-economic 
standard prostatic cancer (PC) is the second most common 
cancer, after lung cancer, occurring in males (Catalona, 
1984). The incidence rate (the nuniller of new cases per 
100,000 males per year) within the United States between the 
years 1973 and 1977 was approximately 40. The incidence rate 
of clinically manifest PC in males above the age of 85 is even 
higher. Thus, PC is a disease more often found in the elderly 
male population. On the other hand in a representative group 
of males aged 47, the incidence rate counted was 0.001 (Cohen 
et al., 1985). Incidence- and mortality figures increase 
nearly logarithmically with age. Below the age of 40 PC is a 
rare tumor. However, PC is sporadically reported in male 
adolescents (Shimada et al., 1980). It is generally belie-
ved, that when prostatic carcinomas found on careful histolo-
gical examination at autopsy are included, PC would be the 
most prevalent cancer in men. 
In the Netherlands its incidence is still increasing and 
in 1982 the incidence rate was assessed at 25.1 (average 
annual age-standardized incidence rate per 100,000 population 
for PC; Zaridze et al., 1984). The increase in incidence is 
predominantly the result of a more frequent use of surgical 
7 
procedures in the treatment of BPH. Furthermore, complete 
submission of the entire specimen for histological examination 
has resulted into an increase of detection of stage A disease 
(see I-6) (Beckner et al., 1985; Dhom et al., 1983). 
As is known for a long period, incidence-figures of PC 
show a remarkable variation of geographic distribution. The 
lowest incidence figures are found among the male population 
in Shanghai (0.84), whereas the highest incidence was recorded 
for the black population in Alameda County, California (1982: 
100.2; Zaridze et al., 1984; 1987) and in Denver, Colorado 
(1977: 115.5; Beckner et al., 1985). 
A similar geographic distribution was noted for the 
mortality with reference to PC. The age standardized 
mortality rate (recorded in 1978) ranged from 0.1 to 29.1 per 
100,000 male population (0.1 for Thailand; 29.1 for St. 
Vincent and Grenadines; Zaridze et al., 1984; 1987). Northern 
European and North American countries have high rates, Israel 
and Latin and South America, and southern European countries 
have intermediate rates, and Oriental and eastern European 
countries have low rates. The mortality figure in Japan 
(1978) was assessed at 2.5; the mortality figure in the 
Netherlands was 15.5 (Zaridze et al., 1987). Interesting in 
this regard is the observation that the prevalence of BPH 
appears also low amongst Japanese compared with Caucasians 
(Wynder et al., 1971). In contrast with these overall figures 
regarding incidence and mortality, the incidence rate of stage 
Al lesions (see I-6) does not show a geographic distribution, 
but is nearly equal within each country. 
The difference between incidence- and mortality figures 
indicates the variation in biological behavior and success of 
intervening therapeutic regimens. Fortunately, only a 
fraction of patients suffering from PC will ultimately die 
from the sequels of this malignancy. However, increased life 
expectation and the introduction of sensitive diagnostic 
techniques have led to a relative growth of registrated 
mortality rate for PC within the last few years. 
3. Etiology of prostatic cancer 
Several different factors are assumed to play a role in 
the etiology of PC: 
- genetic predisposition 
- exposure to chemical carcinogens or chemical promoters of 
carcinogenesis 
- endogenous hormonal influences 
- venereal transmission of an infectious agent 
3.1. Genetic factors in the oncogenesis of prostatic cancer 
Evidence for genetic factors comes from several studies 
suggesting a high incidence of PC among relatives of PC 
patients (Schuman et al., 1977). In spite of this observation, 
a relationship between a specific HLA type and PC has not been 
reported as yet. 
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on the other hand difference in incidence rate among 
whites and non-whites in the United States provides evidence 
for some genetic factor in the ontogenesis of PC. 
3.2 Environmental (socio-cultural) factors 
The potential role of environmental factors in the 
etiology of PC is underlined by the observation that Japanese 
males migrating to Hawaii initially maintain a low mortality 
from PC for about one generation but finally account for a 
mortality closer to that of the American population 
(Winkelstein et al., 1979). A similar phenomenon for Asian 
immigrants in the United states was described by Ross et al. 
(1983). Furthermore, the importance of environmental factors 
is emphasized by the observation that Nigerian blacksshow a 
much lower incidence of clinically manifest cancer than 
Nigerian blacks living in the United States. 
Since a higher number of stage A2 lesions was detected in 
Japanese immigrants in Hawaii compared with Japanese in Japan 
(Akazaki et al., 1973), it is postulated that environmental 
factors may promote biological alterations within initially 
harmless stage A1 lesions resulting in an increase of tumor 
size or leading to a more aggressive variant (see I-6). 
Among these environmental factors exhaust fumes or 
particular air-pollution can be considered (Rotkin, 1977). 
Also exposure or ingestion of cadmium and other heavy metal 
contacts have been introduced as potential promoters in 
carcinogenesis. Cadmium, a non-essential trace element, acts 
as a zinc antagonist in biological systems. Zinc is an essent-
ial trace element which is involved in the regulation of cell 
growth and its presence in large quantities is demonstrated in 
the prostatic gland (Ross et al., 1983). Compared with non-
carcinomatous prostatic tissue the zinc concentration in PC 
seems to be lowered (Muentzing et al., 1974; Feustel et al., 
1984). 
Moreover, ingestion of a high fat diet may be associated 
with an increased risk for PC (Hill et al., 1981; Graham et 
al., 1983; Talamini et al., 1986). This is reflected in the 
strong positive correlation between body mass index and 
subsequent risk of developing PC. Changes in diet have been 
shown to affect endocrine function as measured by changes in 
androgen, estrogen and prolactin serum levels. Excess of body 
fat may influence the availability of steroid hormones (Wynder 
et al., 1971). Furthermore vitamin A is claimed to protect 
against PC (Osegbe et al., 1988; Hayes et al., 1988) and low 
daily intake of fi-carotene and of vitamin A seems to correlate 
significantly with the subsequent development of PC (Oishi et 
al., 1988; Ohno et al., 1988). 
Some reports deal with a potential sexually transmissible 
infectious etiology of PC similarly to the etiology of cervix 
uteri cancer in which it has been postulated that human 
papilloma virus (HPV 16/18) may play an etiologic role 
(Centifanto et al., 1973; Herbert et al., 1976; Jones et al., 
1976; Baker et al., 1981; Campbell et al., 1985). 
In addition there are numerous studies speculating about a 
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relationship to sexual practice (Mishina et al., 1985). 
summarizing, these studies link sexual hyperactivity and 
promiscuity with an increased risk for PC (Catalona, 1984). 
On the other hand Ross et al. (1981) reported that Catholic 
priests had a similar and, in fact, slightly higher incidence 
of PC than controls. 
3.3. Endogenous hormonal factors 
The growth rate of the majority of PC is, at least in the 
initial phase, dependent on androgens. This may be explained 
by the functional presence of steroid receptors for androgens 
within prostatic tissue, especially within the nucleus of 
prostatic (epithelial) cells. Basic investigations of androgen 
action in prostatic tissue indicate the involvement of 
testosterone (T) uptake, conversion to dihydrotestosterone 
(DHT) by the enzyme 5a-reductase and transport of DHT to a 
nuclear localized androgen-binding receptor (AR; see also 
I-9.4) (Kliman et al., 1978). Since interstitial (Leydig) 
cells of the testis are the major source of T, castration 
(surgical or chemical) will benefit the clinical course of 
androgen-dependent PC. The interstitial cells are controlled 
by the interstitial cell stimulating- or luteinizing hormone 
(ICSH = LH) from the anterior pituitary, which in turn is 
influenced by gonadotrophin releasing hormones (LH-RH) from 
the hypothalamus. The pituitary gland also influences the 
prostatic gland by secreting prolactin which stimulates the 
metabolism of the prostate. Androgens are also produced by 
the adrenal cortex. The mechanisms involved have been 
thoroughly investigated in animal studies (Steenbrugge, van 
1988a). 
Further evidence of a potential etiologic role of the 
~ndocrine status of the host is provided by the observation 
that fertile human males have an increased risk of developing 
PC (Armenian et al., 1975). However, this is contradicted by 
other investigators (Wynder et al., 1971). In addition, PC in 
eunuchs is reported. Different alterations in levels of 
estrogens, adrenal steroids and androgens in urine and serum 
samples associated with prostatic malignancies have been 
reported (Hoisaeter et al., 1982; Levell et al., 1985; Nomura 
et al., 1988). This is partly attributed to the fact that T 
serum levels are age dependent. Moreover, the finding that 
the largest fraction of serum-T is bound to a carrier protein 
(sex hormone binding globulin = SHBG) might influence the 
accuracy of the data. 
Contrary, experimental studies have demonstrated that 
long-term administration of T combined with estrogens resulted 
in the development of PC in Noble rats (Noble et al., 1977). 
Subcutaneous administration of T alone also produced prostatic 
adenocarcinomas in rats. T-induced synchronization of prost-
atic cells in a state of proliferation enhanced the carci-
nogenic effect of N-methyl-N-nitrosourea (Bosland, 1989). 
Further evidence that changes in the endocrine status of 
the human host may be of influence on PC is provided by the 
finding that a lower prevalence of PC at autopsy was detected 
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amongst men suffering hepatic cirrhosis. Liver cirrhosis is 
associated with hormonal changes such as hyperestrogenism and 
alterations in the melanocyte stimulating hormone levels 
resulting in hyperpigmentation of the skin (Flanders, 1984). 
3.4. Interrelationship of BPH with prostatic cancer 
BPH has to be considered as a physiological process 
starting in the third decade of life and manifesting itself 
with complaints of prostatism in the male population at the 
age of 60. First pathological evidence of the disease appears 
in men between 40 and 50 years old (Berry et al., 1984). In 
the seventh decade the prevalence of BPH has increased to more 
than 70 per cent. 
BPH results in an increase of the weight of the prostatic 
gland as a consequence of a relatively increased growth rate 
of the stromal and epithelial tissue. In the third decade of 
life the increase in weight is 1.6 g per year. In the subse-
quent decades a decline in growth rate is reported, leading to 
an increase of weight of only 0.4 g per year in the tenth 
decade (Berry et al., 1984). 
It is generally accepted that prostatic hyperplasia occurs 
initially in the periurethral portion of the middle and 
lateral lobes and consists of fibromuscular hyperplasia with 
subsequent involvement of the stroma by proliferating glands 
(Mostofi et al., 1973). The nodular fibromyoadenomatous 
variant of BPH is most frequently encountered. The precise 
role of DHT in the pathogenesis of BPH has to be elucidated. 
Controversial reports are available concerning a possible 
relationship between the adenomatous (or glandular) variant of 
BPH and PC. Those authors who consider a possible causal link 
often do not realise that the frequently occurring coexistence 
of BPH with carcinoma does not exceed the incidence of BPH in 
an age-matched control group without PC (Catalona, 1984; 
Wynder et al., 1971). 
According to Kastendieck (1980) PC may be preceded by the 
genesis of an area of disturbed architecture within a hyper-
plastic nodus (atypical prostatic hyperplasia; see I-4.1). On 
the other hand, the adenomatous variant of BPH is most 
frequently encountered in the periurethral prostatic region, 
whereas the majority of carcinomas originate in the peripheral 
(posterior) areas of the prostatic gland. 
The description of rare types of hyperplasia (such as 
cribriform hyperplasia and basal cell hyperplasia = trans-
itional cell metaplasia) and their possible relationship with 
PC is beyond the scope of this survey (see Dhom, 1985). 
4. Histomorphology of prostatic cancer 
Over 95% of prostate malignancies are adenocarcinomas (Utz 
et al., 1969; Flanders, 1984) and originate from the 
epithelial structures of the tubule-alveolar prostatic glands. 
The morphologic diagnosis of carcinoma of the prostate is 
primarily based on the following criteria: cellular atypia 
(i.e. nuclear anaplasia, mitotic activity, and prominent 
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nucleoli), disorderly arrangement of glands and invasive 
growth (including perineural extension) (Kastendieck, 1980). 
Normal and hyperplastic glands are characterized by an 
epithelial lining consisting of two cell layers, whereas tumor 
glands are recognized by a simple often cuboid (or prismatic) 
epithelial lining of one layer lacking the outer myoepithelial 
cells. The inner surface of the malignant acinus is smooth 
and lacks the normal papillary projections. Since tumor 
glands are often densely packed, presumably caused by 
increased tortuosity of tubule-alveolar units, interacinar 
stroma is found scarcely in tumor areas (dos a dos arrangement 
of tumor glands without interposition of stromal elements). 
Nuclei of epithelial tumor cells are enlarged (resulting into 
an increased nucleus-cytoplasm ratio) and appear to have 
prominent nucleoli. In general, mitotic figures are quite 
often not found in PC (see I-11). Nuclear anaplasia 
(variations from normal in size, shape, staining and chromatin 
distribution of tumor cell nuclei, sometimes variation in size 
and number of nucleoli are also included) varies widely and 
seems of potential prognostic value (see I-5.1). 
For as yet it is believed that prostatic carcinomas (even 
stage A lesions; see I-6) have a multicentric origin (Parfitt 
et al., 1983ab). 
4.1. Potential precancerous lesions within the prostate 
Atypical, irregular epithelial proliferations in the 
prostate in conjunction with primarily benign lesions have 
been reported. The recognition of these lesions has been 
associated with the potential development of PC. However, the 
true existence of premalignant morphologic lesions that can 
easily be detected by pathologists is still a matter of 
controversy. Moreover, the nomenclature of these lesions is 
characterized by a total lack of uniformity among the 
different authors. In general, potential premalignant lesions 
in the prostatic gland have to be subdivided into lesions 
predominantly related with architectural and often with 
proliferative changes (dysplasia) and into those lesions with 
exclusive cytologic abnormalities (Kastendieck, 1980). The 
former lesions are often associated with BPH, whereas the 
latter are more frequently encountered in non-hyperplastic 
glands. However a simple dichotomy is not often possible 
since architectural disorders are nevertheless frequently 
associated with cellular atypia. 
Lesions with predominant architectural abnormalities are 
characterized by an increase of small glands with a reduction 
of the amount of interacinar stroma. The boundaries of these 
proliferative foci with the surrounding tissue are usually 
well defined lacking obvious morphologic parameters of 
invasive growth. Moreover the majority of these glands are 
lined by a double layer of regularly arranged epithelium 
without any cytonuclear atypia. However, exceptions associated 
with nuclear anaplasia have been described. The lesions with 
predominant architectural disturbances are designated as 
adenosis (Brawn, 1982b) or described as atypical prostatic 
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hyperplasia (Kovi et al., 1988). Unlike the simple 
hyperplasia, a clearly raised 3H-thymidine index of these 
lesions is described (Helpap, 1980). 
It can be very difficult to distinguish these potential 
precancerous dysplastic lesions from malignant tumors since 
the judgement of invasive growth within the prostatic gland is 
not always easy. In addition lack of precise definition 
hampers its general acceptance and recognition by patholo-
gists. Mainly these lesions occur in combination with BPH; 
less often they are encountered in glands with signs of 
inflammation. For as yet the identification of such dysplastic 
lesions does not allow any conclusions referring its 
prospective potential. Interesting is the observation that 
the age-adjusted rate of dysplasia precedes that of latent 
(see I-6) PC. out of the various forms of prostatic dysplasia 
the primary atypical hyperplasia shows the highest frequency 
in coincidence with manifest PC. 
Apart from atypical proliferative lesions associated with 
BPH, potential pre-neoplastic lesions have also been 
recognized in non-hyperplastic prostatic ducts and acini 
(McNeal et al., 1986ab; McNeal, 1988b). The latter lesions 
are characterized by cytologic changes, whereas the 
architecture is normal or minimally distorted. These cyto-
nuclear atypia includes nuclear enlargement (anisokaryosis), 
small prominent nucleoli, nuclear hyperchromasia, cell 
crowding with variable pseudostratification, and increased 
density of cytoplasmic staining. 
4.2. Histologic typing of prostatic carcinoma 
Unfortunately, an uniform and commonly endorsed 
histological classification of PC does not exist although the 
variety of divergent structural patterns of the common PC is 
rather limited (Melicow et al., 1976). The reason for this 
might be found in the variability of the histological proli-
feration patterns in a single case as is also demonstrated in 
this thesis (see Chapters II, V and VII). PC often shows a 
pluriform picture with simultaneous occurrence of several 
different growth patterns. Another reason might be the 
existence of differing concepts about the histogenesis with 
respect to the glandular system of the prostate. The Armed 
Forces Institute of Pathology (AFIP) proposed a classification 
into a few principal groups. In addition to adenocarcinomas 
that account for approximately 97 per cent of all malignant 
prostatic neoplasms (Utz et al., 1969), the AFIP distinguishes 
undifferentiated carcinomas, endometrioid carcinomas (of the 
prostatic utricle = periurethral gland carcinoma = papillary 
adenocarcinoma of the urethra, verumontanum; Bostwick et al., 
1985; Walther et al., 1985; Epstein et al., 1986a), adenoid 
cystic carcinomas, transitional cell carcinomas (Nicolaisen et 
al., 1984), and squamous cell carcinomas (Mostofi, 1973). 
Furthermore, the existence of small cell carcinoma (sometimes 
combined with a "regular" prostatic adenocarcinoma; Wenk et 
al., 1977; Schron et al., 1984; Ro et al., 1987), true 
papillary adenocarcinoma (Kuhajda et al., 1984) and carcinoid 
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Table 1. Examples of histologic 
designed for PC. 
classification schemes 
Mostofi and Price (1973) 
usual prostatic carcinoma: 
glandular pattern 
(micro acinar, small, normal, 
large, mixed). 
papillary pattern 
adenocystic pattern 
cribriform pattern 
solid medullary pattern 
rare types of prostatic car-
cinoma: 
endometrioid carcinoma 
transitional cell carcinoma 
squamous cell carcinoma 
adenoid-cystic carcinoma 
Dhom (1977) 
carcinoma with uniform pattern: 
highly differentiated adenocar-
cinoma 
poorly differentiated adenocar-
cinoma 
cribriform carcinoma 
anaplastic carcinoma 
urothelial carcinoma 
squamous cell carcinoma 
mucinous carcinoma 
carcinoma with pluriform pat-
tern: 
highly and poorly different-
iated adenocarcinoma 
cribriform and anaplastic 
carcinoma 
cribriform pattern in other 
types 
(Wasserstein et al., 1979) have been reported. Moreover, 
mucinous carcinomas and even signet ring cell carcinomas of 
the prostate have been described (Remmele et al., 1988; Ro et 
al., 1988). Some classification schemes proposed by different 
authors are summarized in Table 1. Finally, sarcomas can 
develop within the prostatic gland. Relatively frequently 
occurring sarcomas in the prostate are: rhabdomyosarcoma (most 
commonly found in children), leiomyosarcoma and fibrosarcoma. 
One also has to realise the possibility of presence of 
metastases of an elsewhere localized primary tumor or the 
development of a carcinoma originating in the seminal vesicle. 
Also extension of bladder tumors and rectum cancers within the 
prostatic gland is regularly encountered. 
In this thesis we distinguish well, moderately and poorly 
differentiated adenocarcinomas in addition to cribriform 
cancers, clear cell carcinomas (also known as the 
hypernephroid variant of PC), and undifferentiated carcinomas. 
Among the undifferentiated carcinomas we distinguish tumors 
composed of compact well-circumscribed areas of tumor cells 
(the so-called solid tumor areas or medullary cancers) and 
malignancies characterized by solitary cancer cells diffusely 
infiltrating the surrounding fibrous stroma (truely undiffer-
entiated cancers). Many studies demonstrated that cribriform 
and solid patterns possess a higher malignant potential than 
purely glandular carcinomas. Some investigators support the 
idea that centrifugal extra acinous growth results in a 
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glandular pattern of PC, whereas a centripetal, intraglandular 
proliferation of tumor cells leads to a cribriform or 
medullary pattern. 
4.3. Spread of prostatic carcinoma 
4.3.1.Intra-prostatic spread 
PC is considered to develop multifocally within the 
prostatic gland (Hayashi et al., 1987). For as yet it remains 
to be elucidated whether intra-prostatic metastases do occur 
in the natural course of PC. Lack of lymphatic vessels, and 
tissue clefts within the prostatic gland combined with the 
absence of intra-glandular extension makes a possible intra-
organic spread less acceptable. However, recently the 
occurrence of ductal spread in nearly 50% of cases of PC was 
described by Kovi et al. (1988). Often tumor foci originate 
in peripheral parts of the gland. The areas of predilection 
are the dorsal and dorsolateral parts next to the capsule. 
Fortunately, at the dorsal aspect capsular invasion occurs 
relatively late as the fascia of Denonvillier seems to be 
an efficient barrier to tumor extension (Kastendieck, 1980). 
Additional tumor foci can sometimes be found in the ventral, 
pre-urethral region. Especially the stage A lesions (see I-6) 
seem to originate in the anterior portion of the prostatic 
gland (McNeal et al., 1988a). The stromal invasion results 
from destruction of the normal stromal-epithelial barrier. 
Invasive growth results from the splitting up of fibromuscular 
bundles. 
The extension within the prostate first of all takes place 
into the outer area and intermediate part. The inner peri-
urethral portion and the prostatic urethra itself will be 
infiltrated by tumor at the end of intraprostatic extensive 
spread. 
Capsular involvement can be divided in: extension to the 
capsule; invasion without penetration of the capsule and 
penetration of the capsule by tumor. Extension in the peri-
prostatic area may result into spread of tumor in the 
perineural clefts and angie-invasive growth. For as yet the 
perineural localization merely proves the spread into 
interstitial spaces and its precise predictive meaning for 
potentially wide spread (metastasized) disease is questioned 
(Kastendieck, 1980; Dhom, 1985). 
According to Schroeder et al. (1975) invasion around the 
seminal vesicle did not influence survival or cancer death 
rates, when compared to histological stage c lesions (see 
I-6). However the latter is contradicted by other 
investigators (Myers et al., 1983). Progression of the 
disease after seminal vesicle involvement will lead to 
fixation of the prostatic gland to adjacent structures. A so-
called frozen pelvis develops when the whole pelvis is filled 
with tumor. 
Invasion of the rectum per continuitatem with mucosal 
ulceration is rare. 
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4.3.2.Extra-prostatic spread 
PC may disseminate to regional lymph nodes. Regional 
lymph node centres encompass the common iliac, external iliac, 
hypogastric and obturator-fossa nodes. Furthermore the peri-
aortic and sacral lymph nodes are also often involved. 
Invasion of the lymph nodes localized in the groin, supracla-
vicular region and hilar (tracheobronchial nodes) sites are 
usually very late events (Prout et al., 1973). Nodal metasta-
ses develop before skeletal metastases (Saltzstein et al., 
1977). 
Bone metastases most frequently develop within the 
vertebral column (especially the lumbo sacral spine) by means 
of extension within the venous vertebral plexus (Batson) and 
can be visualized by simple roentgenograms or by more 
sensitive techniques such as bone scanning after admini-
stration of a radio nuclide (Tc), CT- and NMR scan. Other 
frequent sites of bone metastases are the pelvis, the ribs and 
the upper parts of the femur (Mostofi et al., 1973). 
Metastatic lesions within the skeleton often induce bone 
formation resulting into the characteristic osteoplastic 
lesions associated with metastases of PC. 
Visceral metastases are most frequently the result of 
hematogenous spread. The most common sites of visceral 
metastases are the lungs, liver, pleura, adrenals and kidneys, 
brain and spleen but almost every organ or structure may 
display involvement (Mostofi et al., 1973; Brawn et al., 
1989). 
As mentioned before, widespread disease is not the result 
of tumor extension by perineural invasion in the prostatic 
gland. Moreover, the tumor extension within the prostatic 
gland is unrelated to the capability of the tumor to 
metastasize. 
Diagnostic punch biopsies seem not to accelerate the local 
and regional growth of PC (Kastendieck, 1980). On the other 
hand transurethral resection (TUR) must be avoided when PC is 
presumed. The influence of TUR upon the spread of PC was 
investigated by Hanks et al. in 1983. Their conclusion was 
that TUR disseminates cancer in patients with T3 and T4 
lesions (see I-6) and has to be limited to relief of severe 
urinary obstruction within a palliative therapeutic regimen. 
However, one has to realise that shrinkage or reduction of the 
prostatic gland with relief of obstruction can also be 
achieved by immediate administration of estrogens or by 
radiotherapy. Moreover suprapubic urinary drainage can also 
be considered. 
Histologically, the morphology of metastases agrees more 
often with the major component than with the worst 
differentiated areas of the primary tumor (Grayhack et al., 
1983). However metastases of PC entirely composed of single 
malignant glands are rarely encountered. Therefore it is 
assumed that primary well-differentiated prostatic adenocarci-
nomas possess a lower metastatic capacity compared with less 
or undifferentiated primary tumors (Brawn et al., 1987). 
Since a differentiation arrest can occur within time, it is 
not permitted to consider primary tumors composed solely of 
16 
malignant single glands as totally harmless. Recently, it was 
also proven that arrest of differentiation may occur with time 
within the secondary tumor deposits (Brawn et al., 1989). 
5. Grading in prostatic cancer: general comments 
Efforts aimed at discrimination and determination of 
parameters with potential prognostic value extracted from 
cancerous tissue have resulted into the development of diverse 
grading systems. Using this wide definition biochemical, 
biological, immunological, morphologic (including morphometry, 
electron-microscopy, and immunohistochemistry) and tumor cell 
kinetic (DNA flow cytometry, DNA precursor uptake techniques, 
etc) data can be arranged in prognostic classes and regarded 
as grading systems. 
Among all diverse grading techniques, histological grading 
is most intensively investigated in tumor pathology and 
applied by pathologists. Histological grading is based on the 
assumption that the degree of malignancy can be determined by 
the histological appearance (often including cytologic 
characteristics) of the original tumor. Broders reported in 
1926 that the amount (percentage) of differentiation (i.e. 
keratinization) within squamous cell carcinomas of the lip was 
of utmost importance in the assessment of prognosis in the 
individual case. In the subsequent decades many grading 
systems have been introduced for cancers of diverse origin. 
In general, histological grading is predominantly based on 
considering the architecture and (or) cellular morphologic 
characteristics (including the presence and number of mitotic 
figures) . 
5.1. Histological grading systems in prostatic cancer 
For PC numerous grading systems have been designed. The 
number of scores in each grad~ng system varies from three 
(most grading systems) to 9 (grading system developed by 
Gleason). Though statistical analysis is often poor, all 
promise an optimal correlation of increasing grading score 
with progressive worse clinical outcome. A short 
(chronological) review of the most important grading systems 
for PC will be presented here (see also Chapter II and III). 
Histological grading systems that can be applied for all kinds 
of tumors including PC will not be discussed in this section 
(e.g. Broders system; 1926). 
Contrary to all other grading systems designed for PC, 
Gleason (1966) has devised a grading method to solve the 
problem of histomorphologic heterogeneity within a single 
tumor. He observed that a majority of prostatic carcinomas 
had either a single pattern or at the most, two patterns of 
differentiation: a predominant pattern and a secondary 
pattern. Considering only tumor architecture within prostatic 
cancers, 5 different growth patterns could be distinguished 
with pattern 1 being the least malignant and pattern 5 the 
most malignant. 
Pattern 1: Very well differentiated, small, closely 
packed, uniform glands in essentially circumscribed masses. 
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Pattern 2: Similar but with moderate variation in size and 
shape of glands and more atypia in the individual cells: 
cribriform pattern might be present; still essentially circum-
scribed, but more loosely arranged. 
Pattern 3: Similar to Pattern 2 but marked irregularity in 
size and shape of glands, with tiny glands or individual cells 
invading stroma away from circumscribed masses, or solid cords 
and masses with easily identifiable glandular differentiation 
within most of them. 
Pattern 4: Large clear cells growing in 
resembling hypernefroma; may also show gland 
Pattern 5: Very poorly differentiated 
solid masses or diffuse growth with 
differentiation into glands (Gleason, 1966; 
1967}. 
a diffuse pattern 
formation. 
tumors; usually 
little or no 
Mellinger et al., 
The Gleason score (ranging from 2 to 10) is determined by 
adding up the numerical values of the primary and secondary 
growth pattern. In those tumors in which only one growth 
pattern is present the numerical value of this single pattern 
is doubled to achieve the Gleason score. In the United States 
the Gleason system is often applied; despite of its complexity 
the interobserver agreement seems reasonable (see I-5.3; 
Fowler et al., 1985). 
The grading system designed and utilized at the Mayo 
clinics (Utz et al., 1969} distinguishes four grades upon 
assessment of seven histological criteria (acinar structure; 
individual cellular structure; nuclear characteristics; 
presence of nucleoli; cytoplasmic characteristics; mitotic 
activity; and degree of invasiveness). 
Combining differentiation with degree of nuclear anaplasia 
Mostofi (AFIP; WHO) has proposed the following grading system 
(Mostofi, 1975). Grade I: well differentiated glands with 
nuclei that show slight nuclear anaplasia. Grade II: gland 
formation but the nuclei show moderate nuclear anaplasia. 
Grade III: glands with marked nuclear anaplasia or tumors that 
are undifferentiated (do not form glands). 
A grading system combining the histological features of 
glandular pattern and nuclear cytology was presented by Gaeta 
et al. (1980 and 1981; 4 grading scores) and has been recom-
mended by the National Prostatic Cancer Project (NPCP}. 
Boecking et al. (1982) devised a grading system with 3 
grades of malignancy combining tumor architecture and degree 
of nuclear anaplasia. In histologically heterogeneous tumors 
only the lowest grade of differentiation is considered. The 
score consists of the sum of the histological points and the 
points granted to the amount of nuclear anaplasia. Subse-
quently 3 grades of malignancy are deduced from the results. 
In their initial report an interobserver agreement of 91% was 
recorded. Moreover, they emphasize the phenomenon of changes 
of tumor grade in time as a result of dominant growth of a 
less differentiated tumor clone. 
Brawn designed in 1982 the M.D. Anderson Hospital (MDAH} 
grading method based on the assumption that differentiated 
(gland forming) prostate carcinomas have a better prognosis 
than undifferentiated (non-gland forming) prostate carcinomas. 
Grade 1: 75-100% of the tumor forms glands; 0-25% does not 
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(grade 1 lesions do not include predominantly cribriform-
papillary tumors). Grade 2: 50-75% of the tumor forms glands; 
25-50% does not (includes tumors consisting of 50% or more of 
a cribriform-papillary pattern). Grade 3: 25-50% of the tumor 
forms glands; 50-75% does not. Grade 4: 0-25% forms glands; 
75-100% of the tumor forms no glands. 
Mostofi and Schroeder proposed a new grading system in 
1985 based on a retrospective multivariate analysis on 
prostatectomy specimens with cancer of patients with a well-
known long-term follow-up (Schroeder et al., 1985abc). Based 
on architectural features, mitotic activity and nuclear 
anaplasia patients could be arranged in 5 classes with 
statistically significant different prognostic outcome. 
Further studies have to be carried out on other patient groups 
to investigate the exact value of this new grading method. 
For as yet its relatively high interobserver agreement (this 
thesis) provides hopeful expectations (see Chapters II and 
III). 
Other grading systems such as those designed by Evans et 
al. (1924), Young et al. (1927) and Shelley et al. (1958). 
These methods are excluded in this overview because they are 
at present of limited practical value. 
5.2. Additional morphology-related prognostic factors in 
prostatic carcinoma 
Apart from those features that are laid down in numerous 
grading systems especially designed for PC, still reports 
occur presenting additional morphologic and biometric 
characteristics within prostatic tumors with potential 
prognostic value. 
The presence or absence of distinct or indistinct cell 
borders of tumor cells was noted to be of potential prognostic 
significance by Epstein et al. (1976). In their retrospective 
multi-variate analysis they also observed a prognostic 
significance of lymphocytic infiltration. The latter might 
suggest that cell-mediated immunity of the host plays a role 
in the natural course of PC. 
Nuclear pleomorphism in PC is often used in grading 
systems and is known as nuclear anaplasia. However, according 
to others the latter term includes also variations 1n the 
nuclear distribution of chromatin. A subdivision regarding 
the degree of nuclear anaplasia (pleomorphism), which is 
sometimes used as solitary grading effort, was introduced by 
Epstein et al. (1976). 
Class I Nuclei are regular with little variation of size 
and shape. 
Class II Nuclei show a moderate variation of size and shape. 
The diameter of the largest nucleus is not more 
than twice the diameter of the smallest. 
Class III Nuclei vary markedly in size and shape. 
Myers et al. (1982) introduced a method of grading 
nucleoli in neoplastic cells. The nucleolar grade (varying 
from 1 to 3) was attached as a superscript to the grade of 
tumor Gleason pattern (see also: Tannenbaum et al., 1982). 
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To objectivate and quantitate morphologic features and to 
diminish lack of reproducibility from examiner to examiner, 
morphometric and biometric studies of PC have been performed 
(Sharkey et al., 1984; Stamey et al., 1988). In general, 
tumor size correlates well with the biological behavior of PC 
and is regarded as a relatively reliable prognosticator (Fan 
et al., 1983). Evidence is available indicating a clear-cut 
relationship between histological grading scores and tumor 
size. This relationship has also been studied in the 
different clinical tumor stages of PC (see I-6). Stage Al 
tumors are nearly always well differentiated adenocarcinomas. 
Guileyardo et al. {1982) stated that within stage A lesions 
(especially A2 neoplasms), tumors with Gleason pattern scores 
greater than 4, were significantly larger than those with 
Gleason scores 4 or less. Hence, for PC it is generally 
accepted that histological differentiation (reflected in 
grade) is related to size and clinical behavior of the tumor. 
Apart from gross biometric parameters, which can be 
determined macroscopically or by low-magnification microscopy 
{Fan et al., 1983), now, computer assisted techniques are 
available to enable biometric studies of detailed histological 
and cytologic characteristics. The latter studies have been 
performed for many tumors including PC; many different 
parameters have been evaluated morphometrically and correlated 
with prognostic data. The major drawback of this technique is 
the subjective choice of the tumor area that will be submitted 
for morphometry. 
Diamond et al. (1982ab) objectivated nuclear morphology 
(changes in size and shape of tumor nuclei) in clinically 
staged B2 prostatectomy specimens by means of computer 
assisted image analysis. It was determined that a nuclear 
roundness factor, the degree to which a nucleus deviates from 
a circle or sphere, could be used to distinguish those stage 
B-2 prostatic cancers with a high lethal potential from those 
B-2 lesions that are less aggressive (see I-6 for the 
explanation of the various clinical tumor stages). Recently 
Mohler et al. {1988ab) stated that the nuclear roundness 
factor correlated even better with prognosis than pathological 
grading by the Gleason method. 
5.3. Controversy in histological grading of Prostatic cancer 
The large number of histological grading methods which 
have been developed during the last decennia already indicates 
the controversy that exists concerning the choice of the 
parameters and their distribution among scores to reach 
general acceptance. Grading methods differ widely as to which 
morphologic aspects of the cancer are most important for 
predicting the prognosis of PC. In some of them, large 
prognostic significance is attributed to architectural 
parameters {Gleason; Anderson), whereas others emphasize the 
prognostic value of cytological features (Mostofi, 1975). 
None of the systems reviewed in short previously is currently 
in use (Gardner, 1982). Reasons for tl1is reluctancy of 
pathologists to use histological grading systems are: 
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- Lack of intra- and interobserver agreement when applied by 
others than the original designer of the grading method. 
- Lack of sufficient statistical evidence of the prognostic 
value of each grading step (or score) within grading 
systems. 
- Lack of precise definition of morphologic criteria such as 
for example nuclear anaplasia (Brooks et al., 1986). 
- The morphologic heterogeneity of PC within a single patient, 
which complicates the use of those grading methods that 
offer only the possibility to judge one growth pattern 
(Dhom, 1985). Often the area of poorest differentiation 
(and highest cellular anaplasia; Boecking et al., 1982; 
McGowan et al., 1983) is selected for grading. In some 
grading methods the most dominant growth pattern of the 
cancer is examined. 
- Lack of consensus concerning the type of the specimen on 
which histological grading has to be performed, because of 
lack of agreement between grade, defined in biopsy and 
radical prostatectomy specimens (needle biopsy specimen 
seems not representative enough; Catalona et al., 1982; 
McGowan et al., 1983; Lange et al., 1983; Babaian et al., 
1985; Dhom, 1985; Mills et al., 1986). 
- Lack of sufficient evidence that the prostatic tumor retains 
the same histomorphologic appearance throughout the life of 
the host and that the tumor is not subjected to morphologic 
changes (due to arrest of differentiation) during the 
natural history of the tumor (Murphy et al., 1979; Brawn, 
1983b). 
Looking at the numerous grading systems for PC introduced 
in literature, it is generally recognized that grading is 
arbitrary and subjective at best. Reasons why these grading 
methods are not generally applied are already mentioned in 
detail above. Here some criticism and comments are presented 
concerning the Gleason grading system, which is frequently 
used in the United States. 
The grading system proposed by Gleason is criticized by 
some authors not to be reproducible and does not include all 
features associated with malignancy (Harada et al., 1977). 
Murphy et al. stated in 1979 that the margin of error of 
reproducibility applying the Gleason system from one 
institution to another could be as much as 50%. Contrary, a 
relatively high interobserver consensus of the Gleason system 
(74%) was found by Bain et al. (1982). Stage A PC (n = 143) 
was independently graded according to the Gleason system by 
two pathologists (Guileyardo et al., 1982). Perfect agreement 
(identical Gleason pattern score) was reached in 81% of cases. 
Intra-observer concordance of the Gleason system seems 
also relatively poor. A considerable improvement can be 
achieved when Gleason scores are rearranged into three 
categories such as proposed by Babaian et al. (1985). Using 
his own grading system Gleason had an intra-observer 
reproducibility of 80% (Murphy et al., 1979). Svanholm and 
coworkers (1985) reached an intra-observer agreement of 65% 
and 42%. Criticism is also presented by McGowan et al. (1983) 
who found, in disagreement with Gleason, that the 
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qualitatively highest histological tumor grade (total lack of 
differentiation) is most important in respect of prognosis. 
The resemblance or lack of resemblance of the primary 
tumor with secondary tumor deposits falls beyond the scope of 
this introduction. 
Comparative studies concerning the prognostic accuracy and 
the reproducibility of grading are not frequently met in 
literature (Kate tenet al., 1986; Morenas et al., 1988; 
Gallee et al., 1989a). We have examined the interobserver con-
sensus of 5 grading methods (Chapter II). In a subsequent 
study the prognostic accuracy of these methods was compared 
(Chapter III) . 
Referring the criticism about histological grading, 
therapeutic dicisions in the individual patient may not be 
made upon grading results alone (Murphy et al. 1979). 
6. Staging in prostatic cancer 
At the present time the individual prognosis and 
biological behavior of PC are predominantly based on 
(histological) grading and clinical staging. Histological 
grading of PC has been discussed in section I-5; results of 
histological grading studies are presented in chapters II and 
III. The clinical stage is assessed by clinical examination. 
In the case of PC these examinations encompass a physical 
survey (i.e. rectal examination), determinations of tumor-
associated markers in body fluids (serum, urine, prostatic 
fluid etc) such as prostatic acid phosphatase (PAP) and 
prostate-specific antigen (PA), roentgenological assays 
(including computer tomography of chest, vertebral column, 
pelvis etc), bone scintigraphy studies, ascending (bi)pedal 
lymphangiography, ultrasonography (Fair et al., 1983; Jansen 
et al., 1989) and tissue biopsy information. Sometimes 
retroperitoneal lymphadenectomy (combined with frozen section 
analysis) is also part of the (clinical) staging procedure 
(Lieskovsky et al., 1980). Results of treatment are generally 
reported on the basis of clinical staging (Gibbons et al., 
1983) . 
Whitmore introduced in 1956 the first classification of 
the clinically determined extension of PC. According to the 
extension of the tumor, PC was categorized into 4 stages. In 
1975 Jewett presented a modified and more detailed description 
of the criteria of the 4 stages, which are briefly summarized 
in Table 2. 
** Stage A PC's are clinically inapparent tumors. They are 
found incidentally by the pathologist either at autopsy 
(latent cancers) or during microscopic examination of 
surgical specimens without clinical suspicion of malignan-
cy (TUR or simple suprapubic prostatectomy). They are 
nearly always localized anteromedially within the prostate 
and do not extend beyond the prostatic capsule (McNeal et 
al., 1988a). These tumors are also known as incidental or 
latent (unsuspected or quiescent) cancers. However, some 
authors confine the term 11 latent11 to tumors that are 
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Table 2. The staging of prostate cancer (after Jewett, 1975) 
A. Not clinically manifest 
1. Focal, low grade 
2. Diffuse andjor high grade 
B. Localized 
1. One lobe only 
2. More than 1 lobe 
(3. Involvement of more than one lobe associated with 
deformity of the prostatic gland) 
c. Local extension beyond the prostatic capsule but no 
metastases 
D. Metastases 
encountered during postmortem examinations. Although 
latent cancers also develop in other organs, such as the 
thyroid gland, gastro-intestinal tract and lung, the 
prostate seems to be unsurpassed in its frequency of such 
tumor foci (Dhom, 1983; see also I-2). The incidence of 
latent cancers appears to increase when the step-section 
technique is employed and the whole specimen is submitted 
for histological examination (Scott et al., 1969; Moore et 
al., 1986). Using this technique Newman et al. (1982) 
found an occurence of incidental cancers in a large series 
of TUR specimens (n = 500) of 8 per cent. Bauer et al. 
(1960) and Parfitt et al. (1983ab) found in approximately 
10 per cent of patients undergoing TUR or enucleation for 
presumed BPH an unsuspected PC. The incidence of latent 
cancers detected in necropsy specimens increases with age. 
An incidence rate of 6.4 per cent was recorded among men 
in the sixth decade of life, whereas above the age of 80 
years 26 per cent of men appeared to have latent PC 
(Halpert et al., 1963). In general, the incidence of 
unsuspected PC varies widely ranging from 4 to 30 per cent 
(Golimbu et al., 1978; Bartsch et al., 1983a). 
Recent knowledge of the biological charateristics has 
resulted into a subdivision within stage A PC of 
relatively indolent stage A1 and more aggressive stage A2 
lesions. The former (focal or A1 tumors) have been 
defined variously as tumors involving less than 3 chips 
(Golimbu et al., 1981), no more than 3 microscopic foci 
(WHO), less than 5 chips and less than 5 per cent of the 
surgical specimen (TUR) (Cantrell et al., 1981; Newman et 
al., 1982; Bridges et al., 1983; Sanda et al., 1984), 
whereas the latter (A2 lesions) encompass more extensive 
lesions and reveal often a high histological grade (Wilson 
et al., 1983; Bartsch et al., 1983a). The A1 lesions are 
known in literature as incidental focal carcinomas. 
Though initially it was generally accepted that these 
lesions did not interfere with life expectancy and did not 
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need any therapy (Bridges et al., 1983), recently data 
have become available that in a subtraction of patients 
with stage A1 lesions (especially high grade lesions) 
relapses do occur after approximately 8 years (Epstein et 
al., 1986b; Blute et al., 1986; Lowe et al., 1988ab; 
Epstein et al., 1988). The A2 lesions are designated as 
incidental multi-focal or diffuse tumors. They are often 
considered as more aggressive (Lowe et al., 1988ab). When 
more than 5 per cent of the TUR tissue contained cancer, 
or the tumor histology showed a Gleason (sum) score of 8 
to 10, 33 per cent of the patients had progressive disease 
within 4 years (Yatani et al., 1982; McNeal et al., 
1988a). There is even evidence that some A2 lesions will 
behave more aggressively than many stage B tumors (Golimbu 
et al., 1978; Bartsch et al., 1983a; Parfitt, 1983ab). 
The age distribution of unsuspected incidental PC 
indicates that the percentage of stage A1 tumors is 
relatively higher under the age of 60. Beckner et al 
(1985) found no poorly differentiated stage A2 lesions at 
younger ages. Conversely, more than two-thirds of the 
incidental tumors in men above the age of 85 were poorly 
differentiated and non-focal. In contrast with stage A2 
lesions, the prevalence of small foci of latent PC (stage 
A1) does not show any geographical distribution (Flanders, 
1984). 
** stage B cancers are those tumors that are clinically 
evident, apparently confined within the prostatic capsule 
and without evidence of regional or distant metastasis. 
This clinical stage has been further subclassified as B-1, 
a nodule or area of induration less than 1.5 em confined 
to one lobe, or B-2, involving both lobes but still 
confined to the prostate (Gibbons et al., 1983). Finally, 
stage B-3 lesions are considered as intracapsular 
malignancies associated with deformation of the gland 
(Whitmore, 1980) . 
** Stage C lesions are clinically evident with apparent local 
extension beyond the prostatic capsule but without 
evidence of metastasis. Apart from capsular perforation 
involvement of seminal vesicles may be present. 
Eventually local tumor extension will lead to a prostate 
that is fixed to surrounding structures. 
** Stage D tumors are clinically metastasized prostatic 
cancers. When a patient with clinical stage A, B, or C 
disease is found to have pelvic lymph node metastasis 
without bony spread or involvement of other organs, he is 
classified stage D-1. If a patient has distant bone 
metastasis, then he is staged D-2. 
Apart from the Whitmore (1956) classification of PC the 
Veterans Administration Cooperative Urogenital Research Group 
(VACURG) suggested in 1974 a four-class staging system 
(Gleason et al., 1974). Moreover, detailed TNM clinical 
staging systems (T = the extent of the primary tumor; N = the 
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absence or presence and extent of regional lymphnode 
metastasis; M = the absence or presence of distant metastases) 
were developed for urogenital malignancies by the American 
Joint Committee for Cancer Staging and End Results Reporting 
(1978). The updated version of the clinical TNM system (1987) 
is summarized in Table 3. The most precise tumor stage, based 
on data obtained at microscopic examination, is represented by 
the pTNM system. Apart from these current staging systems, 
other rarely applied tumor extension classification systems 
have been developed (Hudson et al., 1972; VACURG, 1976; 
McLaughlin et al., 1976; Ray et al., 1976). 
Tab1e 3. TNM classification 
extension (derived 
malignant tumors", 
Cancer; 1987). 
scheme for prostatic tumor 
from "TNM classification of 
International Union Against 
T1 
T1a 
T1b 
T2 
T2a 
T2b 
T3 
T4 
N1 
N2 
N3 
Incidental 
Less than 3 tumor-foci 
More than 3 tumor-foci 
Clinically or grossly (macroscopically) limited to 
gland 
Less than 1.5 em 
More than 1.5 em or involvement of more than one lobe 
Invades prostatic apex; beyond capsule/ bladder neck/ 
seminal vesicle/ not fixed. 
Fixed or invades other adjacent structures 
Single secondary tumor deposit less than 2 em 
Single secondary tumor deposit larger than 2 em and 
smaller than 5 em, or 
multiple secondary tumor deposits smaller than 5 em 
Secondary tumor deposits larger than 5 em 
Several studies have demonstrated that low stage cancers 
frequently show (histologically) low grade tumors (see I-5). 
However, highly specific tumor stage related histological 
characteristics have never been identified. In almost every 
stage of the disease, regardless of treatment modality, 
patients with well-differentiated tumors have a longer 
survival (Grayhack et al., 1983). On the contrary, high grade, 
high stage, and large tumor mass have an independent adverse 
effect on the probable patient course. 
For all tumors including PC, a combined appraisal of 
histological grading and clinical staging raises the 
reliability of prognostic statements (Kastendieck, 1980; 
Mellinger et al., 1967; Gleason et al., 1974; Sogani et al., 
1985). 
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6.1. controversy in clinical staging of prostatic cancer 
Underestimation of the exclusively clinically assessed 
tumor stage frequently occurs (Prout et al., 1973; Kramer et 
al., 1980; Bosch et al., 1986) and becomes evident when 
patients are submitted to surgical procedures i.e. retroperi-
toneal lymphadenectomy and prostatectomy and pathological 
staging can be compared with clinical staging (Lieskovsky et 
al., 1980). Various studies have suggested that up to 25 per 
cent of patients with clinically stage B lesions have regional 
metastases to the lymph nodes (stageD tumors). In patients 
with clinically staged C lesions this percentage is reported 
to be even higher (up to 60 per cent; Whitmore et al., 1973; 
Saltzstein et al., 1977). Grossly, approximately 20-50 per 
cent of tumors seems to be understaged. For this reason some 
authors stated that the stage of PC is of the least prognostic 
significance (Belt et al., 1972; Byar et al., 1981; Culp et 
al., 1973; Whitmore, 1973; Murphy et al., 1976). 
On the other hand, local overstaging has also been 
reported. Bosch et al. (1986) found after thorough pathologic 
examination of the surgical specimen, that 23 per cent of 
patients with clinical stage T3 appeared to be overstaged. 
Inaccurate staging can be considered as the result of 
limitations of the diagnostic armamentarium to judge precisely 
the extent of the disease. Concerning pathological exami-
nation it may also be the result of inaccurate or incomplete 
investigation of the surgical specimen. The necessity of 
microscopic evaluation of the entire specimen for detection of 
stage A cancer in clinically benign prostates is emphasized by 
many workers (Denton et al., 1965; Scott et al., 1969; Yatani 
et al., 1974; Battaglia et al., 1979; Newman et al., 1982; 
Vollmer, 1986; Yamabe et al., 1986). The necessity of 
repeated TUR's in accurate diagnosing stage A disease was 
stressed by McMillen et al. (1976), Bridges et al. (1983), 
Parfitt et al. (1983ab) and Sonda et al. (1984). The availa-
bility of advanced equipment such as ultrasonography, computer 
tomography and nuclear magnetic resonance scanning may help in 
more accurately determining pre-operatively the exact stage of 
the prostatic neoplasm. 
7. Therapeutic management of prostatic cancer 
To date, treatment of PC is primarily based on clinical 
stage. As there often is discrepancy between the assigned or 
clinical stage of tumor and its true extent, one can never be 
completely sure, which stage is being treated (I-6.1). This 
complicates a simple comparison of therapeutic modalities 
presented in literature. The choice of the most suited stage-
related therapy is further hampered as in literature 
sufficient statistical analysis is frequently omitted or not 
comparable. Furthermore, follow-up is usually of too short 
duration to permit meaningful conclusions (Klein, 1979). 
Finally, it is difficult to define exactly objective treatment 
response criteria for PC (Schroeder et al., 1984a). 
Because of the afore-mentioned reasons it is impossible to 
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state exactly which treatment is best for which tumor stage. 
In spite of these restrictions an attempt is made to present 
some major stage-associated therapeutic principles. In 
addition, the role of the major therapeutic approaches in the 
management of PC will be discussed briefly. 
Stage Al cancer needs no special therapy (Byar et al., 
1981); an expectative regimen is justified. The simple 
prostatectomy or transurethral resection can be regarded as 
both diagnostic and curative at the same time. On the 
contrary, stage A2 cancer requires more than careful 
observation. Radiotherapy is applied with moderate success 
(Cobalt-60 teletherapy) . Though radical excision of the 
prostate is not generally accepted in the treatment of stage 
A2 disease, it is quite often performed. These prostatectomy 
specimens obtained after previous transurethral resection 
contain in 50-80 per cent of cases residual tumor (Sonda et 
al., 1984). Hormonal manipulation has no proven efficacy in 
astage A2 disease. 
Stage B cancer (see Table 2) has to be treated by radical 
prostatectomy (Myers et al., 1983). Equally successful 
results are described for external beam radiotherapy (Hanks, 
1988). Hormonal treatment and orchiectomy have no particular 
role whatsoever in stage B PC. 
stage c cancer can be treated by external beam 
irradiation. Schroeder et al. (1975) and Bosch et al. (1987) 
propose a limited role for perineal prostatectomy in (early) 
stage c lesions performed for low grade (1 or 2) tumors 
(according the Mostofi grading system). However, in these 
cases surgical staging (consisting of pelvic lymphadenectomy, 
including immediate microscopic examination) has to precede 
radical surgery. 
For stage D PC many therapeutic modalities have been 
installed. Among these hormonal manipulation and radiation 
therapy (sometimes combined with retroperitoneal 
lymphadenectomy in stage D-1 disease) have proven to achieve a 
maximum of palliation. Controversy exists concerning the 
precise timing of endocrine therapy; early or late treatment 
(when symptoms become manifest) (Aubel van et al., 1985b). 
Some authors report moderate success in patients treated with 
cytotoxic agents and specific or non-specific immunotherapy 
(Guinan et al., 1984; Deguchi et al., 1986). 
7.1. Surgical intervention 
Radical prostatic surgery for PC consists of perineal or 
retropubic prostatectomy. The latter approach has the 
advantage of simultaneous dissection of the retroperitoneal 
lymphnodes combined with the possibility of immediate (fresh-
frozen) histological examination and is considered as the only 
treatment by which PC actually can be cured. Prostatectomy is 
nowadays an accepted treatment for localized limited PC 
(i.e.stage A2 and B lesions) (Paulson et al., 1986; Hanks, 
1988). When radical prostatectomy is carried out for clinical 
stage C lesions, patients whose specimens contain tumor-
positive margins of resection, can be treated successfully by 
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postoperative radiation (Paulson et al., 1986). Adjuvant 
therapy can be given either before or immediately after 
primary surgery. Some reports describe successful results 
following radical prostatectomy on patients with stage C 
lesions whose tumors were regressed during pre-operative 
endocrine therapy (Belt et al., 1972; Myers et al., 1983). 
To prevent complications such as impotence, urethral strict-
ure, morbidity associated with anesthesia and incontinence the 
operation has to be carried out by surgeons with special 
experience in the field of urogenital oncology (Culp et al., 
1973; Finkle et al., 1981). Post-operative follow-up of at 
least 15 years duration seems neccessary to determine whether 
a patient has been cured of this disease (Belt et al., 1972). 
The survival rates after prostatectomy are predominantly 
determined by the microscopic extent of the tumor within the 
prostatectomy specimen (Culp et al., 1973). When cancers were 
less than 1.0 em in greatest dimension, 90 per cent of the 
patients lived at least 10 years post-operatively. 
The precise role of TUR in the treatment of PC is still a 
matter of dispute. Some investigators believe that TUR may 
not be performed in the treatment (palliative or curative) of 
PC for the possible danger of wide spread dissemination 
(McGowan, 1980; Babaian et al., 1988). Others postulate that 
TUR might have a role in the palliative treatment of 
metastasized PC for relief of bladder outlet obstruction or as 
a curative treatment protocol for stage A and B cancers (Myers 
et al., 1983) and even stage c cancer (Bartsch et al., 1983b). 
Contrary to prostatectomy, TUR is regarded as a conservative 
treatment regimen. 
7.2. Hormonal intervention 
In choosing the optimal treatment regimen one must realize 
that approximately 80 per cent of patients respond initially 
to hormonal manipulation, suggesting that this should be the 
therapy of first choice. However, since hormonal intervention 
cannot be considered as a curative therapy, prostatectomy or 
radiotherapy has to be recommended for young patients with 
limited localized cancers, whereas an endocrine regimen has to 
be reserved for patients with high-staged prostatic tumors. 
Initially endocrine manipulation consists of administration of 
anti-androgens and estrogens or castration (orchiectomy). 
Treatment with stilboestrol was complicated by cardiovascular 
side effects (coronary artery disease and myocard infarct) 
especially when large doses were given. Later on, other 
estrogens at lower doses were applied showing considerably 
less cardiovascular side-effects. Among the alternatives of 
stilboestrol belong medroxyprogesterone acetate, diethylstil-
bestrol (DES), anti-androgens such as cyproterone acetate, 
Luteinising Hormone Releasing Hormone (LHRH) analogues, and 
the anti-fungal agent ketoconazole (Kirk, 1985; Schroeder et 
al., 1987). Nevertheless, endocrine manipulation is 
frequently accompanied by side effects such as painful 
gynecomastia and gastro-intestinal symptoms. Cardiovascular 
effects have already been mentioned. Ultimately, a large 
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number of prostatic cancers become insensitive for hormonal 
intervention. Recently, the role of modulation of the AR 
system of regulation of gene expression has been discussed in 
the development of androgen-independent growth of human PC 
(Coffey et al., 1987; see I-9.4). 
7.3. Other therapeutic modalities 
7.3.l.Radiation therapy 
In a large patient group the effect of external beam 
radiotherapy was studied. Seventy-two per cent of patients 
with stage B cancers were alive at 5 years and 44 per cent at 
10 years; a lower percentage was found in patients with extra-
capsular lesions (stage C): survival at 5 years 51 per cent 
and at 10 years 38 per cent (Ray et al., 1973). Application 
of X-ray treatment to truely localized carcinoma, such as 
stage A2, would be predicted to achieve a noteworthy success. 
Hanks did not find any difference in long-term outcome of 
external beam radiation therapy and radical prostatectomy for 
stage A2 and B cancer (Hanks, 1988). 
Next to external beam radiation therapy, patients can be 
treated by implantation of radioactive seeds (interstitial 
irradiation) (Kirk, 1985; Fujino et al., 1986) or a 
combination of these two methods. The effect of radiotherapy 
(measured by ultrasonography) correlates with the histological 
grade of the tumor; poorly differentiated tumors react most 
favourable on radiotherapy (Fujino et al., 1986). Radiation 
therapy is often complicated by chronic proctitis, cystitis 
and impotence (Schroeder et al., 1976). Radiotherapy might 
also be of value in helping alleviate the pain of metastatic 
lesions. 
7.3.2.Chemotherapy 
For advanced stage endocrine-unresponsive PC (stage D 
lesions) the National Prostatic Cancer Project (NPCP) and the 
EORTC urological group have developed diverse multi-agent 
treatment regimens. These include various combinations of 
anti-cancer drugs (e.g. cyclophosphamide, 5-fluorouracil, 
estramustine phosphate (Estracyt), streptozotocin, vindesine, 
imidazole-carboxamide, dacarbazin, procarbazine, prednimusti-
ne, cis-platinum, methotrexate, vincristine, doxorubicin 
(adriamycin), mitomycin-c etc.). In some therapeutic regimens 
these agents are combined with hormonal therapy (Loening et 
al., 1983; Emrich et al.,l985). Torti et al. (1985) reported 
that the combination of doxorubicin and cisplatin showed no 
superiority to single-agent doxorubicin treatment in metas-
tasized PC. These authors also state that the benefit of 
chemotherapy in PC is equivocal and that the response of 
diverse chemotherapeutic schemes can hardly be measured by 
objective parameters. 
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7.4. Therapy induced alterations in histo- and cytomorphology 
of prostatic carcinoma 
Effects of hormonal therapy 
The hormonally induced changes are mainly investigated in 
advanced stages of tumors since these more extended cancers 
are often treated by non-surgical regimens. The cytological 
changes observed in patients having a positive response to 
hormonal therapy include squamous metaplasia, hydropic 
degeneration, reticulation of the nuclear chromatin, and 
pyknosis and rupture of the nuclear membrane. 
Estrogen-induced squamous metaplasia was first described 
by Bainborough in 1952. Most frequently it occurs in non-
neoplastic glands (acini and ducts) and will sometimes lead to 
obliteration of glandular structures. However, Accetta et al. 
(1982} described the presence of large foci of squamous cell 
differentiation in the metastases of widespread prostatic 
adenocarcinoma and discussed the possible role of estrogen 
therapy in inducing these morphologic changes. Moreover, 
estrogen therapy causes also squamous metaplasia of the 
urethra. Experimental work in dogs by Leav et al. (1978) has 
shown that estrogens produce alterations in the two cell 
types. In the inner cylindric cells, features of both 
squamous and glandular differentiation were present with 
perinuclear tonofilaments and secretory vacuoles. In the 
basal cells of the glands, the cells were purely squamous, 
lacking any glandular differentiation. 
Estrogen-induced squamous metaplasia is recently 
contradicted by the report of Voogt et al. (1987) who reported 
that, in prostates of young adults without cancer, treatment 
with a combination of estrogen and anti-androgen (for 8 weeks) 
resulted into stromal cell proliferation and atrofic glandular 
acini, lacking squamous metaplasia. However, the time relapse 
after initiation of therapy to the time point that these 
morphologic changes occured was presumably to short. Dhom 
(1985) postulated that the therapy-dependent morphologic 
phenomena become evident at least 6 months after therapy has 
started. 
Apart from induction by estrogens, squamous metaplasia of 
prostatic ducts may also develop in the region of infarcts, 
after irradiation therapy, and after TUR (Utz et al., 1969). 
In metaplasia due to infarction, the acinar and ductal 
epithelium may also be replaced by transitional epithelium 
(Mostofi et al., 1973). 
Effects of radiation therapy 
The response of tumor tissue to radiation therapy, alone 
or in combination with endocrine therapy, has only recently 
become known. The regressive changes in tumor cells during 
hormonal therapy and radiation treatment (internal and 
external) are basically identical and are listed above. 
Hormonal- and radiotherapy induced cyto- and histological 
changes are similar and do not depend upon the histological 
differentiation of the carcinoma. However, radiation therapy 
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alone will not result in squamous metaplasia. Long-term 
radiotherapy will finally lead to a covert arrangement of 
tumor cells localized within a stroma that shows increased 
fibrosis. In cribriform or solid carcinomas radiation therapy 
seems to be superior to hormonal treatment, whereas endocrine 
or combined endocrine- and radiation therapy are more 
effective in the case of histologically better differentiated 
glandular carcinomas (Kastendieck, 1980; Dhom et al., 1982). 
Benign prostatic glands in the vicinity of tumor areas may 
respond to radiation therapy by the development of moderate to 
severe cytologic atypia. Therefore a problem can rise by the 
differential diagnosis of radiation induced atypia and 
persistent adenocarcinoma when post-radiation biopsies are 
examined (Brawer et al., 1989). 
The effects of therapy upon the expression of prostate-
specific antigen and prostatic acid phosphatase will described 
el~ewhere (see I-9.2). 
8. Monitoring the clinical course of prostatic cancer 
To monitor the natural course of PC or the potential 
effect of an intervening therapeutic regimen different 
approaches have been suggested. Histopathologic or cytologic 
follow-up (Dhom et al., 1982; Freiha et al., 1984; Bishop et 
al., 1985), repeated rectal examination, bone roentgenography 
or bone scintiscan have been more and more replaced by regular 
determinations of tumor related markers in the urine, in the 
prostatic fluid and above all in the blood. Nowadays, even 
periodic transrectal ultrasonometry has been proposed to 
monitor changes in size of the prostatic gland and 
intraprostatic alterations in acoustic impedance under 
endocrine management or radiation therapy (Carpentier et al., 
1986; Fujino et al., 1986). However, the scarcity of truely 
objective criteria to measure the effect of treatment is 
emphasized by Schroeder et al (1984b). 
Of those markers related to PC and that are shed in the 
blood circulation prostatic acid phosphatase (PSAP or PAP) and 
prostate-specific antigen (PSA or PA) are most commonly used 
for the purpose of monitoring patients with PC. They belong 
to the group of prostatic tissue-specific antigens (PTSA) with 
secretory activity. More detailed biochemical and 
immunological features of these antigens are presented in 
section I-9. In addition to PAP and PA, several less well-
known secretory markers, detectable in the blood, prostatic 
fluid or urine and of potential use in monitoring PC patients, 
will be discussed briefly. 
8.1. Markers present in the bloodcircu1ation 
Prostate-specific acid phosphatase (PAP or PSAP) 
In patients with advanced stage PC serum PAP levels can 
be raised (Maatman et al., 1984; Heller, 1987) and may fall 
after initiation of a successful therapeutic regimen. From 
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those patients with PC which have metastasized to the skeletal 
system (stageD PC), 75-90 per cent has elevated serum acid 
phosphatase levels. These high serum PAP levels may fall in 
response to treatment. Persistently elevated values after 
treatment indicate, in general, a poor prognosis. It is 
postulated that the large tumor load such as present in stage 
D cancer is responsible for the elevated PAP serum level, 
though the protein synthesis of individual tumor cells is 
lowered compared with non-neoplastic prostatic cells. 
Therefore, immunohistochemical data do not systematically 
correspond with serum levels of tumor markers. Moreover it 
has been postulated that as a result of tumor-associated 
abnormalities of the cytoskeleton (see I-9.3), the cellular 
translocation of the enzyme may be disrupted, altering the 
secretion kinetics. In patients with limited localized PC 
only a subpopulation will have raised serum PAP levels even 
when highly sensitive (immunological) methods are used (Bruce 
et ·al., 1981). After release into the circulation PAP is 
cleared rapidly with a half life of 0.5 to 2.5 hours 
{Wadstroem et al., 1985). Determination of the PAP serum 
level can be assessed by an enzymatic assay or by an 
immunological assay. Enzymatic assays for the assessment of 
serum PAP are hindered by fluctuations of the serum pH. 
Especially high pH (above 8) values and high temperature block 
the enzymatic activity of PAP. Therefore, depending on the 
specificity of the antibodies and the technique employed (EIA 
or RIA), in general, methods using immunological tools are 
preferable (Vihko et al., 1980, 1982 and 1985; De Vries et 
al., 1982). 
False positive elevations of serum PAP levels not 
associated with PC, are encountered under several conditions. 
These conditions can be subdivided into prostatic and non-
prostatic disorders. A transient elevation of the serum-PAP 
level has been associated with prostatic massage, after 
surgery in the prostatic area and in the case of prostatic 
infarction. Moreover, a rise in serum PAP level has been 
reported in a relatively high percentage of patients with BPH 
{up to 20 per cent; Oosterom et al., 1986; De Vries, 1987). 
Non-prostatic diseases associated with a rise of PAP serum 
level of different durations encompass multiple myeloma, 
osteogenic sarcoma, thromboembolic disease, thrombocytopenia 
(Prout, 1973). Furthermore, gastric carcinoma, lung and breast 
cancers, rectal carcinoid tumors, metastastic pancreatic islet 
cell cancer and several myeloproliferative disorders may be 
associated with elevated concentrations of PAP in enzymatic-
and radio immuno-assays (Heller, 1987). For these reasons an 
elevation of serum PAP is considered as a semi-specific test 
for diagnosing PC. Since a rise is often absent in localized 
PC, measurement of PAP serum level cannot be used for mass 
screening purpose to detect early PC. However, in general, in 
patients with histologically proven PC, a rising PAP should be 
recognized as an objective criterion for progression. 
Measurements of the PAP content in bone marrow aspirates 
(for early detection of bone metastases) falls beyond the 
scope of this survey (Huber et al., 1982). 
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Prostate-specific Antigen CPSA or PA) 
Detailed biochemical and immunological characteristics of 
PA are presented in I-9.2.2. Even more specific for 
monitoring the biological course of PC is the determination of 
serum fluctuations of PA (or PSA). PA is released in the 
circulation of patients with advanced (stages B2-D} PC 
(Papsidero et al., 1980; Kuriyama et al., 1981; Wang et al., 
1981; Pontes et al., 1982; Killian et al., 1985). However, 
similar to PAP, elevated PA levels were also observed in 
patients with BPH. Ercole and coworkers (1987) reported that 
21 per cent of patients with BPH had increased PA levels 
before TUR. Stamey et al. reported in 1987 that the serum PA 
can be elevated in up to 83 per cent of patients with BPH. In 
high-staged PC (stages C and D) PA serum-levels usually exceed 
those in BPH. The PA level increases with advanced clinical 
stage and is proportional to the estimated volume of the 
tumor. Specificity of PA is considered to be higher compared 
with PAP. On the other hand, comparative studies concerning 
the sensitivity of both markers in their use as serum tumor 
markers evoke controversial results. Some agree with the 
opinion that the percentages of patients with high-staged PC 
with elevation of PA serum level without rise of PAP, and 
similarly staged patients showing the opposite serum tumor 
marker profile are almost equal. Other investigators found a 
somewhat higher sensitivity of PA and a better correlation 
with tumor size (Killian et al., 1985; Siddall et al., 1986; 
Stamey et al., 1987; Ercole et al., 1987; Schifman et al., 
1987; Emtage et al., 1987; Buamah et al., 1988). An EIA for 
serum level measurements of PA has been described by several 
authors (Kuriyama et al., 1980; Siddall et al., 1986). In a 
review article Stamey and coworkers (1987) stated that 
repeated PA serum determinations in monitoring patients after 
radical surgery (total prostatectomy) have to be considered as 
extremely specific and regarded as superior compared with PAP 
values. 
Summarizing, it is generally accepted that for as yet 
optimal monitoring of patients with PC has to be done by 
immunological measurements (EIA or RIA) of both prostatic 
markers at the same time and with regular time-intervals. 
However, PA might be prognostically somewhat more useful for 
patient follow-up (Killian et al., 1985). Both markers have 
insufficient diagnostic sensitivity (and specificity in the 
case of PAP) to be used in screening for cancer at an early 
stage. 
Other markers shed in the blood circulation 
Phosphohexoseisomerase (PHI) catalyzes the conversion of 
glucose-6-phosphate into fructose-6-phosphate and seems to be 
useful as a serum marker in monitoring the evolution of 
malignant breast- and prostate disease (Schwemmer et al., 
1985). In prostatic malignant disease its serum level may 
provide a biochemical estimate of the extent of tumor mass. 
The sensitivity for PC of the serum level of 
carcinoembryonic antigen is only limited (Schwemmer et al., 
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1985). 
Tissue polypeptide antigen (TPA) is a membrane bound 
polypeptide which can be present in the circulation in 
patients with cancer of different origin. However, the 
sensitivity of TPA for PC is low (Huber et al., 1983). 
8.2. Markers present in the urine and prostatic fluid 
Apart from fluctuations in the serum level of PAP and PA, 
the concentration of these markers in the urine and prostatic 
fluid have been described as potential parameters indicative 
for PC and presumably related to tumor extension ( Tremblay et 
al., 1987). Tsai et al. (1984) found that the protein content 
of PAP in human prostatic fluid was extremely lowered in 
patients with PC. 
The determination of the ratio LDH5/LDH1, complement 
components C3 and C4, transferrin and PAP in prostatic 
(seminal) fluid assists in identifying individuals with 
increased risk for PC (Grayhack et al., 1981). A comparative 
study of data obtained by two dimensional gel electrophoresis 
of prostatic fluid of individuals with PC and healthy 
volunteers revealed differences in the protein profiles 
between the two groups (Tsai et al., 1984). 
As a secondary effect of PC growth, urine levels of 
fibronectin can be episodically elevated in patients with PC 
(Webb et al., 1980). Because of its transient character, 
sensitivity for the detection of PC can be increased when at 
least three successive analyses are performed. 
9. Immunological aspects of prostatic cancer 
In this short review only attention will be given to the 
immunophenotypic alterations of neoplastic cells of prostatic 
origin compared to their benign counterpart. Special emphasis 
is laid on the immunocytochemical identification of PC linked 
antigens. The immunological response of the human host 
(humoral or cellular mediated) induced by the presence of 
tumor and the mechanisms to modulate this response will not be 
discussed here (see for a review on this subject Guinan et 
al., 1984 and Wirth et al., 1985). 
In general, neoplastic cells can display the following 
changes with reference to their immunophenotypic make-up: 
- an increase of expression or modulation of normally present 
antigens (blood group antigens and tumor-associated antigens 
(TAA)) • 
- occurrence of new antigens associated with malignant 
transformation which are not expressed on normal cells. 
These antigens are known as tumor-specific antigens (TSA). 
Examples of this group are the activated ras oncogenes which 
are mutated in the amino acid sequence. In virus-associated 
malignancies viral antigens are also reckoned to this group. 
- a decrease of normally present antigens (markers associated 
with cell differentiation). 
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Antibodies raised against the various antigenic 
determinants can be applied for detailed characterization of 
the tumor. Particularly in the case of PC one has to 
distinguish antigens that are exclusively present within the 
epithelial cells and antigens that are secreted in the seminal 
fluid and are sometimes also demonstrated in the urine 
(secretory antigens; SA). Since at least some of these latter 
antigens can be shed in the blood circulation in the case of 
invasive PC, they have been used for monitoring purpose. The 
antigens used for monitoring patients with PC and their 
attribution in tumor-staging are discussed in I-8. Among 
those secretory antigens that have been the subject of 
immunohistochemical studies and serological assays, are 
prostatic acid phosphatase (or prostate-specific acid 
phosphatase (PAP or PSAP); see I-9.2.1) and the more recently 
recognized prostate-specific antigen (PA or PSA; see I-9.2.2). 
Many attempts have been made to isolate other prostate 
(tumor) markers. Cell lysates, cell membrane-enriched 
fractions of normal, BPH or cancerous prostatic tissue and 
prostatic tumor cell lines have been used to generate 
polyclonal and monoclonal antibodies (Bazinet et al., 1988). 
Efforts have also been made to generate syngeneic (human) 
monoclonal antibodies against human prostatic tumors (Lowe et 
al., 1984). In part of the studies the antigens detected by 
the antibodies were defined and characterized with reference 
to their tissue- (prostate) specificity andjor specificity for 
carcinoma. The intensive search for tumor-associated markers 
with high tissue-specificity is justified especially for their 
potential application as immunotarget agents carrying 
cytotoxic drugs or radioactive isotopes for therapy or highly 
specific immune-imaging techniques (Goldenberg et al., 1983; 
Vihko et al., 1984; Deguchi et al., 1986; Vihko et al., 1987; 
Larson et al., 1988). 
In addition to characterization of PC, immunohistochemical 
studies may reveal information concerning the functional state 
of the prostatic gland and may correlate particular marker 
profiles with diverse stages of development of the prostatic 
gland (Lehtinen, 1980; Wernert et al., 1987). 
9.1. Tumor-associated - and Tumor-specific Antigens 
Tumor-associated Antigens (TAA) are considered as antigens 
that are expressed on normal cells but are found at a higher 
level or in a modified form in malignant tissue (Carney, 
1988). Tumor-specific Antigens (TSA) are, by definition, 
never found on any normal cell and their presence can be the 
result of either expression of mutated genes (the p21 product 
of the activated ras oncogenes) or the result of expression of 
viral antigens related with a presumed viral etiology of 
certain malignancies. 
Tumor-specific and tumor-associated markers can be 
subdivided into markers related to malignant transformation in 
general (lacking tissue-specificity) and markers with even 
higher specificity i.e. associated exclusively with malignant 
transformation of a specific tissue type (in this survey 
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prostatic epithelium). 
Many attemps have been made to characterize tumor-specific 
or tumor-associated antigens in order to generate antibodies 
against these molecules. Major characteristics of Tumor-
associated - and Tumor-specific Antigens for PC are summarized 
in Table 4. Thus far sufficiently characterized prostatic 
tissue TSAs and TAAs have not been reported. TSAs identified 
for PC are cross-reactive with non prostatic malignant cells 
(and cell lines): the antibodies PrSS, PrE3, and PrD8 show 
cross-reactivity with breast cancer cell lines (Lindgren et 
al., 1986). The antibody D83.21 reacts also with bladder 
carcinoma cell lines (Starling et al., 1985). Some of the 
presumed TSAs have only been tested on several PC cell lines. 
Of special interest may be the recently described McAb's 
P25.48 and P25.91, which were not reactive with benign 
prostatic tissue, but reacted with a subset (especially the 
high grade lesions) of malignant prostatic tissues (Bazinet et 
al., 1988). The antibodies showed a very restricted pattern 
of reactivity in nonprostatic tissues. Some of the markers 
presented in Table 4 are secreted in the urine, the prostatic 
fluid or (in the case of in vitro studies) in the culture 
medium of PC cell lines. 
We generated murine monoclonal antibodies against the 
human androgen-dependent PC cell line PC-82 (see I-10.2.1 and 
Chapter IV: Gallee et al., 1986). No antibodies were detected 
with exclusive binding for prostatic tumor cells. Many 
isolated antibodies displayed interesting cross-reactivity 
profiles with other malignant and non-malignant non-prostatic 
tissues. None of the antibodies produced against the PC-82 
cell line was directed against a TAA or TSA. Antibodies 
against antigens exclusively present in prostatic tissue 
appeared to be reactive against PA and PAP (see I-9.2.1 and I-
9.2.2). 
In future, antibodies against TAA and TSA will enable 
(more or less) specific immune-imaging and immunotherapy of 
malignant tumors. For immunotherapy and immune-imaging cell 
membrane-related, tumor-specific antigens with relatively high 
tissue specificity, lacking antigenic modulation after 
antibody binding are preferable. A secretory characteristic 
of the antigen recognized by these antibodies might be a 
serious drawback. On the other hand secretory TSA and TAA 
might be of use in monitoring the course of PC. 
summarizing the literature with reference to prostatic 
tumor-specific markers, it becomes clear that sofar no 
antibody defined proteins are detected that are solely 
expressed in prostatic neoplastic epithelium. Of fundamental 
interest may be the McAb's recognizing PC cells which show 
cross reactivity with other malignant neoplasms or cell lines 
of different origin (see Table 4). Further research is needed 
to investigate whether these markers are just associated with 
less differentiated cells or whether they are linked to 
processes as malignant or premalignant transformation. 
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9.2. Prostatic-Tissue specific Antigens CPTSA) 
The group of prostatic tissue-specific antigens encloses 
these markers which are exclusively expressed in prostatic 
tissue. An important use of these markers is the 
identification of the prostatic origin of metastatic lesions 
of PC by immunohistochemical techniques. Furthermore these 
markers are of fundamental interest to gain insight in the 
tissue-specific processes in the prostatic gland. In contrast 
to TSAs and TAAs, the biochemical properties of the tissue-
specific markers are much more explored. The major 
representative markers within this group are secreted by the 
prostatic columnar epithelial cells and are under physio-
logical conditions present in the prostatic fluid. Moreover 
under several pathological conditions they can be demonstrated 
in the blood circulation and are useful tools in the 
monitoring of patients with PC (see I-8). Among the PTSAs 
prostate-specific acid phosphatase (PAP or PSAP) and prostate-
specific antigen (PA or PSA) have been most intensively 
investigated. Apart from these PTSAs with secretory capacity 
several less characterized tissue-specific markers for the 
prostatic gland have been developed which are largely not 
secreted and therefore are only demonstrated within the 
prostatic cells. A number of these have been isolated from PC 
cell lines (see also I-10). 
In this brief review special attention is given to the 
immunohistochemical detection of these markers and the 
potential prognostic value related to tumor growth 
characteristics when fluctuations (i.e. lowering of the tissue 
concentration) occur during the process of malignant 
transformation. 
9.2.1.Prostatic Acid Phosphatase (PAP or PSAP) 
Enzymatic and biochemical features 
Acid phosphatases (orthophosphoric monoester phosphohydro-
lase) designate, by definition, a group of enzymes that 
hydrolyze phosphate esters under acidic conditions to yield 
inorganic phosphate (Heller, 1987). Initially it was thought 
that multiple molecular forms with differing electrophoretic 
mobilities were the result of variations in sialic acid 
residues and carbohydrate content (Lad et al., 1984). 
However, presumably, the heterogeneity of acid phosphatases is 
even more complex than can be explained by differences in 
posttranslational modification (Lin et al., 1983). At least 7 
isoenzymes (I, IIA, IIB, III, IV, VA, and VB) are 
distinguished. 
The acid phosphatase secreted by the prostatic gland is 
considered as prostate-specific (PAP or PSAP; predominantly 
consisting of isoenzyme IIA, although isoenzyme IV might also 
be found) (Lam et al., 1979; Vihko, 1979; McTigue et al., 
1982; Ladet al., 1984; Lin et al., 1983; Dang et al., 1986). 
Partial antigenic similarities of PAP exist with other acid 
phosphatases that originate from the pancreas, spleen, kidney, 
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Table 4. I:fajor characteristics of antibodies against presumed TAA arrl 'ISA 
m prostate cancer 
---------~~. ·--------
Innnunization 
Antibodies raised against 
single (IXJ-145) arrl mixtures 
of seveial proStatic cancer 
cell lines (IXJ-145; PC-3; 1013L). 
Extracts arrl viable cells of 
the PC-3 cell line were used. 
IXJ-145 prostatic carcinoma. 
An eaual mixture of PC-3 1 
IXJ-1451 arrl INcaF. 
Fresh prostatic cancer cells. 
PC-3 cell line (a-Pro 3 1 
a-Pro 5). 
Human 1 }'ltli)hcx;:ytes from a 
~ional - <training 1 Vll1Ph node 
from a . patient with- t'C were 
fused with a murine myeloma cell 
line. 
38 
McAb ( 1l11llllU1CXJlobulin class) 
Eiqht McAb 's: 
Pr:Rl6 ~IgG2a) PrlUO figM) 
Prl22 ~1~1 1 Pr011 ~ gG1); PrHk ( 2a 1 Pl:Q12 IQG2aJ 1 J?rl124 ( gG1 1 anQ Pr 1il 
(IgG2a). 
PrS5 (I~1) ; PrE3 (IgM) ; 
PrD8 (IgM). 
D83. 21 (IgM) • 
a-Pro 13. 
P25.48 (IgG3); P25.91 (IgG2a) 
a-Pro 3 
a-Pro 5 
a-Pro 1 
a-Pro 2 
MHG-7 {IgM) (htnnan McAb). 
-----------------------------------------------
Cllaracteristics 
P:rHk. defined a 115 kD antigen; '!he ag's 
res::ognized py PrK16 and PrN10 are 
un.knOwn. McAb PrN10 is reactive on fixed 
tissue; the antigen detected py this McAb 
is probably shed in the ~ medium of 
PC-3 cultures. PrQ12 defined an antigen 
of 100kD; PrL22 and PrOll were bOth 
reactive with a 160 kD antigen. '!he 
antigens defined bv Pl:M24 and P:tP14 are 
not fully characl:erized. Some of the 
antigens are shared with cell lines of 
other human cancer types. 
PrE3 and PrD8 are directed against the 
same ag (gly<;:oprotein with MW 115 kD); 
cross reactiv1ty with red blood cells. 
PrS5 directed against 90 kD ag. Cross 
reactivity witfi breast carcinoma cell 
lines. 
Reactivity limited to prostatic carcinoma 
and bladder carcinoma cell lines. '!he ag 
is a membrane glycoprotein consisting of 
2 chains of of 1BO and 110 kD. Cross 
reactivity was reported for CMV 
transfo:r:mErl fibroblasts. 
Preferential bi.ndinq to the ductal 
epithelium of prostatic tissue. MW under 
reducing conditions 40 kD. racking secre-
tory activity. Most prevalent cross reac-
tivlty with olood vessel endothelium. 
No cross-reactivicy with benign prostatic 
tissue. In high grade tumor lesions 
increased he~enous ilmnunoreactivity. 
Restricted pattern of reactivity in non 
prostatic tissue (no tissue-5pe9ificity). 
Antigen not preserved in forfnalin-fixoo, 
wraffirl--embedded tissues. Both McAb's 
airected against the same antigen. 
Antigen not detectable in PC-3; DJ-145 
and INcaF. 
a-Pro 3 and a-Pro 5 re<;:cx;lnize the same ag 
(MW 54 kD) but react witfi different epi-
topes. Cross reactivity with Bm, nonnal 
prostate and PC tissue. At least McAb a-
Pro 3 and and a-Pro 5 are considered as 
TAA. a-Pro 3 is reactive with PC-3 cells 
but not with 00-145 cells and reacts more 
strongly with PC than with B:m. 
'!he ag is present on INcaF and PC-3 
cells; but is lackincr in DJ-145 cells. 
Cross reactivity with colon and lung 
carcinoma cell lmes (TSA) . 
References 
Lindgren et al. (1985) 
Lindgren et al. (1985) 
Starling et al. (1982; 
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Wright et al. (1983)~ 
campbell et al. (19~b) 
Webb et al. (1984) 
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I.owe et al. (1984) 
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placenta, and neutrophil and eosinophil granulocytes (Vihko et 
al., 1988; Shaw et al., 1981; Yam et al., 1981a; Li et al., 
1980; Choe et al., 1982; Bentz et al., 1982; Warhol et al., 
1985). The existence of a natural substrate with an unique 
specificity for the PAP isoenzyme is still a matter of dispute 
(Serrano et al., 1976; Lee et al., 1982). Hence, the precise 
physiological role of PAP remains unclear. 
PAP is a secretory glycoprotein with a molecular weight of 
110 kD. It is composed of 2 (identical) subunits each of 48-
54 kD. Recently eDNA coding for human PAP was isolated (Yeh et 
al., 1987; Vihko et al., 1988). The genetic information codes 
for a polypeptide of 354 amino acids. 
There are still conflicting data about the hormonal 
regulation of the biosynthesis of PAP in the prostatic gland 
(Pontes et al., 1981; Bolton et al., 1981; Aumueller et al., 
1983a; Dube et al., 1984; Warhol et al., 1985; Vihko et al., 
1988). Alterations in tissue PAP concentrations under 
hormonal therapy have also been ascribed to a secondary 
response to a more general hormonal (growth and metabolism 
stimulating) effect on the cell. Steenbrugge van et al. 
(1983) reported that the PAP tissue concentration in the 
prostatic cancer cell line PC-82 (see I-10.2.1) was not 
controlled by androgens. However, changes in immunohistochemi-
cal staining activity for PAP have been described in patients 
following diethylstilbestrol therapy (Vernon et al., 1983ab; 
Grignon et al., 1985). 
Initially, detection of PAP was only possible by enzymatic 
assays. Inconsistent results were often encountered and 
attributed to the different substrates used (Serrano et al., 
1976; Vries de, 1987). Later on, more reliable enzymatic 
assays enabled to measure the presumed prostate-specific 
fraction based on the inhibitory effect of L(+) tartrate on 
the enzymatic activity of PAP (Jacobsson, 1960). 
Recent knowledge of the immunogenic properties of PAP has 
resulted in the production of numerous antibodies (Choe et 
al., 1982). For preparation of antibodies PAP can be isolated 
from seminal plasma (Vries de et al., 1979) or extracted from 
prostatic cell lysates (BPH andjor PC) (Taga et al., 1983). 
The secretory acid phosphatase (PAP) is predominantly present 
in seminal plasma, whereas the cellular extract (prostatic 
homogenate) also contains lysosomal and microsomal acid 
phosphatases (Aumueller et al., 1983ab; Vries de, et al., 
1986). Therefore, the source of the antigen and degree of 
purification determine the specificity of the prepared (poly-
clonal) antibodies. The antibodies have become an essential 
tool for detection and quantification of PAP in serum, in 
prostatic fluid, in tissue sections (immunocytochemistry) and 
in cell extracts. Compared with enzymatic assays the sensiti-
vity of the immunological assays is considerably higher (Vihko 
et al., 1985}. Both polyclonal and monoclonal antibodies 
recognizing PAP have become available (Joebsis et al., 1978; 
Joebsis et al., 1981; Nadji et al., 1982; Foti et al., 1975, 
Vihko et al., 1978; Vihko et al., 1980; Lee et al., 1978; Lee 
et al., 1980; Choe et al., 1978; Yam et al., 1981b; Sinha et 
al., 1988; Shevchuk et al., 1983; Dang et al., 1986; Shaw et 
al., 1981; Lam et al., 1979; Gallee et al., 1986; Teillac et 
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al., 1987; Kuciel et al., 1988). Prostatic tissue as well as 
prostatic fluid have been used for preparation of antibodies. 
In our attempt to generate tumor-specific antibodies against 
the prostatic cancer cell line PC-82, we isolated several 
antibodies directed against PAP. After further purification 
of PAP using the McAb 8F9 we prepared a monospecific 
polyclonal antiserum that could be applied on formalin-fixed 
tissue (Chapter V). 
The first observation of an elevated serum acid 
phosphatase level in metastasized PC was described by Gutman 
et al. in 1936. For this reason PAP can be considered as the 
first tumor marker ever found. Details regarding the value of 
PAP for the purpose of monitoring patients with PC are 
outlined in I-8. The use of antibodies recognizing PAP in 
tissue sections (immunocytochemistry) will be discussed here 
in more detail. 
Detection of PAP in tissue sections 
Before antibodies against PAP were available, the 
enzymatic activity of PAP has been used for the detection of 
PAP in tissue-sections. However, since most of the enzymatic 
activity of PAP disappears during tissue processing (ethanol 
inhibits irreversibly the enzymatic activity; formaline seems 
not to interfere with enzymatic activity) assays were only 
successful on fresh-frozen or formalin-fixed cryostat sections 
(Gomori, 1950). 
When antibodies became available immunohistochemical 
surveys could be performed for detection of PAP. Several 
antibodies were applicable on formalin-fixed and paraffin-
embedded tissue sections and were even able to detect the 
antigen after previous decalcifying procedures (Joebsis et 
al., 1978; Henwood et al., 1982). Immunohistochemically, PAP 
has been demonstrated in normal prostatic glands, in BPH, in 
primary prostatic tumors and in metastases of PC (Lippert et 
al., 1982; Nadji et al., 1982 and 1983). Equivocal data are 
available regarding the presence of PAP in the epithelial 
lining of the seminal vesicle. This observation, and 
sporadically described cross-reactivity with other tissues, 
may be largely dependent on the (lack of) specificity of the 
antibodies used. In the non-neoplastic tissues PAP seems only 
present in the inner columnar (secretory) cells of normal and 
hyperplastic (BPH) prostatic glands (in the cytoplasm and on 
the cell surface) and is often detected within the glandular 
lumina. In fact, the majority of PAP is being located 
extracellularly (Bolton et al., 1981). PAP has not been 
demonstrated in the cytoplasm of the basal cells. Immune 
electron microscopy studies revealed the presence of PAP in 
lysosomes and secretory vesicles (Warhol et al., 1985; 
Zondervan et al., 1986). 
In cancerous tissue PAP can be identified within the 
cytoplasm of carcinoma cells. Demonstration of PTSAs such as 
PAP has become a valuable aid in the differentiation of 
primary transitional cell carcinoma from prostatic cancers and 
can be of great help in the elucidation of the initially 
unknown primary tumor in patients with metastasized malignant 
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disease. Most investigations indicate that the 
immunohistochemical staining intensity in carcinoma cells is 
weaker than in non-tumorous epithelium. This observation 
agrees with biochemical studies measuring the concentration of 
PAP (immunologically and enzymatically) in cancerous and non-
cancerous prostatic tissue (Loor et al., 1981; Copland et al., 
1983; Pretlow et al., 1985). However, the precise 
relationship between the amount of PAP detectable in PC and 
tumor differentiation status remains controversial (Joebsis et 
al., 1981; Ito et al., 1986). Pretlow et a1. (1985) reported 
that the enzymatic activity of PAP extracted from primary 
cancerous tissue was reduced compared with BPH but that the 
decrease in enzymatic activity was not significantly related 
to Gleason grade. A similar absence of a relationship between 
Gleason tumor grade and PAP assessed by an immunohistochemical 
assay was recently described by Hammond et al. (1989). In con-
trast to these findings, Sinha et al. (1988} reported a 
progressive decline in the PAP staining in moderately and 
poorly differentiated tumors. Earlier, Bates et al.(1982) and 
Shevchuk et al.(1983) reached a similar conclusion. Further 
immunohistochemical surveys to gain more insight in the 
interrelationship between PAP expression and tumor differ-
entiation have been carried out by Pontes et al. (1981), 
Bentz et al. (1982), Yam et al. (1983), and Gallee et al. 
(1989c). To circumvent problems associated with histological 
grading (see Chapter I-5.3 and Chapters II and III) we 
investigated the correlation between staining intensities of 
PAP and PA (see I-9.2.1 and I-9.2.2) and architectural growth 
patterns of PC within prostatectomy specimens. Using well 
characterized polyclonal antibodies against PAP we found no 
consistent relationship with growth pattern of PC. Though the 
immunohistochemically assessed concentration of PAP in PC was 
lowered compared to BPH areas, PAP was demonstrated more 
readily in neoplastic tissue than PA. 
Apart from simple alterations in staining intensities in 
PC compared with non-malignant prostatic tissue, an increase 
in the variability of the staining intensity was detected in 
less differentiated tumors (Bates et al., 1982; Nadji et al., 
1982). Irrespective the growth characteristics of PC, Hammond 
et al. (1989) found a significant correlation between 
survival and the immunohistochemical demonstration (subjective 
grading of intensity) of PAP. 
Data concerning the sensitivity of antibodies against PAP 
for immunohistochemical detection of PC cells are conflicting 
(Lippert et al., 1982). In some cases well defined polyclonal 
antibodies are to prefere above monoclonals (Shevchuk et al., 
1983). On the other hand, Choe et al. (1982) developed McAb's 
that were exclusively reactive with antigenic determinants of 
PAP that were not shared with determinants on lysosomal acid 
phosphatases. Tissue processing techniques may interfere with 
the detectability of PAP since antigenic sites might be 
destroyed by tissue handling. 
Contrary to the afore mentioned subjects, consensus exists 
about the finding, that there is no consistent relationship 
between serum PAP levels and tissue concentration of PAP 
(Shevchuk et al., 1983). 
42 
PAP expression is retained in a number 
prostatic in vivo and in vitro cancer cell lines. 
lines are therefore convincingly established as 
from prostatic tissue. Information refering the 
which have maintained PAP expression is presented 
Table 7. 
9.2.2.Prostate-specific Antigen 
Enzymatic and biochemical features. 
of different 
These cell 
originating 
cell lines 
in I-10 and 
In 1979 Wang and coworkers discovered a new highly speci-
fic prostatic antigen {PSA or PA). This protein was isolated 
from prostatic epithelium and is clearly distinct from ?AP. 
It is a single chain prostate tissue-specific glycoprotein 
(Watt et al., 1986) with a molecular weight of 34 kD. The 
carbohydrate configuration and amino acid composition have 
been determined (Watt et al., 1986). Similar to PAP, PAis 
secreted into the prostatic fluid in high concentration (Ban 
et al., 1984) and can also be demonstrated in the ur~ne 
{Tremblay et al., 1987). In addition, in advanced stages of 
PC, PA can be found in the serum of patients and it has been 
used intensively for monitoring tumor behavior and effects of 
therapeutic intervention (Papsidero et al., 1980; Stamey et 
al., 1987). For detailed information concerning this 
particular application of PA see I-8. Compared with PAP, 
specificity of PA for prostatic epithelium is even higher; it 
could not be isolated from any other organ nor was its 
presence reported in female serum (Chu et al., 1986). Under 
physiological conditions only small amounts of PA can be found 
in the male serum. 
PA is a serine protease belonging to the family of 
kallikrein and kallikrein-like proteins (Akiyama et al., 
1987). The homology with the human glandular kallikrein hGK-1 
is 80% {Schedlich et al., 1987) and that with human pancreatic 
renal kallikrein 62% (Evans et al., 1988). The PA substrate 
is probably a high molecular weight seminal vesicle protein 
known as seminogelin, which is secreted by the seminal 
vesicles and is responsible for the gel-like consistency of 
the semen. Recently, the molecular cloning of human PA cDNAs 
has been described (Lundwall et al., 1987; Riegman et al., 
1988; Schulz et al., 1988). The protein encoded by the cDNAs 
consists of 237 amino acids. It was proven that the PA gene 
and the human glandular kallikreine-1 {hGK-1) gene are closely 
linked and are both located on chromosome 19 (Riegman et al., 
1989a). The human renal pancreatic kallikrein gene has also 
been mapped on chromosome 19 (Evans et al., 1988). Expression 
of the hGK-1 gene, like that of PA, seems also to be 
restricted to the prostate (Chapdelaine et al., 1988). 
Various different antibodies against PA have been 
described {Frankel et al., 1982; Papsidero et al., 1983; Ford 
et al., 1985; Gallee et al., 1986; Chu et al., 1989; Gallee et 
al., 1989c). Major characteristics of the antibodies are 
summarized in Table 5. Using purified PA as immunogen we 
isolated McAb's directed against at least three different 
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Table 5. Major characteristics of antibodies reported in literature 
recognizing prostate-specific antigen (PA or PSA) . 
Irmnunization 
benign hypertrophic prostatic tissue 
prostatic tissue or seminal plasma 
prostatic tissue 
purified PA 
human prostatic cancer cell line PC-82 
purified PA from BFH 
Olaracteristics 
1F3 ; 2G7 ; 1C5 (all of the 
Ig91 subclass) the three 
MCAb' s define two unique 
detenninants on PA 
McAb F5 (IgG1; K) * 
IqG preP?;l:9.tion of poly-
clonal rabbit antiserum; ag 
was demonstrated in INcaP 
and PC-3 cell lines 
Mc.Ab's: lAS, 2A4, 3F1, F5*( 
3Al2 (all IgG1 sub-Class1 directed against two dis-
tinct ~tially related 
antigenic domains 
Mc.Ab Is ER-Pr 1 and ER-Pr 2 (both IqG1 subclass) • 
Probably airected against 
the same antigenic domain 
Mc.Ab's: ER-Pr 8~ ER-Pr 12, 
ER-Pr 27 (all IQG1 ~ 
class). Directe::l against 
byo antigenic domains dis-
tlllct from ER-Pr 1, 2.; and 
rabbit polyclonal antiserum 
* '!his is the same McAb; the F5 antibody was initially described by 
Papsidero in 1983. 
epitopes of PA. All of these could be visualized on formalin-
fixed prostatic tissue. Of potential interest was the 
observation of Chu et al. (1984) who found in patients with 
advanced stages of PC an elevated level of a serum FA-binding 
immunoglobulin. The precise role of this antibody as an auto-
antibody or as an anti-tumor antibody as a result of patients' 
immune response is not understood. 
Precise insight in the biosynthesis and mechanism of PA 
secretion are still lacking. Moreover, the exact role of 
androgens (T and DHT) in these processes remains to be 
elucidated. However, hormonal manipulation (DES therapy in 
patients with PC) seems to interfere with the 
immunohistochemical detectability of PA (Grignon et al., 
1985). Similarly, in the LNCaP prostate cell line PA 
expression is androgen-regulated (Trapman et al., 1988b). 
Detection of PA in tissue sections 
The availability of 
chemical detection of PA 
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antibodies enabled the immunohisto-
in tissue sections. Many of the 
Application of antibodies 
radioimmunoassay 
~emistl:y (fo:t11.'alin 
fixation resistent} 
innnunocytohistcx:::hemistry 
~emistcy; demonstration of PA in 
prostatlC cell lines 
radio immunoassay and inununocytochemistry 
imnrunocytoc:hemistry 
inununocytoc:hemistry and affinity 
chromatography 
References 
Frankel et al. (1982) 
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Gallee et al. (1989c) 
antibodies generated can be applied on formalin-fixed and 
paraffin-embedded tissue samples (Sinha et al., 1986; Gallee 
et al., 1989c). At light-microscopic level PAis localized in 
the cytoplasm of the inner columnar cells and on the cell 
membrane, with slightly greater reactivity in the paranuclear 
area on the luminal sites of the cells. Immunoreactive PA is 
also found within the lumina of the normal and hyperplastic 
prostatic glands. There still remains doubt concerning the 
presence of PA in the cytoplasm of the basal cells. 
Immunoelectron microscopic studies provided data that PA is 
synthesized at the rough endoplasmic reticulum, stored in 
secretory vesicles and vacuoles and released into the 
glandular lumina by exocytosis (Warhol et al., 1985; Zondervan 
et al., 1986). 
The majority of immunohistochemical studies provides 
evidence that the PA concentration is lowered in PC (Purnell 
et al., 1984). However, the precise relationship between PA 
expression and histological grade or tumor differentiation is 
still a controversial topic (Papsidero et al., 1983; Sinha et 
al., 1986). Controversy is partly caused by the absence of a 
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generally accepted histological grading system that is 
commonly used by pathologists and to which immunohistochemical 
data can be compared. Irrespective of the histological grade 
of the tumor Hammond et al.(1989) did not find a correlation 
between subjectively graded immunocytoreactive intensity of PA 
and survival. Contrary to this observation, it had been shown 
by several investigators that at least part of high grade 
prostatic cancers (poorly differentiated) do not stain for PA 
(Stein et al., 1982; Ellis et al., 1984; Feiner et al., 1986; 
Svanholm, 1986; Keillor et al., 1987; this thesis). These 
observations agree also with the finding of Epstein et al. 
(1984a) who reported that in stage A2 prostatic lesions an 
increase in immunostaining variability and a lowered immuno-
detectability for PA were significantly related with a 
subsequent progressive course of this initial incidental 
lesion. 
In this thesis it was attempted to correlate the 
immunohistochemical expression of PA recognized by different 
antibodies with the histological growth pattern of PC. 
Results presented in Chapter V indicate a correlation of 
immunohistochemical detection of PA and architectural growth 
pattern of PC. 
Within several established PC cell lines PA expression is 
retained (Trapman et al., 1988b; Riegman et al., 1988; this 
thesis). However, the concentration of PA detected in these 
cell lines may be lower than those found in prostatic 
specimens directly obtained from patients. 
As was stated previously for PAP, no consensus has been 
reached concerning the existence of a relationship between 
serum PA levels and tissue PA concentration in patients with 
PC. 
9.2.3.Comparison of immunohistochemical features of PAP and PA 
several studies that compare the immunohistochemical 
characteristics of PA and PAP have been published (Epstein et 
al., 1984a; Allhoff et al., 1983; Bentz et al., 1984; Shah et 
al., 1985; Svanholm, 1986; Keillor et al., 1987; this thesis). 
A simple comparison of those studies is hindered by the fact 
that different antibodies have been used. It is generally 
accepted that the specificity of PA is higher than that of 
PAP. However, concerning the question which of both markers 
displays the highest sensitivity, conflicting data have been 
presented (Shah et al., 1985; Keillor et al., 1987). In 
general the sensitivity of well-characterized polyclonal 
antibodies is higher than that of monoclonal antibodies. 
However, when several McAb's defining different predominant 
antigenic domains are mixed the sensitivity reached by McAb's 
may become the same as for (monospecific) polyclonal antisera. 
Stein et al. (1984) report in a small series a sensitivity of 
PAP to stain primary PC of 81% whereas that of PA was counted 
for 75%. Similar figures reported by Bentz et al. (1984) were 
92% and maximally 89% respectively for PAP and PA. On the 
other hand Shah et al. (1985) and Svanholm et al. (1986 and 
1988) reported a slightly higher sensitivity for PA (94%) 
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compared with PAP (90%) when commercial immunoperoxidase kits 
were used. Similar results were described by Ellis et al. 
(1984). Our results presented in Chapter V indicate a 
slightly larger sensitivity for PAP to label PC cells whereas 
PA expression in tumors is more related with differentiation 
status. Some of the monoclonal antibodies seem to be as good 
as a polyclonal antiserum. 
Finally one has to realize that though no exact 
relationship of serum concentration of the two markers with 
histological differentiation of the tumor is known as yet and 
no generally accepted consensus exists concerning the exact 
sensitivity of these markers, the absence of PAP and PA in at 
least poorly differentiated cancerous tissue does not 
unequivocally eliminate the possibility of PC. The use of 
both markers in immunocytochemistry increases considerably the 
likelihood of correctly identifying PC. 
9.2.4.Therapy-induced alterations in immunohistochemical 
expression of PA and PAP 
Treatment induced effects on the immunohistochemical 
staining of PAP and PA in PC tissue has been sporadically 
described in literature. Hormonal treatment (androgen depriva-
tion or estrogen therapy) reduces the intensity of immune-
staining of PAP (Joebsis et al.,1983) and PSA (diethylstil-
bestrol; treatment interval 2-63 months; Grignon et al., 
1985). Other investigators have disagreed with this 
observation and stated that especially the immunohistochemical 
detection of PAP, but to lesser extent also that of PA, were 
maintained even after different therapeutic regimens despite 
therapy-induced morphological changes (Vernon et al., 1983ab; 
Mahan et al., 1980). PAP staining remained present in areas 
of squamous differentiation in PC (Accetta et al., 1982). 
After radiotherapy Mahan et al. (1980) observed the immunohis-
tochemical retention of PAP in prostate biopsy samples. 
9.2.5.8-microseminoprotein (8-MSP) 
fi-microseminoprotein (fi-MSP) is also known as fi-inhibin 
and as PSP94 (Prostatic Secretory Protein of 94 amino acids; 
Seidah et al., 1984; Dube et al., 1987ab). The precise 
function of fi-MSP is not known as yet. Together with PA and 
PAP, fi-seminoprotein belongs to the group of three predominant 
proteins secreted by the normal prostatic gland (Tremblay et 
al., 1987; Lilja et al., 1988). Moreover they all are 
considered as PTSAs. When PC has developed, fi-MSP can be 
demonstrated in the serum of patients and therefore it has 
also been used for monitoring. In addition, the excretion of 
fi-MSP may be increased in the urine of men with PC (Tremblay 
et al., 1987). 
The first report concerning the immunohistochemical tissue 
distribution of fi-MSP in hyperplastic and cancerous prostatic 
tissue was presented by Okabe et al. (1983). Abrahamsson et 
al. (1988) reported an increase in the variability of the 
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immunohistochemical staining intensity for fi-MSP in the 
moderately and poorly differentiated PC's. Though an uniform 
relationship with differentiation status could not be proven 
by these investigators, a decreased immunoreactivity parallel 
to the degree of differentiation was reported by others (Dube 
et al., 1987a; Doctor et al., 1986). For as yet no 
information is available refering a possible androgen-
regulated expression and secretion of fi-MSP. 
9.2.6.0ther prostatic tissue-specific markers 
In addition to the most intensively investigated prostatic 
tissue-specific markers discussed above, several authors 
claimed to have generated antibodies directed against new 
PTSAs distinct from PAP, PA and fi-MSP. A brief summary of 
these markers is outlined in Table 6. Most of these markers 
have initially been detected in prostatic cancer cell lines 
(PC-3; DU-145; LNCaP) and showed afterwards cross-reactivity 
with non-malignant prostatic tissue. Clarke et al. (1982), 
Frankel et al. (1982ab) and Starling et al. (1986) used BPH 
specimens to produce antibodies against new PTSAs. Some of 
these appeared later on also present in prostatic cancer cell 
lines. Of potential value are the markers isolated recently 
by Horoszewicz et al. (1987) out of the cell line LNCaP (see 
I-10.2). These markers could also be demonstrated in the serum 
of patients with PC. However, further characterization of all 
these new PTSAs is necessary to ascertain their prostatic 
tissue specificity and to compare their sensitivity with that 
of PA, PAP and fi-MSP. 
9.3. Markers related to cell differentiation status 
Antigens related to cell differentiation status do not 
necessarily have to possess tissue (prostate) specificity. 
Antigens that belong to this group can be absent or 
structurally altered in tumor cells, whereas their expression 
is consistent in prostatic epithelial cells of the adult non-
neoplastic gland. During the early development of the 
prostatic gland (embryogenesis) these antigens can be absent 
or present. Prostatic markers that have been associated with 
cell differentiation are: 
- Prostate-specific antigen and prostatic acid phosphatase: 
Since the tissue concentration of PAP and PA is lowered in 
PC compared to benign prostatic tissue, PAP and PA are 
linked with prostatic epithelial cell differentiation. It 
has been demonstrated that immunoreactivity of secretory 
prostatic acid phosphatase (PAP) was not present in fetal 
and infantile glands, but developed progressively in puberal 
specimens with increasing age (Aumueller et al., 1983a). 
More details refering PAP and PA are presented in I-9.2. 
-Blood group-related antigens (BGA; BgRAg): Posttranslational 
glycosylation of especially membrane and secreted proteins 
frequently occurs. The carbohydrate make up determines at 
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least partially the antigenicity of glycoproteins. Among 
the heavily glycosylated cell membrane-bound antigens are 
the blood group-related markers (BGA). Within this group 
the isoantigens of the ABO(H) blood group system have Deen 
most thoroughly investigated. Under non-pathological 
conditions the tissue-bound blood group and the blood group 
antigen recognized on red blood cells are identical. 
However, when malignant transformation occurs the tissue-
bound blood group type may differ from the normal patients• 
blood group. These structural alterations of the BGAs are 
ascribed to changes of the processes involved in 
glycosylation linked to impaired differentiation of cancer 
cells (Hakomori, 1985; Coon et al., 1986). BGAs differences 
associated with malignant transformation have initially been 
described in transitional cell cancers of the urogenital 
tract (Cooper et al., 1982; Flanigan et al., 1983). In non-
invasive bladder cancers conversion of tissue bound blood 
group A or B into blood group O(H) is considered to be 
associated with prospective agressiveness of the lesion and 
precedes invasive growth (Finan et al., 1982; summers et 
al., 1983; Coon et al., 1985; Cuadrado et al., 1986). 
Availability of antisera and McAb's recognizing specific A, 
B, and O(H) carbohydrate configurations has facilitated the 
research in tumor-associated glycosylation abnormalities and 
has replaced the use of the specific red cell adherence test 
and the application of lectins for this particular purpose 
(Voak et al., 1980; Sacks et al., 1981; Stein et al., 1981; 
Cooper et al., 1982; Ghazizadeh et al., 1983; Ernst et al., 
1984; Gooi et al., 1985). Several types of cancer have been 
studied for the immunocytochemical expression of BGAs 
(Vowden et al., 1986ab; Compton et al., 1987). Recently, 
interest was also focused on PC (Walker et al., 1984; Vowden 
et al., 1986c; Chastonay et al., 1986; Abel et al., 1987; 
Abel et al., 1989). Contrary to the patients• blood group, 
expression of BGA A and B was rarely found in cancerous 
tissue. Components of BGAs in prostatic tissue (epithelial 
cells) might be lipid-based or present as glycoproteins 
(Abel et al., 1989). Therefore, immunohistochemical studies 
related to this subject in prostatic tissue are recommended 
to be performed on fresh-frozen specimens to achieve 
reliable results (Abel et al., 1987). The precise meaning 
of this altered BGA expression in PC and especially its 
relationship with biological course warrants further 
research. 
- cytoskeleton proteins: In general, benign and malignant 
epithelial cells are characterized by the expression of 
cytoskeleton proteins that belong to the cytokeratin family 
(Cooper et al., 1985). The cytokeratin family is reckoned 
to one of the five classes of intermediate filaments. Apart 
from cytokeratins, vimentin, glial fibrillary acidic protein 
(GFAP), desmin and neurofilaments are also regarded as 
intermediate filament proteins or cytoskeleton proteins. 
Based on molecular weight and biochemical analyses at least 
19 cytokeratins have been documented (Feitz et al., 1986). 
McAb's against nearly all these cytoskeleton proteins are 
available (Muijen et al., 1984). Combined expression of 
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Table 6. Major characteristics of Prostatic Tissue-Specific Antigens (PISA) other than PAP and PA. 
----------------------------------------------------------------
I:mmunization McAb's ( llllllllll'lOglobulin class) 
INcaF cells were used as :imnunogen. 7Ell-c5 figG1); 
9H10-A4 ( gG1) 
'!he PC-3 cell line was used as :imnunogen. 
'!he ag is secreted in the seminal pa§ll'a and 
urine from healthy individuals. It can 
also be demonstratea. in the growth medimn 
of PC-3 cultures. :KR-P8 is reactive on 
fonnalin-fixed. tissue. 
:KR-P8 
Membrane preparations derived from 'IUR 
9J?E!Cllnens or BFH and PC were used as 
:imnunogen. Reactive with both BFH and PC. 
'IURP-27 (IgG3) 
Reactive with PC-3 cells; MCAb 24 reacts 
nore strongly to nonnal p:r;ostate than to 
PC. Membrane enriched fractions of hmnan 
BFH were used as :imnunogen. 
'!he PC-3 cell line was used as an inununo-
gen. 
F77-129 MCAb 
Hurna.n BFH tissue extracts were used as 
:imnunogen. 
several MCAb' s 
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clusters of these keratin filaments are specific for 
particular differentiation routes within epithelial cells 
(squamous-, transitional cell- (stratified epithelia), and 
adeno- (or glandular-)differentiation; Ramaekers et al., 
1983). Hence, in the postpubertal prostatic acinus keratins 
from human stratum corneum, including cytokeratin 5, are 
exclusively demonstrable in the basal cells, whereas 
keratins 8 and 18 are only present in the inner secretory 
epithelium (Feitz et al., 1986; Wernert et al., 1987; Nagle 
et al., 1987). Keratins 7 (only focally present) and 19 are 
shared by both cell types (Wernert et al., 1987). The 
keratins 7, 8, 18 and 19 are regarded as typical keratins 
for the so-called simple epithelia. Differences in keratin 
profiles between basal and cylindrical cells of the 
prostatic acinus were also demonstrated by Molinolo et 
al.(1985), and Brawer et al.(1985). Of interest is the 
partial co-expression of keratins and vimentins in the 
secretory epithelium which was reported by Wernert et al. 
(1987) and was also found within the most malignant and 
highly metastatic subline of the Dunning rat prostatic tumor 
model system (Feitz et al., 1986; see also I-12). 
Hormonally induced metaplasia and malignant transformation 
Cllaracteristics 
Antigen is detectable in the sennn of 
wtients with PC. No cross reactivity 
with PC-3 or IlJ-145 cells. '!he 9ffiO.A4 
defined ag is exclusively present on 
INcaF cells ('ISA?) • 
'!he ag (P8) is identified on the cell 
surface of 90% of PC-3 cells and 67% of 
IlJ-145 cells. Cross reactivity with 
benign protatic tissue. m ~e of the 
ag 48-75 kD. '!he ag is heavily 
glycosylated. 
'!he ag is not present in the cell lines 
IlJ-145, PC-3, and INcaF. 
Antigens recognized by these antibodies 
are present on mal.ignant and non-
mali9J'l9Ilt _prostatic tissue as well as on 
a lnniteer number of other malignant 
tissues. 
'!he ag is poorly characterized but is 
believEd to I:le a product of differ-
entiated prostatic acinar cells. The ag 
is suggested to be present in the 
prostat1c fluid. 
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are associated with a different immunophenotypic keratin 
profile (Grignon et al., 1985). In PC diminished differenti-
ation is accompanied with absence of expression of keratins 
from the stratum corneum. All other keratins are found in 
variable extension independent of the differentiation status 
of the tumor. 
9.4. The Androgen Receptor CAR) 
It is well established that prostate growth and differ-
entiation are dependent on androgens (Cunha et al., 1987). In 
the initial phase most PC's also are androgen responsive. 
Therefore, a benificial effect of treatment with substances 
that block androgen products or inhibit further steps in 
androgen action is to be expected. Androgens evoke their 
effects by an interaction with the androgen receptor (AR). 
Interaction of androgens with the AR results into an activated 
AR complex that is presumed to be able to modulate specific 
expression of target genes. In vivo DHT has the highest 
affinity for the AR. Until recently it was only possible to 
detect the AR in tissue using a ligand binding assay (Bowman 
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et al., 1986). 3H-Methyltrienolone (R1881) is mostly used for 
this purpose. Using this technique the AR was found to be 
within the nucleus of prostatic cells. Presumably its 
presence is largely restricted to the epithelial cells of the 
prostatic acinus (Bashirelahi et al., 1980; Peters et al., 
1987). As the epithelium/stroma ratio is higher in the 
peripheral zones compared with the central zone of the 
prostatic gland, only a low AR concentration was found in the 
periurethral area of the non-diseased gland (Bowman et al., 
1986). 
Recently, the primary structure of the human AR as deduced 
from the eDNA has been elucidated (Trapman et al., 1988a; Tan 
et al., 1988; Chang et al., 1988; Lubahn et al., 1988ab; Faber 
et al., 1989). The primary structure of the human AR is 
closely related to that of other steroid receptors such as the 
progesterone receptor, the glucocorticoid receptor, the 
mineralocorticoid receptor, and the estrogen receptor (Faber 
et al., 1989). The amino acid composition of the human AR 
shows the highest homology with the human progesterone 
receptor. This is particularly true for that part of the 
receptor which is believed to interact directly with specific 
sequences in the promoter/enhancer region of target genes (DNA 
binding domain). Immunocytochemical staining using polyclonal 
antibodies localized the AR to epithelial cell nuclei in the 
rat ventral and human prostate (Tan et al., 1988; Lubahn et 
al., 1988b; Laar van et al., 1989 in press). Remarkably, 
staining seemed exclusively present in the nuclei of the inner 
cylindric epithelial cells (see Figure 1). Sporadically, a 
nucleus of the stromal cells showed immunoreactivity. 
Availability of series of antibodies should be effective in 
further analysis of structure-function relationship of 
specific domains of the AR. 
Naturally occuring mutations resulting in defects of 
synthesis and/or properties of the human AR are presumably 
involved in human disease especially disturbed male sexual 
differentiation and development (androgen insensitivity 
syndrom; Wilson et al., 1985). 
Detailed knowledge concerning the AR in PC is not 
available as yet. Increased, decreased and unaltered 
concentrations (compared with BPH or non-diseased prostatic 
tissue) of AR in PC have been described (Bowman et al., 1986; 
Aubel van et al., 1985a; Benson et al., 1985; Barrack et al., 
1983). Using immunological tools and the ligand technique 
simultaneously it will be possible to correlate the presence 
of the AR with its androgen-binding capacity, while 
morphological features can be retained. The presence of a 
(functional) AR in PC might be associated with a favourable 
response of endocrine intervention. On the other hand 
modulation of the AR system may result in the androgen-
independent growth of PC. Further studies have to be 
initiated to provide more evidence for these hypotheses. 
9.5. Additional and functional markers in prostatic cancer 
Apart from the markers associated with benign and 
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Figure 1: 
Immunocytochemical localization of the androgen receptor in 
cryostat sections of glandular BPH. Notice the exclusive staining 
of the nuclei of the inner cylindric epithelial cell layer. 
(magn. 1A:150x; 1B:600x). 
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malignant prostatic tissue as discussed in the previous 
sections some other factors have been suggested to play a role 
in malignant transformation and are of potential interest in 
the management of PC. A limited review of the most important 
factors in this regard is presented here. 
Estrogen Receptor (ER) 
The presence of estrogen receptors in prostatic tissue is 
still controversial. Though Harper et al. (1986) failed to 
prove the immunohistochemical presence in the prostate, Seitz 
et al. (1987) described the localization of ER in normal 
prostate and a fraction of prostatic cancers. However, the 
concentration of the ER seems considerably lower than that of 
the AR. Moreover, the ER seems to be predominantly located in 
cells belonging to the fibromuscular interstitial stroma of 
the prostatic gland. Therefore, the therapeutical effects of 
estrogens in patients with PC have to be ascribed to 
suppression of androgen synthesis rather than to a direct 
inhibitory effect upon the growth of prostatic cancer cells. 
Oncogenes, growth factors and growth factor receptors 
In recent years evidence has accumulated that malignant 
transformation and tumor progression are associated with 
mutation andjor altered expression of specific genes. These 
genes are known as (proto-)oncogenes or cellular oncogenes. 
To date, over 30 oncogenes have been identified. The number 
of potential oncogenes is still increasing. Oncogenes may be 
activated by a mutation in the gene, resulting in a 
structurally and functionally altered protein (e.g. oncogenes 
of the ras family), by chromosomal translocation (e.g. myc, 
abl), or by gene amplification (myc). In non-human 
vertebrates infection with retroviruses containing mutated 
(viral) homologues of oncogenes can lead to tumor induction. 
The precise function of the protein products of oncogenes 
is not fully understood. A number of the products of proto-
oncogenes seem related to regulatory mechanisms controlling 
cell growth and trans membrane signal transduction (tyrosine 
kinases, ras oncogenes). Some of these encode for growth 
factors, whereas others are structurally and functionally 
closely related to cell membrane localized growth factor 
receptors. The erb-B oncogene, for example, encodes for a 
truncated variant of the epidermal growth factor (EGF) 
receptor. The c-fms gene product is related to the receptor 
for the macrophage colony stimulating factor {Slamon, 1987a). 
The sis oncogene encodes for platelet derived growth factor 
{PDGF). Most nuclear oncogenes probably are involved in 
regulation of gene expression (e.g. fos and myc). Recently, 
it has been shown that the fos oncogene exhibits its action by 
interaction with a second (onco)gene protein (jun). The 
expression of c-myc is rapidly induced prior to cellular 
proliferation; the fos gene is expressed within a few minutes 
after quiescent cells are stimulated to proliferate (Thompson 
et al., 1985). The function of the p21 protein of the ras 
oncogenes has been associated with signal transduction 
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involved in normal cell proliferation and differentiation. 
Ras proteins act relatively late in the G1 phase (as do the 
growth factors EGF and insulin). 
In addition to DNA and RNA probes, antibodies recognizing 
mutated and normal oncogene products will enable the 
investigation of all kinds of tumors and to screen tumors for 
the presence of (activated) oncogenes. Apart fr·.:>m an increase 
in knowledge of the fundamental processes associated with 
malignant transformation, for some tumors (e.g. breast 
cancers) a direct correlation was suggested between proto-
oncogene amplification (neu) and survival (Slamon et al., 
1987b; Vijver van de et al., 1988). 
Thusfar only a few of such studies have been performed on 
PC: Abnormalities referring the expression of the p21 protein 
or altered expression of ras genes at the mRNA level in 
prostatic (malignant) tissue were reported by Viola et al. 
(1986), Peehl et al. (1987), Fan (1988), Treiger et al. 
(1988). Recently, the role of ras oncogenes in the etiology 
of PC was emphasized by Bosland (1989). The latter 
investigator provided evidence for the occurence of a point-
mutated c-Ki-ras proto-oncogene in chemically (N-methyl-
N-nitrosurea) induced PC in the rat. Out of a small number 
(8) of human PC tissues only one activated Ki-ras oncogene 
could be detected in the 3T3 cell transformation assay (Peehl 
et al., 1987). Viola et al. (1986), using the McAb RAP 5 
(that lacks the capacity to distinguish mutated and unaltered 
p21), provided data indicating that the levels of expression 
of the H-ras-oncogene in human PC correlate with the 
histological grade of the tumor. The p21 protein could not be 
detected in normal prostates and BPH samples. Recently, Fan 
(1988) presented results suggesting that p21 expression can be 
used to identify a subpopulation of a PC cell line with a 
potential metastatic capacity. 
c-Myc mRNA levels can be low in normal human prostate and 
elevated in benign prostatic hyperplasia and prostate 
adenocarcinoma (Fleming et al., 1986; Buttyan et al., 1987). 
A correlation of an elevated c-myc expression and high tumor 
grade (according the Gleason system) was suggested by Buttyan 
et al. (1987). The c-myc gene is amplified in the PC-3 
prostate cancer cell line (Trapman et al., 1988b). Fos 
express1on is decreased in the PC-82 tumor after androgen 
depletion (Rijnders et al., 1985). It will be obvious from 
the fragmentary results summarized above that much work 
remains to be done in order to establish the role of 
(modified) oncogenes in prostate carcinogenesis. 
Prostatic growth is influenced by prolactin that interacts 
with the prolactin receptor. Prolactin and prolactin 
receptors have been identified in benign and malignant 
prostatic tissue (Purnell etl al., 1982; Kadar et al., 1988a). 
In male mice the growth-stimulating effect of artificial 
hyperprolactinemia can by blocked by McAb's directed against 
the prolactin receptor (Sissom et al., 1988). In the Dunning 
rat prostate adenocarcinoma model membrane receptors for 
luteinizing hormone-releasing hormone (LH-RH), somatostatin, 
and prolactin were present (Kadar et al., 1988b). Moreover a 
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growth stimulatory effect on rat prostate epithelial cells in 
culture has been reported for EGF, TGF-a, glucocorticoid, 
insulin and cholera toxin (McKeehan et al., 1984). Similarly, 
EGF is able to stimulate the growth of the human prostate cell 
line LNCaP (Schuurmans et al., 1988a). Interestingly, so far 
transcription of TGF-fi has only been found in androgen 
independent prostate cell lines and not in androgen dependent 
cells (Trapman et al., 1988b; Wilding et al., 1989). In PC 
specimens the EGF receptor concentration was significantly 
higher than in BPH (Eaton et al., 1988). 
Other markers used in PC: 
Independent of all markers discussed previously incidental 
reports announced additional markers with potential interest 
in characterization of PC. Among these are carcino embryonic 
antigen (CEA; Reynoso et al., 1972; Heyderman et al., 1977; 
Purnell et al., 1984); human choriogonadotrophin (Purnell et 
al., 1984) and the Leu 7 antibody with cross reactivity for 
prostatic epithelium (Wahab et al., 1985; Rusthoven et al., 
1985; May et al., 1987). 
10. Prostate tumor model systems 
In the last few decades several PC model system have 
become available (Williams, 1980). Among these are 
spontaneously occuring carcinomas of the prostatic gland in 
laboratory animals. Some of these are well characterized and 
transplantable on recipient animals and possess metastatic 
capacity or can readily be propagated in tissue culture 
systems. In addition, hormonally or chemically induced tumors 
in rodents and domestic animals have been described. Finally 
several human model systems have been developed as 
transplantable xenografts on rodents or as in vitro models. A 
major disadvantage of human prostatic cancers (that is shared 
by other epithelial malignancies) is that these tumors are 
difficult to maintain and propagate in tissue culture systems 
(Okada et al., 1976; Merchant et al., 1983). 
10.1. Non-human prostatic cancer models 
In contrast to the human male population, prostatic carci-
nomas seldomly occur naturally in other mammalian species 
including laboratory animals. Among those rare tumors that 
have developed spontaneously belong the Dunning prostatic 
adenocarcinoma model (Dunning, 1963), the Pollard model 
(Pollard et al., 1973, 1975, 1980, 1984; Chang et al., 1977; 
Tazume et al., 1985), and the AXC rat model (Shain et al., 
1975, 1977, 1981, 1984). Dunning reported in 1963 the 
development of a spontaneous PC in the Copenhagen rat. The 
Dunning R3327 rat prostate adenocarcinoma system consists of a 
series of in vivo transplantable tumors and in vitro growing 
cell lines which vary in their differentiation status, growth 
rate, androgen sensitivity and metastatic ability (Voigt et 
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al., 1974; Isaacs et al., 1978; Isaacs et al., 198l,b; Isaacs 
1987). Numerous studies using the Dunning model have been 
carried out highlighting diverse aspects of PC (Isaacs et al., 
1978; Vere White et al., 1983; English et al, 1986; Feitz et 
al., 1986; Zachary et al., 1986; Cooke et al., 1988ab; Treiger 
et al., 1988; see for a review Isaacs, 1987). Of special 
interest is the recent article of Treiger and coworkers 
(1988). These investigators reported a conversion of a 
tumorigenic nonmetastatic Dunning rat prostate adenocarcinoma 
cell line to a highly metastatic state after transfection with 
the v-H-ras oncogene. Using the same prostatic adenocarcinoma 
model Cooke et al. (1988ab) reported an increased expression 
of the c-H-ras gene at the mRNA level that seemed to coincide 
with a relatively high metastatic potential, aneuploidy, 
increased anaplasia and androgen-independent growth. 
Incidental reports described the spontaneous occurrence of 
prostate malignancies in the dog, the hamster and the mastromy 
(Fortner et al., 1963; Snell et al., 1965). 
Apart from the aforementioned PC models in laboratory 
animals hormones and chemical agents have been used to induce 
malignancies of the prostatic glands in rodents (Noble, 
1977ab, 1980ab; Drago, 1984; Bosland, 1989). More recently, 
single oncogenes and combinations of oncogenes introduced by 
in vitro infection have been used to mimic in a mouse model 
system the process of prostate carcinogenesis (Thompson et 
al., 1989). 
10.2. Human prostatic cancer models 
Especially the gland forming (more differentiated) tumors 
are difficult to propagate in tissue culture. Those prostatic 
cancer cell lines that can be maintained in in vitro tissue 
culture are with only one exception (LNCaP) undifferentiated 
prostatic tumors. In addition to their lack of histomorpholo-
gic differentiation, the tumor cells have often lost their 
characteristic prostatic immunophenotype. The major 
characteristics of in vivo and in vitro human prostatic cancer 
cell lines are summarized in Table 7. 
Among the human prostatic cancer cell lines that can be 
cultured in vitro and propagated in host animals are PC-3, 
LNCaP and DU-145. The PC-3 cell line is derived from a bone 
metastasis of PC (Kaighn et al., 1979). Growth in vitro 
resembles the histological appearance of a poorly differen-
tiated carcinoma. Its growth is hormone-independent and the 
tumor lacks the biosynthesis and secretion of PAP. 
Controversial data exist concerning the retention of PA in 
this cell line (Papsidero et al., 1981; Trapman et al., 
1988b). The PC-3 cell line is tumorigenic in nude m1ce. 
Xenografted onto nude mice the tumor can evolve into a 
spontaneously metastasizing malignancy (Ware et al., 1982b). 
The cell lines PC-133 and PC-135 can be maintained exclusively 
in vivo (Steenbrugge van et al., 1988a). They are derived from 
primary prostatic tumor deposits and are poorly differen-
tiated. Both cell lines are characterized by the lack of 
androgen-dependent growth and absence of PAP and PA 
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Tab1e 7. Major characteristics of the most well-known human 
prostatic cancer in vivo and in vitro model systems: 
--------------------------------------------------------------
PC-82 PC-3 PC-133 PC-135 DU-145 LNCaP PC-EW HONDA 
PAP + + + + + 
PA + +j- + + ? 
AS a + + + + 
pjsb p s s p s s s s 
vivo + + + + + + + + 
vitro + + + 
a AS Androgen sensitivityjresponsivenessjdependency 
bpjs Derived from primary (p) or secondary (s) tumor deposit. 
expression. The cell line LNCaP has been the subject of many 
studies (Hasenson et al., 1985; Berns et al., 1986; Schuurmans 
et al., 1988b). This cell line was derived from a lymph node 
metastasis of PC (Horoszewicz et al., 1980). In vitro the 
LNCaP shows an androgen responsive cell growth. AR's were 
demonstrated to be present in this cell line. The LNCaP model 
is the only in vitro PC cell line with hormone-responsive 
growth. However, growth in nude mice seems less dependent of 
the gender or hormonal status of the recipient animal 
(Horoszewicz et al., 1983). A variant cell line (LNCaP-r) has 
been established that seems to be hormone insensitive; the 
androgen receptor content is only 10% of the parental line 
(Hasenson et al., 1985). PAP and PA are still produced and 
secreted by LNCaP cells (Papsidero et al., 1981; Schulz et 
al., 1985). DU-145 is a hormone independent cell line 
orginating from a brain metastasis (Stone et al., 1978). 
Though the retention of PA in this cell line was doubted by 
Papsidero et al. (1981), Larson et al. (1988) performed 
successful immunoscintigraphy studies with antibodies against 
PA on mice bearing xenografts of the DU-145 cell line. 
Among the human prostatic cancer cell lines that can be 
exclusively propagated as xenografts transplanted 
subcutaneously onto recipient animals, are the HONDA cell 
line, the PC-EW, the cell lines PC-133 and PC-135, and the 
PC-82 model. The HONDA cell line is derived from a human 
metastasis of PC localized in the testis (Ito et al., 1984). 
It is a hormone-dependent serially transplantable moderately 
differentiated adenocarcinoma. High levels of human PAP were 
detected in sera from tumor-bearing male mice. High affinity 
androgen receptors were also present (Ito et al., 1985). The 
PC-EW is a serially transplantable human prostatic carcinoma 
cell line, which has been developed through hetero-
58 
transplantation of human tumor derived from 
metastasis (Hoehn et al., 1984). Growth of this 
androgen-dependent. Histologically it appears 
moderately differentiated adenocarcinoma with 
areas. The serum PAP level of tumor bearing mice 
10.2.1.The PC-82 human prostatic cancer model 
a lymph node 
cell line is 
a poor to 
cribriform 
is elevated. 
The PC-82 cell line was transplanted initially from a 
human primary prostatic tumor deposit and propagated 
subcutaneously into nude mice (Hoehn et al., 1980; Romijn et 
al., 1982; Steenbrugge van, 1988a). Tumor growth is androgen-
dependent and therefore only successful in intact male mice, 
or female mice supplemented with T (Hoehn et al., 1982; 
Steenbrugge van et al., 1984). Radioactively labeled ligand 
studies have provided evidence for the presence of the AR 
within the nucleus. After numerous passages (approximately 
40) the histology of the tumor still resembles the original PC 
(cribriform adenocarcinoma). PAP and PA can be demonstrated 
irorounohistochemically in tissue sections (Hoehn et al., 1980; 
this thesis). Moreover, in tumor bearing animals PAP can be 
detected in the blood circulation of the recipient animals. 
The doubling time was determined as 18 days. Using this cell 
line McAb's have been prepared. Some of these recognized 
antigenic sites of PAP and PA (Gallee et al., 1986). Recently 
eDNA's coding for PA were isolated from a PC-82 eDNA library 
(Riegroan et al., 1988). Several studies have been performed 
to gain insight into the effects of hormonal manipulation upon 
tumor growth. The latter was objectivated by biometry, AR 
content, PA and PAP expression (tissue concentration and serum 
levels), hormone levels in the serum and tumor cell kinetic 
data (Steenbrugge van et al., 1983 and 1984; Gallee et al., 
1987). 
11. Cell-kinetic data in benign and malignant prostatic 
tissue 
It has been known for decades that mitotic figures, which 
reflect the growth activity in tissue sections, are often more 
numerous in malignancies associated with an unfavorable 
biological course. 
Apart from counting of mitotic figures, cell kinetic 
information can be gained by several other established 
techniques. In viable systems, incorporation in recipient 
cells of DNA precursors is currently employed. !nitially, 
autoradiographic studies were performed using H-labeled 
thymidine. To date, the availability of antibodies against 
the synthetic DNA component bromodeoxyuridine (BrdU) enables a 
simple immunocytochemical procedure to determine s-phase 
fractions (Schutte et al., 1987). DNA flow cytometry is also 
applicable on (non-viable) fixed tissue. This technique 
enables to determine cell fractions in S-phase and M-phase 
(Tribukait, 1987). Different markers associated with cell 
division, cell growth, or cell proliferation have been 
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recognized. Out of these the antigen defined by the McAb 
Ki-67 has become a successful tool for cell biologists and 
pathologists (Gerdes et al., 1983, 1984a, 1985). This antigen 
with a still unknown function is retained in fresh-frozen 
tissue sections and exclusively present in the nuclei of cells 
in cell cycle. The antigen seems to be absent in the GO-phase 
(quiescent or resting cells) and in the early G1-phase. 
Growth fraction assessment by the Ki-67 method (Ki-67 score) 
reveals higher figures than those obtained with the previously 
mentioned techniques. The Ki-67 antibody has been used to 
determine the growth fraction in various malignancies (Burger 
et al., 1986; Gatter et al., 1986; Schrape et al., 1987; 
Landolt et al., 1987; Barnard et al., 1987; McGurrin et al., 
1987; Walker et al., 1988; Brown et al., 1988; Gallee et al., 
1987; 1989b). 
In benign, hyperplastic and malignant prostatic tissue, 
mitotic figures are rarely found. Presumably for this reason 
these data are seldomly incorporated in the criteria of 
histological grading systems designed for PC. Nevertheless 
when present, mitotic figures are associated with a presumed 
unfavorable clinical course. In the grading system of 
Mostofi-Schroeder the presence of mitoses is considered as a 
bad prognostic sign (grade V tumor) (Schroeder et al., 
1985abc). Data concerning cell kinetics in prostatic tissue 
are scarce in literat~re. In vitro exposure of surgical 
prostate specimens to H-thymidine revealed extremely low 
s-phase fractions in normal and diseased prostatic tissue 
(Meyer et al., 1982; Helpap, 1985). The thymidine labeling 
index in normal prostate was estimated at 0.12%, in glandular 
BPH it was measured at 0.31%, whereas in PC an average value 
of 0.90% was determined (Meyer et al., 1982). Helpap (1985) 
found somewhat higher figures and a correlation with 
differentiation status. Well-differentiated adenocarcinomas 
showed a thymidine labeling index of 0.1-0.4%, whereas 
cribriform- and medullary cancers revealed an index of 
2.3-5.6% (Helpap, 1985). In situ exposure of PC cells to BrdU 
revealed identical high S-phase fractions for PC (up to 6.29% 
for medullary carcinomas; Nemoto et al., 1989). Recently 
Raymond et al. (1988) determined growth fractions in human PC 
with the McAb Ki-67. An average Ki-67 score of 16.3% was 
obtained in PC, whereas in hyperplastic glandular epithelium a 
mean Ki-67 value of 4% was reached. A possible relationship 
between cell kinetics and scores of histological grading 
systems (i.e. the Gleason method and the Mostofi system) was 
suggested. We circumvented the use of histological grading 
methods and examined the correlation of Ki-67 score with 
generally accepted histological PC growth patterns (Gallee et 
al., 1989b). Ki-67 scores were generally lower when compared 
to those measured by Raymond et al. (1988). Cancers composed 
of solid undifferentiated sheets or cribriform patterns were 
characterized by relatively high Ki-67 scores. However, 
infiltrative, undifferentiated cancers showed growth fractions 
almost equal to those obtained in gland forming tumors. 
Cell kinetic data are also available for the PC-82 cell 
line. DNA flow cytometry revealed that 85-90% of the cells 
are in GO/G1 phase, the fraction of cells in G2/M phase was 
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found to be less than 10%, whereas the fraction of S-phase 
cells was estimated not to exceed 5% of the total number of 
cells. In this thesis we describe growth fraction determina-
tions in the PC-82 cell line using in vivo exposure of tumor 
cells to BrdU and the Ki-67 method (Gallee et al., 1987}. In 
the intact model average values were assessed at: Ki-67 score 
16% ; BrdU incorporation 9.3%. These figures are in agreement 
with those obtained with DNA flow cytometry. Approximately 
15% of the cells in the PC-82 cell line are in cycle. In 
addition we have examined the influence of androgen withdrawal 
upon the Ki-67 score. Short-term androgen depletion resulted 
in a decline of the Ki-67 score, whereas repletion after 
10-days withdrawal led to an increase and even a rebound 
effect of the growth fraction assessed by means of the BrdU 
uptake and the Ki-67 assay. Similar results indicating a 
relationship between cell proliferation and steroids, were 
obtained by other investigators (English et al., 1985; 1986; 
Shain et al., 1987). Others studied proliferative activity in 
the non-tumorous rat ventral prostate and in the Dunning 
~ndrogen-dependent rat adenocarcinoma model using the 
H-thymidine labeling technique (English et al., 1985; 1986). 
Special attention was given to changes in proliferative 
activity resulting from hormonal manipulation. Androgen 
depletion resulted in a slight reduction in the percentage of 
S-phase nuclei, whereas repletion initiated a significant 
increase of proliferative activity. A possible role of the 
induction of such an increase of cells in S-phase might be to 
potentiate cytotoxic chemotherapy for treatment of 
adenocarcinoma of the prostate. On the other hand, Bosland et 
al. (1989} have recently used this method of synchronization 
of cells in proliferation phase followed by intravenous 
administration of MNU to induce rat prostatic adenocarcinomas. 
12. Aims and outlines of the study 
This study was initiated in order to gain insight in the 
value of different parameters that are associated with the 
prognosis of PC. As it is generally accepted that morphologi-
cal features are associated with clinical behavior, histologi-
cal grading methods for all kinds of malignancies have been 
designed. These systems allow to score tumors based upon 
cyto-nuclear morphological characteristics and patterns of 
tumor architecture in such a manner that a relatively good 
correlation is found between these scores and the natural 
course of that particular cancer. In the case of PC numerous 
grading systems have been developed. The large number of 
grading systems available for PC leads to questions concerning 
which system is most suited to use in general practice and why 
the number of grading systems for this particular neoplasm is 
so extensive. The latter problem is presumably related to the 
high prevalence of PC and the subjectivity that is always 
associated with the performance of histological grading. 
Moreover, single prostatic tumors are often characterized by 
the presence of more than one histological growth pattern 
(histological heterogeneity). In an attempt to examine the 
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interobserver variation in histological grading of PC, we have 
studied the consensus of assigning histological scores to PC 
using a selection of 5 more commonly used grading systems. 
The general grading system described by Broders (1926), 
designed for histological typing of neoplasms irrespective of 
its origin was selected in addition to 4 systems especially 
designed to score prostate malignancies. These latter grading 
systems encompass the MDAH method (1982) and systems described 
by Mostofi (1975), Gleason (1966) and the more recently 
introduced method of Schroeder-Mostofi (1985abc). Out of 
these systems the Mostofi method is characterized by a large 
impact that is laid upon nuclear features, whereas the other 
methods also include architectural criteria of tumor growth. 
The Gleason system is commonly used in the United States. It 
is the only grading method for prostatic tumors that makes use 
of the possibility to score two histomorphological growth 
patterns within the same neoplasm. These 5 systems were 
utilized by 5 pathologists on tissue sections of 50 patients 
with a long follow-up period. Results of these studies are 
presented in Chapters II and III. 
In addition, we have searched for other (more objective) 
parameters characteristic for PC. We attempted to generate PC 
specific antibodies using the well characterized human PC cell 
line PC-82. However, none of the antibodies displayed an 
exclusive specificity for PC. Interesting cross-reactivity 
profiles of some antibodies were observed. Some of the 
antibodies isolated were directed against epitopes of PA and 
PAP. Since some of the prepared antibodies were applicable on 
formalin-fixed tissue we correlated immunohistochemical 
expression of PA and PAP with generally accepted architectural 
growth patterns of PC. The use of grading scores was avoided. 
Results of these studies are presented in Chapters IV and V. 
It is widely accepted that cell kinetic data are of 
prognostic value in many tumors. A high mitotic activity in 
malignant tumors has always been associated with a poor 
clinical outcome. In breast tumors the number of mitotic 
figures is regarded as an independent parameter with a high 
prognostic impact (Baak et al., 1985). As cell kinetic data 
available for human PC are scarce we investigated cell growth 
fractions in human PC samples within prostatectomy specimens 
and in the human prostatic cancer cell line PC-82. As data 
obtained with the Ki-67 method paralelled those measured by 
the BrdU uptake technique (Chapter VI), we could use the 
former method to investigate the correlation of growth 
fractions with architectural growth pattern of PC (Chapter 
VII). In Chapter VI an interesting correlation was noticed in 
the PC-82 tumor model between the endocrine status of the host 
animal and the Ki-67 defined growth fraction in the PC-82 
tumor. Alterations of cell kinetics seem to precede light 
microscopic changes after short-term androgen depletion. 
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SUMMARY 
In order to investigate the reproducibility of grading 
systems for prostatic carcinoma currently in use, a compa-
rative histological grading study was done. These studies 
were carried out on tissue sections from radical prostatectomy 
specimens (n = 50) stained with hematoxylin and eosin. Five 
pathologists with varying professional experience participated 
in the study, using five different grading systems: those of 
the Broders, Brawn, Gleason (for statistical compilation the 
modified version), Mostofi, and a modified Mostofi grading 
method recently described by Schroeder and Mostofi. Weighted 
kappa coefficients ranged from 0.21 to 0.52. None of the 
systems investigated demonstrated a high degree of reproduci-
bility (k > 0.70 ). Reproducibility of the systems described 
by Broders and Brawn was reasonably good (k = 0.52 and 0.41, 
respectively). With the modified Gleason method (rearrange-
ment of Gleason scores into 3 grades), a considerable differ-
ence was noted between the numerical agreement score (among at 
least 3 observers) and the measured kappa value (100% and 
0.30, respectively). The methods described by Mostofi and 
Schroeder-Mostofi revealed only limited reproducibility 
(k = 0.21 and 0.34, respectively). 
INTRODUCTION 
Prostatic carcinoma is a major cause of death among the 
male population in most developed countries (8,36). Its preva-
lence and incidence is even higher, making this malignancy the 
most common neoplasm of the male urogenital tract (36). The 
discrepancy between mortality and morbidity rates reflects the 
wide scope of its clinical behavior, ranging from neoplasms 
found only incidentally at post-mortem examination (nearly 
10%) to those that metastasize early and eventually lead to 
death (8,36). 
In order to predict the clinical behavior and aggressive-
ness of prostatic carcinoma so that the most appropriate 
therapeutic regimen can be chosen and the prognosis deter-
mined, several grading systems have been developed by 
pathologists (10,11,13,15,19,21). Nevertheless, much contro-
versy still exists as to the most reliable grading method 
( 1, 12 1 17 1 2 8) • 
Boecking et al. (5) have described the main objectives 
that a grading system should fulfil: 
1. Each diagnostic criterion has to correlate with biological 
behavior and prognosis. 
2. It must display sufficient reproducibility. 
3. Grading done on random biopsies should, whenever possible, 
be representative of the tumor as a whole. 
In some systems, grading is performed upon the least 
differentiated areas; in others, a selection of the most 
predominant growth patterns is made. Thus far, approximately 
30 grading systems have been described. Some use low-power 
microscopy, taking into consideration only histological growth 
characteristics and their relationships to the surrounding 
90 
stroma (5,20,39). However, in most, prognostic significance 
has been attributed to cytological features (9,27,30,38). 
Combinations of both histological and cytological features 
form the basis of yet other systems. Also, in some studies, 
cytological features are examined by use of morphometry 
(9,12). 
To investigate the degree of reproducibility, we have 
examined the interobserver variation of five grading systems 
in current use. Two methods, described by Broders (7) and 
Brawn (M.D. Anderson Hospital) (6), were chosen as their 
prognostic value is predominantly based upon histological 
criteria. The method described by Gleason (16,18,20,22,25,37) 
was included for its general reputation and the attention 
given to both growth characteristics and interaction of tumor 
with the surrounding stroma. To incorporate a system that 
utilizes cytological features as a prcgnostic indicator, the 
method of Mostofi was selected (27,28). Finally, a recently 
introduced method described by Schroeder and Mostofi was 
included (33,34,35). The latter system was based upon a 
retrospective multivariate analysis of a large number of 
histological and cytological criteria. 
MATERIALS AND METHODS 
Patients and Materials 
Out of 464 patients of the original series of Belt and 
Schroeder (1930-1970), who had total perineal prostatectomy 
for limited prostatic cancer, 50 patients were randomly 
selected (4,32). Average age at the time of surgery was 
66 years, ranging from 48 to 83 years. The mean period of 
follow-up lasted for 125 months, ranging from 8 to 317 months. 
The survival curves and curves of time interval until first 
recurrence for the 50 patients included in this grading study 
did not differ significantly from that of a much larger random 
selection in the series of Belt and Schroeder. None of the 
50 patients of this study were lost to follow-up. In some of 
these cases the histology was not optimal. These 50 patients 
are a random selection of those previously graded by Mostofi 
and Schroeder (33,34,35), one of the few series to date with a 
follow-up of more than 10 years. The data recorded by Mostofi 
were also utilized for statistical analysis. 
Prostatectomy specimens were fixed in a buffered 4% 
formaldehyde solution, and sectioned in a stepwise fashion. 
All sections were routinely stained with hematoxylin and eosin 
and an average of 4 slides per case was available for 
histological examination. The number of slides per prosta-
tectomy specimen varied from 2 to 11. The number of slides in 
which tumor was present varied from 1 to 9 (mean: 3). 
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Grading systems 
The 50 cases were evaluated by five pathologists using 
five grading systems in common use. The major criteria as 
well as the scoring systems are summarized briefly in Table 1 
(6,7,18,25,27,33,34,35). 
The final Gleason score was assessed by the total of the 
scores of the two quantitatively predominating growth 
patterns. In those tumors in which only one growth pattern 
was recognized, the value of the growth pattern selected was 
doubled. For statistical compilation as proposed in the 
literature (2,14), Gleason scores were rearranged in 3 main 
grades (or groups) in the following manner: specimens assigned 
as Gleason sum 2, 3, and 4 tumors were included in grade 1; 
tumors with Gleason scores 5, 6, and 7 in grade 2 and those 
with Gleason scores 8, 9, and 10 in grade 3. This is referred 
to as the modified Gleason grading method. 
The grading method described by Schroeder and Mostofi was 
originally developed using 346 cases from the series of Belt 
and Schroeder (4,32). After collecting both cytological and 
histological features, they performed a retrospective 
multivariate analysis and were finally able to distinguish 
five categories of prognostic significance, predominantly 
based upon combinations of glandular differentiation, degree 
of nuclear anaplasia, and mitotic activity (33,34,35). The 
50 patients included in the present study are a random 
selection of those previously graded by Mostofi and Schroeder. 
The data recorded by Mostofi were also utilized for 
statistical analysis. 
statistical analysis 
Data was analyzed by calculating a measure of agreement 
among the five pathologists for each grading system. For most 
grading methods included in this study "standard" scores 
assigned by referee pathologists were not available. 
Therefore, weighted kappa coefficients were calculated as the 
best parameter of interobserver agreement. In order to 
incorporate the ordinal scales of the grading systems and to 
make the agreement of assessments for each system comparable, 
the so-called weighted kappa (k) coefficients were used 
together with quadratic disagreement weights (31). 
RESULTS 
Grading results obtained for all five methods are 
summarized in Tables 2 and 3. Table 2 presents the number of 
scores assigned by all pathologists to each grade for the five 
different methods evaluated in this study. A total of 
250 scores per method were available (5 pathologists and 
50 specimens). For the Mostofi and Mostofi-Schroeder methods, 
referee scores recorded by Mostofi himself were available and 
added to this table. 
Table 3 presents data related to the measure of agreement 
and disagreement for each grading method. 
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Table 1. Major grading criteria of the five systems evaluated in this 
study 
----· -------------------------------
BI::OOers (1926) (ref. 7) 
Grade 1 100%-75% glandular differentiation; 0%-25% undifferentiated 
Grade 2 75%-50% glandular differentiation; 25%-50% undifferentiated 
Grade 3 50%-25% glandular differentiation; 50%-75% undifferentiated 
Grade 4 0%-25% glandular differentiation; 100%-75% undifferentiated 
Gl~ (1966) (ref. 18,19,20) 
Pattern 1 ~1-diff~tiated, ~lt.. closely packed, unifonn glan:ls 
1n essent1.all y ci.rcumscn . oea ImSSeS 
Pattern 2 similar to pattern 1 with moderate variation in shape arrl 
size of glan:ls arrl more atypia in the tum:>r cells; more 
loosely arranged thougl_l still circumscribed 
Pattern 3 similar to ~ttern 2 with marked ~arity in size arrl 
shaw of glarrls with small glandS or ili:lividual cells 
invadglg the strorra 
Pattern 4 raqqeclly infiltrating, fused glandular tum:>r, ?equently 
wiffi pa,Le cells, may :tesernble fiypen1e~ of kidney 
Pattern 5 anaplastic carcl.nOlTla with · minimal glarrlular 
differentiation, diffusely infiltrating prostatic strorra 
H:Etofi (1975) (ref. 27) 
Grade 1 glandular differentiation with slight nuclear anaplasia 
Grade 2 glandular differentiation with moderate nuclear anaplasia 
Grade 3 glandular differentiation with marked nuclear anaplasl.a or 
Undifferentiated tum:>r 
Brawn (M.D. Anderson, 1982) (ref. 6) 
Grade 1 75%-100% glandular differentiation; 0%-25% of the tum:>r does 
not fonn glarrls. Excluded are cribrifonn-papill?Q:Y tum:>rs 
Grade 2 50%- 75% glandular differentiation; 25%-50% of the tum:>r does 
not fonn glarrls. Included are tum:>rs consisting of 50% or 
more of a cribrifonn-}2a_pill?IT pattern 
Grade 3 25%- 50% glandular differentiatl.On; 50%-75% of the tum:>r does 
not fonn glarrls. 
Grade 4 0%- 25% glandular differentiation; the remainder is 
undifferentiated 
Schroeder/Mostofi (1985) (ref. 33,34,35) 
Class 1 glandul~ differentiation, absence of mitoses, slight nuclear 
anaplasl.a 
Class 2 glafldular diffe:rentiation, absence of mitoses, moderate 
nuclear anaplasl.a 
or: glandular differentiation, mitotic activity, slight 
or: Undifferentiated tum:>r or cribrifonn <J!.UWI;:fi variant, 
absence of mitoses and sligl:lt nuclear anaplasia 
Class 3 glandular differentiation and mitotic activity combined with 
fuoderate or marked nuclear anaplasia 
or: glandular diff~tiation, absence of mitoses, marked 
nuclear anaplasl.a 
or: undifferentl.ated or cribrifonn grcMth variant, absence of 
mitoses, moderate anaplasia 
or: undifferentiated or cribrifonn QrOWt:h variant, presence 
of mitoses, slight nuclear anaplasia 
Class 4 undifferentiated tumor or cribrifonn grcMth variant, absence 
of mitoses, marked nuclear anaplasia 
or: undifferentiated or cribrironn gi'9Wtl) variant, presence 
of mitoses, moderate nuclear anaplasia 
Class 5 undifferentiated tum:>r or cribrifonn grcMth variant, presence 
of mitoses, marked anaplasia 
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Broders grading method 
Tumors in which glandular formation predominates (i.e. at 
least 50% consists of glandular formation) relatively 
outnumber tumors in which a minor part is differentiated. Of 
the 250 gradings performed, 207 (83%) were recorded as grade 1 
or 2 (Table 2). Most agreement was also observed in the lower 
grades, i.e. 62% and 18% agreement for grades 1 and 2, respec-
tively, by at least 3 observers (data not shown). The weigh-
ted kappa coefficient measured for the Broders method was 0.52 
(Table 3). In 14 cases, the recorded scores differed by more 
than one grade. In 5 cases only 2 pathologists agreed with 
each other (10%). The latter demonstrates almost total 
disagreement among the participating pathologists. 
M.D. Anderson method 
Of the total of 250 scores, 210 were conferred upon tumors 
predominantly characterized by glandular or cribriform-
papillary growth pattern (84%) (Table 2). The kappa coeffi-
cient calculated for the Anderson system was 0.41 (Table 3). 
Most agreement was found for grade 1 and 2. Agreement existed 
between at least 3 pathologists in 78% related to grade 1 and 
2 tumors. In 16 cases (32%) more than one grade difference 
was observed. Concordance between only 2 pathologists was 
noticed in 7 cases (14%). 
'.labl.e 2. Distribution of grades (1-5) arrl Gleason s=res (1-10~ated ~telE)' 
for ea~~ ~ as assessed by the partJ.cipa · pathologi (A-
arrl by fi himself* 
Grading systems Grade Total 
no. of 
1 2 3 4 5 6 7 8 9 10 s=res 
B:ro:l.ers 144 63 31 12 250 (58%) (25%) (12%) (5%) 
M.D. An:l.erson 102 108 26 14 250 (41%) (43%) (10%) (6%) 
Mostofi 22 120 108 250 (9%) (48%) (43%) 
Mostofi* 1 32 17 50 (2%) (64%) (34%) 
Gleason 0 4 24 45 117 27 21 6 6 250 (0%) (2%) (10%) (18%) (47%) (11%) (8%) (2%) (2%) 
Modified Gleason 28 189 33 250 
(11%) (76%) (13%) 
Mostofi -Schroeder 5 34 91 84 36 250 (2%) (14%) (36%) (34%) (14%) 
Mostofi -Schroeder* 1 3 21 17 8 50 
(2%) (6%) (42%) (34%) (16%) 
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Table 3. Absolute and percentual measure of agreement and kappa values for each grading method 
tabulated separately 
Broders Anderson Mostofi Mod. Gleason Mostofi-Schroeder 
4--g:r:ade 
system 
4--g:r:ade 
system 
3--g:r:ade 
system 
3-g.p;ide 
system 
5--g:r:ade 
system 
Agreement among: 
5 observers 13 (26%) 12 (24%) 6 (12%) 18 (36%) 1 (2%) 
4 observers 14 (28%) 16 (32%) 19 (38%) 15 (30%) 8 (16%) 
3 observers 18 (36%) 15 (30%) 20 (40%) 17 (34%) 29 (58%) 
At least 3 observers 45 (90%) 43 (86%) 45 (90%) 50 (100%) 38 (76%) 
A difference of more 
than 2 grades 14 (28%) 16 (32%) 12 (24%) 2 (4%) 29 (58%) 
Total no. of specimens 50 (100%) 50 (100%) 50 (100%) 50 (100%) 50 (100%) 
Kappa values 0.52 0.41 0.21 0.30 0.34 
Mostofi gradinq method 
Glandular differentiation combined with slight nuclear 
anaplasia was only recorded in 22 scores out of a total of 250 
(9%) (Table 2). The scores assessed earlier by Mostofi for 
the same material are also summarized in Table 2. The overall 
weighted kappa score was calculated at 0.21 (Table 3). 
Complete agreement among all pathologists was never found for 
grade 1 tumors (data not shown). More than one grade 
difference per specimen was observed in 12 cases (24%). Only 
in 5 cases was a total lack of concordance seen. 
To obtain insight into the measure of agreement (or 
disagreement) of each participating pathologist with the 
grading results obtained by Mostofi himself, an individual 
kappa score was assessed. None of the 5 pathologists attained 
a weighted kappa coefficient of agreement above 0.40. 
Gleason grading method 
Grading results determined according the traditional and 
modified Gleason methods are shown in Table 2. None of the 
tumors received a traditional Gleason score of 2. In Table 3, 
the measure of agreement is presented only for the modified 
results of the rearranged Gleason scores (2,14). The weighted 
kappa score was calculated at 0.30. In all 50 cases (100%), 
at least 3 investigators agreed with each other concerning the 
chosen modified Gleason grade. As groupjgrade 2 was most 
frequently chosen, maximal agreement was found in this 
category. More than one grade disagreement of the modified 
system was found in only 2 cases. 
Mostofi-Schroeder grading method 
In Tables 2, 3 and 4, results using the Mostofi-Schroeder 
method are shown. Besides the distribution of scores obtained 
by the 5 participating pathologists, Table 2 also includes the 
results obtained by Mostofi. The weighted kappa coefficient 
as a measure of agreement among pathologists was calculated at 
0.34. An overall percentage for all prognostic classes of 76% 
was a measure of agreement of at least 3 pathologists. In only 
5 cases grade 1 was recorded. Regarding grade 5 tumors, 
agreement among 3 pathologists was only achieved in 2 cases. 
Disagreement reflected in the number of cases in which 
pathologists differed by more than one grade was recorded in 
29 cases. Using the data recorded by Mostofi himself as a 
"standard", the individual weighted kappa coefficient as a 
measure of agreement for each pathologist was assessed 
(Table 4). With the Mostofi-Schroeder method, unlike the 
Mostofi method, 2 of the 5 pathologists scored a kappa value 
above 0.40. 
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Table 4. Measure of agreement of each particiwt~ pa'l;hologist (A-lj:) 
~ to the scores of Mostoii {M) USl.l'lg tile Mostofl.-
Sc:hl:ueder method (1-5) 
Pathologist A Pathologist B 
0 
8 
22 
18 
2 
50 
Weighted K coefficient A: K = 0.14 
Patholggist c 
1(M) 2(M) 3(M) 4(M) 5(M) 
T 1 0 0 0 0 1 2 c 0 1 2 0 0 3 3 c 0 1 6 3 2 12 4 c 0 1 10 9 2 22 5 c 0 0 3 5 4 12 1 3 21 17 8 50 
Weighted K coefficient c: K = 0.46 
Patholggist E 
1(M) 2(M) 3(M) 4(M) 5(M) 
T 0 0 1 1 0 2 2 E 1 2 7 3 1 14 3 E 0 1 11 8 2 22 4 E 0 0 1 4 3 8 5 E 0 0 1 1 2 4 1 3 21 17 8 50 
Weighted Kcoefficient E: K= 0.35 
DISCUSSION 
1 B 1fr) 2fM) 3fr") 4fM) 5bM) 
2!Bl 0 1 4 1 1 3 B 1 1 10 4 1 
4 B 0 0 6 8 5 
5 B 0 0 1 3 1 
1 3 21 17 8 
2 
7 
17 
19 
5 
50 
Weighted K coefficient B: K = 0. 35 
Patholggist D 
1(M) 2(M) 3(M) 4(M) 5(M) 
T 0 1 0 0 0 0 2 D 1 0 0 1 0 2 3 D 0 3 10 3 2 18 4 D 0 0 8 7 2 17 5 D 0 0 3 6 4 13 1 3 21 17 8 50 
Weighted K coefficient D: K = o. 42 
Kappa values for each method separately indicate that none 
of the grading systems had a high degree of concordance 
(k > 0.70). Kappa values reflecting fair to reasonable 
reproducibility (kappa ranging from 0.40 to 0.70 ) were only 
found by the Broders and Anderson grading methods (Table 3). 
However, in contrast to these values, in both the Broders 
system and the Anderson grading method (in 14 and 16 cases, 
respectively), disagreement among observers of more than two 
grading steps was noted (Table 3). Such lack of agreement may 
be partly attributed to impaired tissue preservation and 
fixation. Furthermore, when the distribution of grades is 
considered for both methods, by far the most tumors were 
assessed as grade 1 or 2 (Table 2). Preponderance of such a 
relatively large number of well-differentiated tumors may be 
attributed to the inclusion of only prostatectomy specimens in 
this study. 
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In contrast to the low kappa score obtained by the Mostofi 
method, the percentual agreement was markedly better 
(Table 3). In fact, in 90% of the cases, at least 3 observers 
shared the same opinion about the assignment of tumor grade 
(Table 3). However, when this agreement per tumor grade was 
analyzed (data not shown), concordance was achieved most 
frequently for grade 2 tumors. Discrepancy of kappa values 
and percentual agreement score may be explained by the fact 
that observers are often inclined to classify tumors most 
frequently as grade 2 when a three-step grading method is 
used. In addition, inadequate preservation of tissue slides 
has undoubtedly influenced precise judgement of cytologic 
features such as degree of anaplasia. Furthermore, lack of 
sufficient experience and poor definability of slight, 
moderate and marked nuclear anaplasia may also contribute to 
this low kappa value. 
Applying the modified Gleason method, a maximal numerical 
agreement score was achieved. In all specimens investigated, 
at least 3 observers agreed after rearrangement of results 
into a three-step grading system (100%). However, a low kappa 
value was a measure reflecting the low degree of accuracy. 
The latter may be explained by an unbalanced distribution, 
since grade 1 and 3 tumors are scarcely represented (Table 2). 
Although a kappa value was not determined for the traditional 
Gleason system, our results seem to be in contrast to those 
presented by others (16,22,24,26,29,37). Harada et al. (23) 
stated that, for the primary growth pattern, agreement was 
found in 64% of cases; for the secondary pattern, agreement 
was obtained in 44%. When the primary and secondary patterns 
were compared to those of Gleason, agreement was recorded in 
only 38% (23). Gleason (23) postulates that the margin of 
error of reproducibility from one institution to another could 
be as much as 50% and probably reflects the degree of 
experience of the particular observer. Bain et al. (3) stated 
in their study concerning the reproducibility of the Gleason 
method that agreement was reached among 7 pathologists in 
74%-93% of the cases studied (n = 58; kappa ranged from 60.5% 
to 83.6%). However, grading in this study was performed 
predominantly upon transurethral resection specimens. 
Although the percentual numerical scores of the Schroeder-
Mostofi method demonstrate a nearly total lack of agreement 
(Table 3), the weighted kappa coefficient can be considered as 
relatively high (0.34). Again, lack of numerical concordance 
may be partly due to the fact that, in addition to 
histological criteria, cytological features, especially 
nuclear anaplasia and mitotic activity are incorporated in 
this grading system. Ordinal scale correction for this five-
step grading method has undoubtedly influenced the kappa score 
favorably. 
As the treatment decision for prostatic cancer is often 
influenced by the results of grading, accuracy and reproduci-
bility of grading methods are of the utmost importance. 
However, even when sufficient tissue sections are available, 
accuracy of grading, as this study shows, is considered to be 
relatively low. Simple methods involving only histological 
features seem to have a better interobserver agreement than 
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those systems using cytological features. However, low 
agreement scores found for the Mostofi method and the recently 
described system introduced by Schroeder and Mostofi can be 
attributed to lack of optimal fixation and preservation of 
tissue sections, resulting in difficulty of evaluating nuclear 
anaplasia. In addition, our results may also indicate that, 
in practice, pathologists are more accustomed to dealing with 
well-defined (histological) criteria as compared to less 
circumscribed criteria such as degree of nuclear anaplasia. 
Calculation of the weighted kappa scores may hamper 
precise interpretation of the value of the accuracy of grading 
scores, especially when the tumors selected are not equally 
divided among the diverse grades. Finally, reproducibility is 
largely dependent upon training and experience and is 
considerably facilitated by the elimination of ambiguity in 
the definition of predictive morphological criteria. As yet, 
it remains to be determined to what extent morphometrical 
techniques will enhance the accuracy and reproducibility of 
grading methods. 
Since the final aim of grading is to predict the clinical 
behavior of neoplasms, grading results obtained so far will be 
correlated with survival and recurrence rates and the data 
will be presented in a second report. 
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ABSTRACT 
The prognostic accuracy of 5 current histological grading 
systems (Broders, Anderson, Mostofi, Gleason, and Mostofi-
Schroeder) was compared. The histological grading was 
performed by 5 pathologists upon 50 prostatectomy specimens. 
By averaging the grading results of the 5 pathologists the 
impact of the interobserver variation was eliminated. The Cox 
proportional hazards model was used for estimating the 
relationship between the average grading scores and time-to-
recurrence (respectively, time-to-death by prostatic carci-
noma). Age at surgery was adjusted for as a possible confound-
ing factor. The prognostic impact of the 5 grading systems 
(related to both recurrence and death caused by prostatic 
carcinoma) was judged by the likelihood ratio (LR) test score. 
The LR test score (which is chi-square distributed with 1 df) 
for time-to-recurrence for the Mostofi-Schroeder score 
appeared to be 6.54, whereas a value of 1.79 was measured for 
the Gleason system. A stepwise procedure demonstrated that 
with the Mostofi-Schroeder - and Broders systems used together 
the best prognostic performance was reached (with Mostofi-
Schroeder weighted 1.5 times larger than Broders). For time-
to-recurrence also the median grading result was used giving 
results similar to the mean grading result. For time-to-death 
by prostatic carcinoma the LR test scores for all grading 
systems were relatively low. In this analysis the outcome of 
the Gleason system did show a minimum of prognostic ability, 
whereas the grading systems of Broders as well as the recently 
introduced system of Mostofi-Schroeder had a reasonable 
predictive power. Since the interobserver variation of the 
Schroeder-Mostofi system was large, the Broders system is to 
be preferred. Restrictions and implications of this study are 
discussed and a brief review of the prognostic importance of 
grading of prostatic carcinoma is presented. 
INTRODUCTION 
Carcinoma of the prostate is a frequently occurring 
malignancy. The incidence of prostatic carcinoma demonstrates 
a geographically and demographically related distribution 
ranging from 0.84 for Shanghai to 100.20 among the black 
population in Alameda County, California per 100,000 male 
population (Zaridze et al., 1984; Catalona, 1984; Ross et al., 
1983; Wynder et al., 1971). The reason for these geographical 
and demographical differences in incidence and prevalence 
remains for as yet unknown. As latent or incidental 
carcinomas are erroneously omitted (Yamabe et al., 1986; Dhom, 
1983), the actual figures concerning incidence and prevalence 
of prostatic carcinoma are often underestimated in the 
literature. Mortality resulting from disseminated prostatic 
tumours also shows a geographical and demographical variation 
ranging from 2.51 (Japan) to 29.1 (St. Vincent and 
Grenadines), per 100,000 male population (Zaridze et al., 
1984; catalona, 1984; Ross et al., 1983; Wynder et al., 1971). 
The large difference between incidence- and mortality rate 
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reflects a wide variation in clinical behaviour of prostatic 
carcinoma. At initial diagnosis prostatic carcinoma may 
present itself as incidental carcinoma which is considered 
harmless, or as an extended tumour with a tendency to 
metastasize, ultimately leading to death. As for 
histopathology nearly 97% of prostatic tumours shows acinar 
structures and these tumours are therefore designated as 
adenocarcinomas (Utz and Farrow, 1969}. 
Pathologists have searched for histological, cytological, 
immunological and morphometric parameters in an attempt to 
predict biological aggressiveness. Several histological 
grading systems have been developed to forecast the biological 
behaviour of the carcinomas (Murphy and Whitmore, 1979; 
Mostofi, 1976; Grayhack and Assimos, 1983}. 
The large number of grading systems presented in the 
literature already indicates the controversy concerning the 
choice of the most reliable grading system, due to large 
inter- and intra-observer variation as demonstrated in a pre-
vious report (Ten Kate et al., 1986). In this sequel report 
we will present these data again, now correlated with the 
clinical follow-up of patients incorporated in this survey. 
MATERIALS AND METHODS 
Patients and materials 
From the original series of Belt and Schroeder of 464 
patients, who underwent total perineal prostatectomy for 
localized limited prostatic carcinoma (Whitmore, 1956), 50 
patients were randomly selected (Belt and Schroeder, 1972; 
Schroeder and Belt, 1975). In this group the average age at 
the time of surgery was 66 years with a range from 48 to 
83 years. The mean period of follow-up lasted for 125 months, 
ranging from 8 to 317 months. The survival curves of time-to-
death and time-to-first recurrence for these 50 patients did 
not differ from the curves of a much larger random selection 
of the series of Belt and Schroeder. The original series of 
Belt was recently used to devise a new grading method as 
described by Mostofi and Schroeder (Schroeder et al., 1985a; 
Schroeder et al., 1985b; Schroeder et al., 1985c). 
We were able to obtain the follow-up of all the 
50 patients. At the end of follow-up 11 patients were still 
alive without progression. For the analysis of time-to-first 
recurrence (19 patients), 31 patients were considered 
"censored"; and for time-to-death by prostatic carcinoma 
(16 patients), 34 patients were considered "censored" (Figu-
re 1}. None of the patients who showed progression is still 
alive. This series is one of the few to date with a mean 
follow-up period of more than 10 years. Recurrence after 
prostatectomy occurred in 19 patients. The time interval 
until first recurrence varied from 8 months to 133 months with 
a mean period of 51 months. Treatment modalities of these 
recurrences differed and were according to the current 
protocol at that time period. All of the patients who had a 
tumour which showed progression died at time intervals ranging 
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Data concerning the follow-up of the 50 patients included in this study_ 
from 1 to 164 months with a mean period of 45 months. 
However, included are 3 patients who died from another cause. 
After excluding these patients time-to-death in the recurrence 
group ranged from 1 to 164 months with an average of 
33 months. 
Prostatectomy specimens were fixed routinely in 4% formal-
dehyde solution. Section was performed in a stepwise fashion 
and each specimen was submitted completely for histologic 
examination. Slides were stained routinely with Mayer's haema-
toxylin and eosin. The number of slides available for 
microscopic survey per prostatectomy specimen ranged from 
2 to 11. The number of slides in which tumour was present 
varied from 1 to 9 (mean: 3). 
Grading systems 
The 50 cases were evaluated by 5 pathologists using the 
general grading system of Broders, the Anderson (hospital) 
system, the Mostofi system, the system described by Gleason 
and the Mostofi-Schroeder system (Broders, 1926; Brawn et al., 
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1982; Mostofi, 1975; Gleason, 1966; Mellinger et al., 1967; 
Schroeder et al., 1985abc). The Gleason system was used as 
originally reported since, by definition, a crude linear 
transformation realised by rearrangement of Gleason scores in 
three main groups will not increase the prognostic impact of 
this system (Babaian and Grunow, 1985). 
The percentual distribution of grading-scores for each 
grading system separately is listed in Table 1 (Ten Kate et 
al., 1986). 
Table 1. Percentage of tumours attributed to the various 
grades of the Broders, Anderson, Mostofi, Gleason, 
and Mostofi-Schroeder grading systems assigned by 
all pathologists together. 
Broders 
grade 1 58% 
grade 2 25% 
grade 3 12% 
grade 4 5% 
grade 5 
grade 6 
grade 7 
grade 8 
grade 9 
grade 10 
Statistical analysis 
Anderson Mostofi Gleason 
41% 9% 
43% 48% 0% 
10% 43% 2% 
6% 10% 
18% 
47% 
11% 
8% 
2% 
2% 
Mostofi-
Schroeder 
2% 
14% 
36% 
34% 
14% 
Statistical analysis was performed using the Cox 
proportional hazards model (Cox, 1972; Cox, 1975). The 
following events ("endpoints") were considered: 
Progression (N 19) and 
irrespective of the occurrence of progression: 
Death caused by prostatic 
carcinoma (N = 16). 
The BMDP-program 2 L was used (Dixon, 1983). The 
likelihood ratio (LR) test score was used for judging and 
comparing the predictive ability of each one of the 5 grading 
systems. The contribution of an explanatory variable to the 
likelihood function is supposed to represent its predictive 
ability (Green and Symons, 1983). This contribution is quant-
ified by means of the likelihood ratio (LR) test score which 
has an asymptotical chi-square distribution with 1 degree of 
freedom. The contribution is significant (at the 5% level) if 
the LR test score exceeds the value 3.84. The five scores (of 
the 5 pathologists) of each grading system were summarized 
into one interval-scaled explanatory variable by taking the 
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average score. For the endpoint progression also the median 
score was considered and compared with the average score. For 
each grading system a separate analysis was done, with age at 
surgery always included as a confounding variable. For the 
endpoint progression also a stepwise analysis was performed, 
starting from a model including all 5 grading systems followed 
by stepwise elimination of insignificant grading methods. The 
purpose of this latter analysis was to investigate if two (or 
more) grading systems used simultaneously provide better 
prognostic information than one single system. 
RESULTS 
Cox proportional hazard model and LR test scores for 
progression of prostatic carcinoma 
Patients' age (at time of surgery) and the average 
(respectively, the median) grading score were chosen as 
explanatory variables. The average (median) grading score was 
calculated for each patient and for each grading system as the 
arithmetic mean (as the median) of the scores of the 
5 pathologists. Nineteen out of 50 patients developed progres-
sion (Figure 1). Time-to-progression was computed after date 
of surgery as zero-point. Progression was defined as local 
recurrence or metastastic disease irrespective of a possible 
lethal course. The estimated coefficients of the proportional 
hazard function and LR test scores are summarized in Table 2. 
Estimated coefficients for the average grading scores varied 
from 1.497 (Mostofi) to 0.327 (Gleason) and represent the 
estimated proportional increase in risk of progression to an 
increase of one score in the grading system applied. LR test 
scores ranged from 6.54 (Mostofi-Schroeder) to 1.79 (Gleason). 
As the latter values are used for judging the prognostic 
performance, our results indicate that the Mostofi-Schroeder 
system as well as the Broders system have the highest 
prognostic capability. The Gleason system reveals the poorest 
prognostic power. 
An identical ordering in prognostic accuracy was obtained 
when median grading scores were used instead of the mean 
values (results are not tabulated). 
The results of the stepwise procedure are presented in 
Table 3. It appeared that the Mostofi-Schroeder and the 
Broders systems (both mean- and median values) remained 
together in the model at the final step along with the forced 
presence of age at surgery. This result indicates that these 
two grading systems reflect different dimensions of grading 
prostatic carcinoma. From the estimated coefficients in Table 
3 it can be concluded, that a weighted average of the Broders 
system and the Mostofi-Schroeder method might be the best 
prognostic tool for progression (with the Mostofi-Schroeder 
system weighted 1.5 times larger than the Broders method). 
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Table 2. Estimated proportional hazards model for progression 
(of prostatic carcinoma) and results of the chi-
square likelihood ratio (LR) test per grading system 
(single regression analysis). 
Mostofi-Schroeder: 
average grading-score 
over pathologists 
age 
Broders: 
average grading-score 
over pathologists 
age 
Anderson: 
average grading-score 
over pathologists 
age 
Mostofi: 
average grading-score 
over pathologists 
age 
Gleason: 
average grading-score 
over pathologists 
age 
SE = standard error 
coefficient 
1.145 
0.058 
0.822 
0.038 
0.839 
0.034 
1.497 
0.030 
0.327 
0.054 
SE 
0.474 
0.031 
0.309 
0.032 
0.383 
0.033 
0.741 
0.034 
0.240 
0.032 
LR 
test score 
6.54 
6.32 
4.44 
4.36 
1.79 
Cox proportional hazard model and LR test scores for death 
from prostatic carcinoma. 
Explanatory variables chosen for this statistical 
elaboration were identical to the ones described in the 
previous section. The endpoint considered here is time-to-
death caused by prostatic carcinoma. Out of 50 patients, 
16 patients died from the sequels of disseminated prostatic 
carcinoma (Figure 1). The estimated coefficients of the 
hazard function ranged from 0.999 (Mostofi) to 0.189 
(Gleason). However, for all of the grading systems the 
prognostic performance of grading systems for death from 
prostatic carcinoma as reflected by the LR test score was poor 
and varied from 2.17 (Mostofi-Schroeder) to 0.59 (Gleason). 
Results of this analysis are shown in Table 4. Because of the 
similar results with the mean and median score obtained for 
the end-point progression, only the mean score was analyzed 
here. 
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Table 3. Final results of repeated inserting and withdrawing 
in the stepwise analysis for progression of prostatic 
cancer. Coefficients of the Cox proportional hazards 
model and the chi-square likelihood ratio (LR) test 
scores. 
age 
Broders (median) 
Mostofi-Schroeder (median) 
age 
Broders (average) 
Mostofi-Schroeder (average) 
SE standard error 
coefficient 
0.040 
0.637 
1.157 
0.041 
0.649 
0.943 
SE 
0.032 
0.275 
0.400 
0.032 
0.318 
0.486 
LR 
test score 
4.81 
9.19 
3.82 
4.05 
Individual prognostic accuracy (including data of Mostofi) for 
progression of prostatic carcinoma. 
For both the Mostofi system and the Mostofi-Schroeder 
system the scores assigned by Mostofi himself were available. 
In fact, the same slides of the 50 cases included in this 
study were evaluated by Mostofi. The individual prognostic 
accuracy for progression of prostatic carcinoma of 
6 pathologists (Mostofi and pathologists A-E) was calculated 
for the Mostofi and Mostofi-Schroeder grading system 
{Table 5). Again, the LR-test was used for judgment of the 
prognostic performance. 
In both grading systems a large inter-observer variation 
was noticed {Table 5). With reference to the Mostofi-
Schroeder system 3 pathologists revealed statistical 
significance (Mostofi, pathologist A and pathologist B). LR 
test scores varied from 9.18 (pathologist B) to 0.18 
(pathologist C). Using the Mostofi system statistical 
significance was only assessed for the grading data of Mostofi 
himself and pathologist B. The prognostic performance 
reflected by the LR test scores ranged from 6.26 (Mostofi) to 
0.13 (pathologist D). 
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Table 4. Estimated proportional hazards 
(caused by prostatic carcinoma) 
chi-square likelihood ratio (LR) 
system. 
Broders: 
average grading-score 
over pathologists 
age 
Anderson: 
average grading-score 
over pathologists 
age 
Mostofi: 
average grading-score 
over pathologists 
age 
Gleason: 
average grading-score 
over pathologists 
age 
Mostofi-Schroeder: 
average grading-score 
over pathologists 
age 
SE standard error 
DISCUSSION 
coefficient 
0.436 
0.051 
0.557 
0.048 
0.999 
0.044 
0.189 
0.061 
0.672 
0.059 
model for death 
and results of the 
test per grading 
SE 
0.294 
0.036 
0.380 
0.036 
0.767 
0.038 
0.245 
0.035 
0.465 
0.034 
LR 
test score 
2.01 
1.99 
1. 75 
0.59 
2.17 
In the present study the prognostic performance of 
5 current grading systems was determined. Since an uniquely 
long period of follow-up after surgery of all patients was 
available, it was even possible to use time-to-death as a 
response. 
In order to enable comparison of the prognostic accuracy 
of the grading systems the impact of the inter-observer 
variation on the various grading systems was eliminated by 
averaging the grading scores over the 5 pathologists. This 
might be debatable since a grading score is considered an 
ordinal1y-scaled covariate. Therefore, in the statistical 
analysis for progression of prostatic cancer also the median 
grading values (measured over 5 pathologists) were used. The 
dependency of the responses (recurrence or death by prostatic 
carcinoma) on these average (and median) grading scores was 
estimated by Cox proportional hazards model, while correcting 
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Tab1e 5. Estimated proportional hazards model for progression 
and results of the chi-square likelihood ratio (LR) 
test for two grading systems (Mostofi and Mostofi-
Schroeder) and 6 pathologists (including Mostofi). 
coefficient 
Mostofi-Schroeder: 
grading-scores of Mostofi 0.668 
age 0.087 
grading-scores of pathologist A 0.700 
age 0.064 
grading-scores of pathologist B 0.847 
age 0.057 
grading-scores of pathologist c 0.107 
age 0.064 
grading-scores of pathologist D 0.395 
age 0.052 
grading-scores of pathologist E 0.333 
age 0.058 
Mostofi: 
grading-scores of Mostofi 1.147 
age 0.066 
grading-scores of pathologist A 0.396 
age 0.052 
grading-scores of pathologist B 0.924 
age 0.049 
grading-scores of pathologist c 0.607 
age 0.054 
grading-scores of pathologist D o. 219 
age 0.060 
grading-scores of pathologist E 0.564 
age 0.053 
SE = standard error 
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SE 
0.310 
0.034 
0.302 
0.033 
0.288 
0.030 
0.257 
0.030 
0.316 
0.031 
0.233 
0.030 
0.456 
0.031 
0.427 
0.033 
0.457 
0.030 
0.477 
o. 032 
0.617 
0.033 
0.379 
0.030 
LR 
test score 
4.89 
5.31 
9.18 
0.18 
1.58 
1.90 
6.26 
0.91 
4.37 
1. 76 
0.13 
2.26 
for age at surgery. This model allows one to relate multipli-
catively the instantaneous risk of 'failure' (in this study 
progression or death by prostatic carcinoma) to a set of 
candidate covariates. Moreover, a stepwise analysis including 
initially six candidate covariates (age and 5 grading methods) 
was performed to study the influence of using two or more 
grading systems, simultaneously upon the prognostic performan-
ce. The antilog of the estimated coefficients represent the 
multiplicative increase in risk of progression or death 
related to one unit increase in the explanatory factor. 
The chi-square likelihood ratio test score was used for 
judging and mutually comparing the prognostic performance of 
the grading systems. 
In a previous report the interobserver variation in 
assignment of grading-scores to prostatic carcinomas of 
50 patients was described (Ten Kate et al., 1986). As 
(dis)agreement score the kappa-value for each grading system 
was measured, but in none of the grading systems a high degree 
of consensus (kappa > 0.70) was reached as judged from the 
kappa-values (Ten Kate et al., 1986). However, the agreement 
among pathologists using the Broders and Anderson system was 
considered as fair to reasonable (kappa ranging from 0.40 to 
0.70). The remaining grading systems showed a poor agreement 
among participating pathologists (kappa< 0.40). 
When the results of this study presented in Table 2 and 4 
are compared it becomes evident that histological grading can 
better predict the event of progression (Table 2) than the 
event of death by prostatic carcinoma (Table 4). This 
discrepancy could partly be attributed to the follow-up data 
of one patient who revealed progression 46 months after 
surgery, but lived afterwards for an extremely long period of 
164 months before dying of the sequels of disseminated 
prostatic carcinoma. Therefore, we decided to use time-to-
progression (Tables 2, 3) for the comparison of the prognostic 
performance of the different histological grading systems. 
From Cox regression it appeared that all but one grading 
systems were statistically significant; the Gleason system was 
the only one which was not significant (LR test score 1.79). 
The prognostic performance for the event of progression 
(Table 2) of the grading systems of Broders and Mostofi-
Schroeder are superior to the other systems. The use of 
median values instead of average values did not result into a 
different ranking of grading systems referring their 
prognostic accuracy with respect to progression. 
For the risk of death by prostatic carcinoma (Table 4), 
none of the grading systems reached statistical significance. 
Nevertheless, the trend reflected by the LR test scores for 
death is similar to that for progression (Table 2). 
The stepwise analysis (performed for both average and 
median values) provided evidence that the Broders system and 
the Schroeder-Mostofi method used together, supplied 
additional prognostic information (Table 3), with the Mostofi-
Schroeder method weighted 1.5 times larger than the Broders 
method. This might be explained by the fact that next to 
architectural features, that are exclusively used in the 
grading performance according to Broders, cytonuclear charac-
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teristics such as encorporated in the Mostofi-Schroeder 
system, provide additional prognostic information. 
Comparative studies on the prognostic impact of grading 
systems in prostatic carcinoma applied upon the same set of 
slides are scarcely found in literature. Comparison of these 
studies with ours is complicated by the use of different 
statistical techniques and diverse prognostic risk- or hazard 
functions. Mostofi (1976) reviewed grading systems for 
prostatic carcinoma introduced over a period of half a century 
(Broders 1926; Young 1926; Muir 1934; Kahler 1938; Shelley 
1958; Evans 1942; Herbut 1952; Edwards 1953; Gleason 1966; 
Mobley 1968; Utz 1969; Hanash 1972; Vickery 1963; Carriere 
1970; Rous 1972). He stated that according to the devisers 
they all promise to give the best prognostic value in the 
individual course of prostatic carcinoma. Nevertheless, 
reproducibility of all of these systems is poor. 
In an extensive retrospective study in which multivariate 
analysis was used Schroeder et al. (1985abc) demonstrated that 
coexistence of several architectural patterns favours the 
prognosis as compared to tumours composed of only one 
prognostically bad histological pattern. In addition, nuclear 
and mitotic activity should also be implemented as these are 
important prognosticators to a grading system. Using these 
three parameters (gland formation; mitoses; and nuclear 
anaplasia) 5 different prognostic groups of patients can be 
identified. 
Brawn introduced in 1982 (Brawn et al., 1982) a new 
grading system and compared the prognostic accuracy of his 
system (Anderson) with those described by Mostofi and Gleason 
in a group of 182 patients with locally advanced carcinoma 
(stage C) treated by radiotherapy. Follow-up of patients 
ranged from 3 to 7 years. Grading was performed upon trans-
urethral specimens, needle biopsies or both. Survival-curves 
were obtained using the Kaplan-Meier statistical method. 
Statistical significance of survival curves by histologic 
grades was computed using the Wilcoxon method. statistical 
significance was obtained for grade 1 and grade 4 lesions 
according the Anderson system. 
The system of Gleason is probably most often applied and 
data about its prognostic potentials are frequently reported. 
Cantrell et al. (1981) studied the natural course of stage A 
(incidental) prostatic carcinoma in 117 patients followed for 
2 to 15 years. Until relapse developed no therapeutic 
intervention had been performed. In 14 patients progression 
occurred. To obtain insight into factors that might predict 
clinically evident prostatic carcinoma at 4 years andjor 
predict a crude 4-year survival, a retrospective discriminant 
analysis using diverse variables was carried out. Of the 
variables chosen, grading scores of the Gleason system and 
extension of tumour at initial diagnosis revealed the highest 
prognostic impact. No patient with a low-grade lesion 
(Gleason score 2-4; n = 14 ) and only 2% of patients with less 
than 5% tumour-volume showed progression. Grading was 
performed on transurethral currettings or specimens obtained 
by simple enucleation. 
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Parfitt et al. (1983) studying stage A2 disease 
(incidentally found extensive carcinomas), reported that the 
Gleason grade had some predictive value. Of 16 patients with 
primary tumours with a Gleason score less than 4, none 
appeared to have lymphnode metastases on subsequent staging 
lymphadenectomy. 
Kramer et al. (1980) also studied the predictive value of 
Gleason scores of primary tumours for nodal involvement at 
staging pelvic lymphadenectomy. In their group of 228 
patients, irrespective of primary clinical stage, 93% of 
patients with Gleason sums more than 7 in initial biopsies 
showed evidence for lymphnode metastases. However, the sensi-
tivity in this study was not as high since 31% of the patients 
(26 patients out of 84) with histologically proven lymphnode 
metastases revealed Gleason's sums ranging from 5 to 7. The 
latter might be attributed to a sample error resulting from 
the use of small tissue samples for grading. Especially when 
the Gleason system is applied on small tissue samples, it is 
possible that only one or two minor histological growth 
patterns are present, whereas a whole specimen contains often 
much more tumour patterns. 
Results presented by Wilson et al. (1983) may also be 
confounded by grading inaccuracy resulting from sample error. 
They studied prospectively 115 fully staged (including pelvic 
lymphadenectomy) patients with localized prostatic carcinoma 
(stages A-C). Grading according to a modified Gleason system 
was carried out on needle-biopsies or transurethral specimens. 
Two of 6 low-grade (Gleason sum 2-4) lesions of 16 A2 tumours 
and 4 of 35 low-grade lesions of 53 Bl tumours revealed 
metastases during follow-up (ranging from 8 to 71 months). 
Wilson et al. (1983) postulate that low stage, low grade 
prostatic carcinoma can retain the potential for widespread 
metastatic disease. Even more interesting is their 
observation that 9 patients with high grade tumours and 
without evidence of metastases did not show any progression of 
their malignancy during follow up. 
Guinan et al. (1983) compared the prognostic ability of 2 
grading systems (Gleason and Broders) for the risk of 
recurrence in 111 patients with clinically localized carci-
nomas treated by radical surgery. Follow-up ranged from 
6 months to 8 years. Statistical significance was computed by 
means of a chi-square test. Of the 2 systems studied the 
Gleason classification system was the least accurate. 
Studies reviewed above do not give unequivocal information 
about which grading system reveals the highest prognostic 
power. Although most studies present relatively favourable 
results for the Gleason system, our data demonstrate a low 
interobserver accuracy (Ten Kate et al., 1986) and only a 
limited prognostic ability of the latter grading system (this 
study). The system of Mostofi also exhibits a large inter-
observer variation (Ten Kate et al., 1986). Nevertheless, 
compared with the Gleason system its prognostic accuracy of 
average (and median) grading scores for the occurrence of 
progression is relatively high. Our data indicate that less 
complicated systems as the ones described by Broders and Brawn 
(Anderson) reveal not only the highest interobserver reprodu-
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cibility (Ten Kate et al., 1986), but also a high prognostic 
impact. Though inter-individual agreement was low, as 
reflected in the present study (Table 5), data obtained on the 
recently introduced system of Mostofi-Schroeder also seem 
promising. The finding of additional prognostic information 
provided by the use of more than one histological grading 
system upon the same tumour is of utmost interest and 
necessitates further investigation using larger series and 
other combinations of grading systems. 
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SUMMARY 
For production of monoclonal antibodies (McAbs), hybrid 
cells were prepared by fusion of spleen cells of BALB/c mice 
immunized with the human prostatic cancer cell line PC-82 and 
the P3 -X63Ag8.653 murine myeloma cell line. Supernatants of 
approx1mately 500 hybrid clones were screened for prostate 
specific antibodies using an ELISA on PC-82 cells. A select-
ion of antibodies was further tested for their specificity on 
a large series of different tissues. A broad cross reactivity 
pattern was obtained. Most cross reactivity was with pancre-
atic tissue, kidney, and bowel. One antibody turned out to 
react with prostate stromal cells. Two McAbs (ER-Pr 1 and 
ER-Pr 2) reacted solely with prostatic epithelium. Monoclonal 
antibody affinity chromatography combined with SDS-PAGE showed 
that both antibodies were directed against a 35-kD protein. 
Immunoblotting revealed that this protein is identical to 
prostatic antigen (PA). The epitope detected by ER-Pr 1 and 
ER-Pr 2 was largely preserved after formalin-fixation of 
prostatic tissues which renders these antibodies very suitable 
for routine exa~ination of tissue sections. 
INTRODUCTION 
On the basis of the formation of gland-like structures, 
most tumors of the prostate are known as adenocarcinomas. 
Various grading systems, based on histological and cytological 
criteria, all trying to predict the biological behavior of the 
tumor, have been put forward (1-3). In addition to 
morphological data, the use of immunological methods can be of 
value for further characterization of human tissues of unknown 
origin and as differentiation markers (4-6). 
Knowledge of prostatic tumors and their characteristics 
has increased by the isolation of several prostatic cancer 
cell lines derived from primary or secondary human tumor 
deposits (7-10). From these, the PC-82 cell line is one of 
the best characterized (8,11,12). It can be propagated in 
nude mice and its growth is androgen dependent {13,14). It 
has also been shown to contain prostatic acid phosphatase 
(PAP) (8,14). The solid tumor shows prostate carcinoma morpho-
logy, i.e. a predominantly cribriform growth pattern. The 
stromal component and vascularization are of murine origin 
(8,11). In this study we describe the generation and 
properties of monoclonal antibodies (McAbs) against this cell 
line. 
MATERIALS AND METHODS 
Cell line 
In 1977 the PC-82 cell line was isolated from a primary 
tumor of the prostate and since then has been grown subcuta-
neously in homozygous male nude mice. Its characteristics 
have been well documented (8,11-14). 
120 
Immunization and cell fusion 
Male ~ALB/c nuj+ mice were immunized subcutaneously with 2 
to 5 x 10 PC-82 cells at three-week intervals. PC-82 cell 
suspensions were prepared from chopped solid tumor fragments 
that were incubated overnight in tissue culture medium 
supplemented with collagenase (200 Ujml). Prior to immuniza-
tion, PC-82 cells were washed and resuspended in RPMI 164g 
(Flow Labs, Irvine, UK) at a density of at least 8 x 10 
cellsjml. Three days before removal of the spleen, a final 
combined intravenous/intraperitoneal booster was given. 
For preparation of hybrid cells, spleen cells of immunized 
animals were fused to the P3-X63Ag8.653 mouse myeloma cell line at a ratio of 5:1. The metnod used was essentially 
identical to that of Frankel et al. (15). Immediately after 
fusion, the cell suspension was seeded into 96-well tissue 
culture plates containing a macrophage feeder layer and grown 
in selective medium (HAT). Supernatants of large clones were 
scored for the presence of antibodies to PC-82 cells. 
Enzyme linked immunosorbent assay 
Terasaki plates were coated with fC-82 cells and human 
lymphocytes at a concentration of 5 x 10 cellsjwell. Cells 
were fixed by incubation in glutaraldehyde (0.1%) for 15 min. 
An indirect ELISA was performed utilizing a horseradish 
peroxidase conjugated rabbit anti-mouse serum (DAKO) as the 
second reagent. 0-phenyl diaminedihydrochloride (Eastman 
KODAK, Rochester, NY) (0.2% in 0.1 M phosphate buffer, pH 6.0) 
activated by 0.03% H2o2 was used as a substrate for the peroxidase enzyme (16,17). 
Immunodiffusion 
Subclasses of the mouse antibodies were determined by 
standard agar gel diffusion(Ouchterlony). Specific antisera 
directed against the various subclasses were purchased from 
Nordic. 
Human tissues 
Prostatic tissue was obtained from various sources. Fresh 
tissue was collected from transurethral specimens obtained 
from clinically diagnosed benign prostatic hyperplasia (BPH) 
patients. In addition, samples of radical prostatectomy 
specimens were snap frozen and stored in liquid nitrogen. 
Tissues were used for preparation of BPH cell lysates and for 
immunohistochemical assays on cryostat sections. Paraffin-
embedded tissues from prostatic carcinoma, BPH (transurethral, 
biopsy, and prostatectomy samples), and from a large series of 
different control tissues were used for the immunoperoxidase 
assay on formalin-fixed sections. 
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Immunohistochemial techniques 
An indirect immunoperoxidase assay was carried out on 
acetone fixed 5 ~ thick cryostat tissue sections using 
peroxidase conjugated rabbit anti-mouse antibodies (DAKO) as 
the second reagent. Diamino benzidine (0.05% in 0.2 M Tris-
HCl, pH 7.0) was used as the enzyme substrate. Tissue 
sections were counterstained with hematoxylin. A similar 
technique was employed for formalin-fixed sections (8). In 
some experiments, slides were preincubated with pronase (0.1% 
in phosphate-buffered saline, PBS) for 7 min at room 
temperature (19,20). Rabbit polyclonal antibodies directed 
against PAP and PA were obtained from Immulok. 
Preparation of cell lysate 
For preparation of a lysate, BPH tissue (approximately 
0.5 g) was minced into small pieces and suspended into 2 ml 
Tris-HCl buffer (0.01 M, pH 7.5) containing 0.15 M NaCl, 0.05% 
Triton X-100 and 1 mM phenylmethyl sulfonyl fluoride (PMSF). 
Cells were further disrupted by pottering and sonication 
(small probe, 30 sec, max speed, Branson B 12 sonifier). The 
lysate was clarified by centrifugation (15 min 12,000 g). 
Protein concentration of the supernatant was approximately 
8 mgjml as measured in the Biorad protein assay (BSA 
standardized). 
Monoclonal antibody affinity chromatography 
Protein in 1 ml of ascites of hybridoma bearing BALB/c 
mice was bound to 1 g CNBr-activated Sepharose 4B using 
conditions described by the supplier. A 3-ml column was poured 
and 0.5 ml of BPH lysate analyzed over this column. Elution 
of this affinity column was at 1.5 ml/h and 4oc in PBS 
containing 1 mM PMSF; 1-ml fractions were collected. After 
six fractions, the velocity was increased to 10 ml/h. After 
two hours, bound proteins were eluted by 3 M KSCN in phosphate 
buffer (pH 7.6, 1 mM PMSF). Protein containing fractions were 
pooled and dialyzed overnight against PBS at 4°C. The 
purified protein was concentrated 25-fold on an Amicon 
centricon-10 filter. 
Electrophoresis 
Fractions of a monoclonal antibody affinity column were 
further analyzed by SDS-polyacrylamide electrophoresis 
according to Laemmli (21). (Concentrated) column samples of 
20 ~1 were mixed with 5 ~1 of sample buffer and boiled for 
5 min, followed by electrophoresis on a 10% gel for 3~ hours 
at 17 mA. Gels were stained with Coomassie Blue using 
standard procedures. 
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Immunoblotting 
Proteins were transferred from a gel to nitrocellulose 
sheets (22). After transfer, filters were washed and incuba-
ted with the appropriate mouse monoclonal antibody, polyclonal 
rabbit PA, or PAP antiserum (22,23). If mouse antibodies were 
used, filters were further incubated in a rabbit anti-mouse Ig 
antibody solution. Next, nitrocellulose sheets were incubated 
for 30 min at room temperature in alkaline phosphatase 
conjugated goat antirabbit IgG antibody solution (Tago). 
After washing, the filters were developed in a 0.2 M Tris-HCl 
buffer, pH 9.1, containing 10 mM Mgcl2 and supplemented with 4-amino-diphenylaminediazonium sulfate (0.3%, Sigma, St. 
Louis, MO) and Naphthol AS-MX phosphate disodium salt 
(0.1 g/100 ml, Sigma, St. Louis, MO). Incubation was for 
5-10 min at room temperature. 
RESULTS 
Generation of monoclonal antibodies 
Hybrid cells were 
BALB/c mice immunized 
line P -X6 3Ag8.653. 
about Soo microtiter 
obtained by fusion of spleen cells of 
with PC-82 cells with mouse myeloma cell 
Growth of hybrid cells was obtained in 
plate wells. Supernatants of the cultu-
res were analyzed for their reactivity to PC-82 cells; human 
lymphocytes were used as control cells. In this initial 
screening, approximately 25% of the supernatants were found to 
contain antibodies positive to PC-82 cells and negative to the 
control cells. After rescreening by ELISA, supernatants of 54 
stable cell lines were tested for their specificity using the 
immunoperoxidase assay on frozen tissue section of human 
prostate cancer, brain, and spleen. Thirty four samples which 
either reacted with all of these different tissues or did not 
react at all were discarded (10 of these preparations detected 
nuclear associated antigens). The remaining supernatants were 
further analyzed for reactivity with BPH, bowel, pancreas, 
liver, kidney, and skin, and were rescreened against prostate 
cancer, spleen, and brain tissue. The reaction pattern 
obtained is summarized in Table 1. Most cross reactivity in 
this final panel of McAbs was found with pancreas (this 
includes both ductal epithelial lining and exocrine acini), 
kidney (almost exclusively in tubuli), and bowel tissue. A 
positive reaction to liver was found predominantly in 
hepatocytes (diffuse or focal) or in the epithelial cells 
lining the bile ducts; positive reactions were also seen in 
sweat- and sebaceous glands, epidermis and in brain capillary 
walls. 
McAbs ER-Pr 1, 2, 6, and 7 showed a very limited andjor 
highly specific cross reactivity pattern (Table 2). McAb 
ER-Pr 6 reacted with a fraction of stromal cells in the 
prostate and with smooth muscle cells in the large bowel 
(Fig. 1). This antibody also reacted with the stromal 
component of PC-82 tumor grown in nude mice, a surprise 
finding since the stroma is of murine origin. Some light 
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Tab1e 1. Reactivity patterns of McAb's raised against PC-82 
cells tested on frozen sections of different human 
tissues. 
Tissue 
BPH 
Prostate carcinoma 
Pancreas 
Kidney 
Bowel 
Skin 
Liver 
Brain 
Spleen 
No. tested 
20 
17 
13 
15 
19 
11 
13 
17 
17 
Percentage 
of positive 
90 
90 
68 
60 
55 
45 
40 
30 
25 
Tab1e 3. Reactivity of McAb Er-PR 1 against formalin-fixed and 
frozen sections of different human tissues. 
N 
BPH (fr) 11 
Prostate care. (fr) 10 
BPH (ff) 16 
Prostate carc.(ff) 18 
Parotid gland (ff) 2 
Ureter (ff) 3 
Testis (ff) 1 
Seminal vesicle (ff) 2 
Stomach care. (ff) 19 
Colon care. (ff) 11 
Kidney care. (ff) 12 
Pancreas care. ( ff) 10 
Lung care. ( ff) 10 
Bladder care. (ff) 8 
Mammary care. ( ff) 19 
fr = frozen sections; ff 
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Positive 
(%) 
11 (100) 
10 ( 100) 
13 ( 81) 
11 ( 61) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
formalin-fixed; 
Positive after 
pronase treatment 
(%) 
ND 
ND 
13 ( 81) 
14 (78) 
ND 
ND 
ND 
ND 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
ND not done 
I-' 
N 
U'1 
Table 2. Specificity of four monoclonal antibodies, raised against PC-82 cells, 
detennined by an immunoperoxidase assay on frozen tissue sections. 
Prostate Prostate 
BFH carcinoma Bc:Mel Pancreas Kidney Brain Liver Skin Spleen 
ER-Pr 1 + + 
ER-Pr 2 + + 
ER-Pr 6 +s +s +m 
ER-Pr 7 + + +ga +d,a +gl +p +sg 
s = stroma; m =muscularis; ga = ganglion cells; d = excretory ducts; 
a = exocrine acini; gl = glO!liE!l:Uli; p = parenchyma; sg = sebaceous glands 
staining was also found in the PC-82 epithelial cells. In 
addition to the reaction to prostate, ER-Pr 7 was the only 
antibody of the entire series found to be positive to 
glomerular cells and large bowel ganglion cells (Fig. 2), 
indicating detection of an antigen shared by very diverse, but 
specific cell types. 
McAbs ER-Pr 1 and ER-Pr 2 reacted with epithelial acinar 
cells of the prostate (Fig. 3). All other tissues tested, 
including salivary gland, bladder, ureter, and mammary gland, 
were negative. Because of their exclusive prostate specific 
reaction pattern, these antibodies were investigated in more 
detail. Experiments on the further characterization of ER-Pr 6 
and 7 are in progress. 
Characterization of ER-Pr 1 and ER-Pr 2 
As measured in an Ouchterlony assay, both ER-Pr 1 and 
ER-Pr 2 were found to be IgGl antibodies. The corresponding 
antigen was purified from a lysate of human BPH tissue by McAb 
affinity chromatography and further analyzed by SDS-PAGE. The 
results of this experiment are illustrated in Fig. 4. The 
electrophoresis pattern shows the presence of two major bands 
in the fraction eluted at high salt concentration. After 
reanalysis of this sample over an ER-Pr 1 column, most of the 
high molecular weight material was found in the flow through 
fraction, whereas the low molecular weight band (MW 35 kD) was 
retained in the high salt wash. In some experiments, an 
additional 25-kD component was observed in the high salt 
fraction. An essentially identical pattern, as shown for 
ER-Pr 1, was found for an ER-Pr 2 column. 
For further characterization, the purified protein was 
analyzed by immunoblotting using ER-Pr 1, ER-Pr 2, and 
polyclonal PAP and PA antibodies. As demonstrated in Fig. 5, 
the 35-kD band is stained by ER-Pr 1 proving that this McAb is 
directed against this protein. Furthermore, incubation of 
filters with PAP (data not shown) and PA antibodies clearly 
demonstrated that the antigen against which ER-Pr 1 (and 
ER-Pr 2, data not shown) is directed is identical to PA. 
Properties of ER-Pr 1 and ER-Pr 2 on frozen and formalin fixed 
tissue sections 
To investigate in more detail the properties of ER-Pr 1 
and 2, a series of 23 different prostate carcinomas and BPH 
tissue samples, all freshly frozen and obtained at autopsy or 
from surgery, were further tested by immunoperoxidase 
. staining. Results are summarized in Table 3. All hyperplasia 
and carcinoma tissue sections investigated were stained by 
ER-Pr 1, ER-Pr 2, and polyclonal PA antibody. In contrast to 
the polyclonal antibody, ER-Pr 1 and ER-Pr 2 varied in 
intensity and in the number of epithelial acinar cells 
stained. These differences concern both the inner and outer 
cell layer of the acini. The most intense staining was in the 
cytoplasm, but positive reactions were also noted in the 
lumina of the acini. 
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Figure1: 
(A) Immunoperoxidase 
interacinar stroma of 
staining of fibromuscular cells 
the prostate using McAb ER-Pr 6 
in the 
(x150). 
(8) Staining of the muscularis mucosae by McAb ER·Pr 6 <x60). 
The staining of eosinophilic granulocytes in the lamina 
propria is caused by endogenous peroxidase activity. 
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Figure 2: 
(A) Immunoperoxidase staining of ganglion cells in the 
myenteric plexus by ER-Pr 7 (x380). (B) Staining of glomerular 
cells in the kidney by McAb ER-Pr 7 (x60). 
Figure 3: 
(A) Immunoperoxidase staining by ER-Pr 1 of the 
(X60). Notice variation in staining of cells lining 
acini. (B) Granular staining in cytoplasm of inner 
cell layer of prostatic glands by ER-Pr 1 (x380). 
prostate 
prostatic 
and outer 
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94 kD-
67 kD-
43kD-
30 kD_ 
20kD_ 
14 kD 
Figure 4: 
1 2 3 4 
SDS-PAGE analysis of a BPH cell lysate separated on an 
ER-PR 1 affinity column. Experimental details are 
described in Materials and Methods. Lane (1) marker 
proteins; (2) original lysate; (3) flow through 
fraction; (4) high salt wash fraction. 
In addition to the frozen tissues, both antibodies were 
tested on a large series of formalin-fixed samples of prostate 
and control organs. Both normal and malignant counterparts 
were incubated (Table 3). The negative data obtained on non-
prostate tissue confirm the results obtained on frozen 
tissues. In experiments with the formalin-fixed tissues, most 
of the BPH (81%) and 61% of carcinomas were stained. If 
tissue slides were pretreated by pronase for a short time 
period, the percentage of positive carcinomas increased to 
78%. The data indicate that the epitope of PA detected by 
ER-Pr 1 is slightly sensitive to the fixative treatment. 
Moreover the results suggest that the PA concentration is 
higher in BPH than in carcinoma tissue, but additional 
experiments are necessary to substantiate this finding. 
Absence of positive reactions in a few biopsy samples could be 
explained by the absence of those acini with the antigenic 
determinant of ER-Pr 1 antibody, and was only observed in 
small biopsies with a limited number of tubular structures. 
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35 kD--. 
1 2 3 4 
Figure 5: 
Immunoblotting of BPH proteins separated by ER-Pr 1 
antibody affinity chromatography. Details are 
described in Materials and Methods. Lane (1), high salt 
wash fraction incubated with ER-Pr 1; lanes 2, 3, and 
4 are incubated with polyclonal PA antibody. Lane (2) 
high salt wash of ER·Pr 1 column; lane (3) flow through 
fraction; lane (4) original BPH cell lysate. 
Data obtained so far show that ER-Pr 1 and ER-Pr 2 detect 
the same antigenic site of PA. Since ER-Pr 2 always shows some 
background staining to stromal components of the prostate, we 
believe that ER-Pr 1 and ER-Pr 2, although closely related, 
are not completely identical to each other. 
DISCUSSION 
In this study the properties of McAbs raised against the 
PC-82 prostatic carcinoma cell line are presented. The 
suitability of this cell line for generation of prostatic 
antibodies is based on certain of its features that are akin 
to differentiated human prostate carcinoma, including its 
histological appearance, androgen dependence for prolifer-
ation, and the presence of PAP. The isolation of antibodies 
against PA, as described herein, implies the presence of this 
prostate specific marker in PC-82 tumors. 
In our panel of antibodies, we were unable to detect anti-
bodies which were specific to carcinoma and which were less 
active or not active at all against BPH or normal prostate 
tissue. Several carcinoma specific antibodies have been 
described in sets of McAbs raised against the PC-3, Du-145 or 
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LNCaP prostatic cell lines (24-29). None of these antibodies 
was prostate specific. It still has to be seen whether these 
McAbs will be of value for characterization of patient tissue 
samples. It is possible that our series of antibodies was too 
small to find carcinoma specific McAbs, however, in additional 
experiments, not discussed herein, we also failed to isolate 
such antibodies. Therefore, it is possible that the PC-82 
cell line is not the best source for raising carcinoma 
specific antibodies. 
As expected, most of the antigens detected by the set of 
McAbs were shared by other cells originating from different 
malignant or normal tissues. Cellular components of the 
pancreas often showed immunologic similarity to the antigenic 
phenotype of prostatic cells. Four antibodies which showed 
striking staining patterns were described in greater detail. 
As found in this study for ER-Pr 6, two antibodies previously 
described react with stromal cells in the prostate and smooth 
muscle cells in large bowel tissue sections (30). Because the 
antibodies have not been further characterized, a direct 
comparison of the various McAbs cannot be made. Antibody 
ER-Pr 7 showed an unique cross reactivity pattern not 
previously described for an antibody raised against prostate 
tissue. 
From all McAbs screened, two (ER-Pr 1 and ER-Pr 2) were 
selected for their complete prostatic specificity as 
demonstrated on frozen and formalin-fixed tissue sections. 
Characterization of the corresponding antigen provided 
evidence that the antibodies were directed against PA. In a 
recent experiment we also generated a McAb against PAP using 
PC-82 cells for immunization (data not shown). Prostatic 
antigen, which so far may be the only prostate specific marker 
besides PAP, was first described by Wang et al. (31). These 
authors also raised polyclonal and monoclonal antibodies 
against PA (15,32). Distinct from the previously described 
McAbs (15), ER-Pr 1 and ER-Pr 2 showed no cross reactivity to 
renal tubular epithelium nor to renal adenocarcinoma cells. 
Also, in contrast to previous findings (15), frozen sections 
of prostate tissue contained at least equal amounts of immuno-
logically active PA reacting to ER-Pr 1 and ER-Pr 2 as 
compared to formalin-fixed tissue sections. ER-Pr 1 and 
ER-Pr 2 are also different from McAb F5, which is directed 
against PA and is prostate specific (33). This antibody 
recognizes over 95% of all acini. ER-Pr 1 and 2 react with 70% 
or less of the acini. 
In comparison to the commercially available polyclonal 
antibodies against PA, the sensitivity of ER-Pr 1 and ER-Pr 2 
was essentially equal. As mentioned above, differences in 
staining of the epithelium of adjacent acini were observed and 
therefore will be a minor disadvantage in utilizing McAbs in 
the immunoperoxidase assay on tissue sections. PA can be 
detected in sera from patients in more advanced stages of 
prostate cancer and can be used for monitoring (34,35). A 
panel of different McAbs, which probably will be available 
soon, could be useful for increasing the sensitivity of the 
assay. 
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SUMMARY 
A series of 55 randomly chosen radical prostatectomy 
specimens was analyzed for expression of prostate-specific 
antigen (PSA} by immunohistochemical techniques. Tissue 
sections were selected in such a manner that in addition to 
glandular benign prostatic hyperplasia (BPH}, one or more 
different prostatic tumour growth patterns were present. Four 
monoclonal antibodies, directed against three different PSA 
epitopes, and one polyclonal anti-PSA antiserum were used. 
Expression of PSA was compared with that of prostate-specific 
acid phosphatase (PAP}, recognized by two different polyclonal 
antisera. A critical dilution aimed at a maximum of staining 
intensity on BPH tissue sections was chosen for all 
antibodies. Anti-PSA and anti-PAP antisera stained essentially 
all BPH samples (over 90%). Irrespective of the nature of the 
antibodies used, PSA expression was found to be decreased in 
prostatic carcinoma. A clear cut relationship was found 
between immunoreactivity for PSA and the degree of 
differentiation of the tumour area. Under the experimental 
conditions used the PSA monoclonal antibodies stained only 1 
out of 10 undifferentiated carcinomas, whereas 50% to 70% of 
the well- and moderately-differentiated carcinomas showed 
immunoreactivity. This correlation was less pronounced with 
the PAP staining pattern. If the PSA antibody titer was 
raised the percentage of clearly staining undifferentiated 
carcinomas could be considerably increased (up to 60%-100%), 
indicating that PSA expression is not absent, but lowered in 
most (if not all} undifferentiated carcinomas. 
INTRODUCTION 
Prostate-specific antigen (PSA) was first described by 
Wang and co-workers (21,28,29}. It belongs to a family of 
kallikrein-like serine proteases and has a molecular weight of 
33-35 kD (3, 30}. Recently, the primary structure of the PSA 
protein obtained by direct sequencing or deduced from the eDNA 
sequence has been elucidated (18,24,30). PSA is exclusively 
secreted by the epithelial cells of the prostatic gland. 
Because of its tissue-specific expression pattern, PSA became 
of interest as being a prostate-specific (tumour) marker. 
Availability of specific polyclonal and monoclonal antibodies 
also made its immunohistochemical detection in neoplastic and 
non-neoplastic prostatic tissue possible (6,11,12,22). In 
addition, it turned out that the presence of PSA in sera of 
patients could be used for monitoring the natural course of 
prostatic cancer and to evaluate the success or failure of 
therapeutic (often endocrine) regimens (27). 
Especially because of the general acceptance of PSA as 
being the most reliable and sensitive prostate (tumour) marker 
in serological assays, detailed analysis of PSA expression in 
prostatic tumours is of high importance. Several studies have 
been presented aiming to gain a better insight into the 
specificity and sensitivity of PSA expression in prostatic 
tumours (1,2,5,7,8,9,10,16,23,26}. To extend our knowledge 
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further in this regard we investigated PSA expression in 
tissue sections derived from radical prostatectomy 
preparations. Prostatectomy was performed for localized 
prostatic carcinoma. Prostatic carcinomas are often composed 
of different growth patterns within a single tumour. This 
provided an ideal opportunity to compare in detail the 
immunohistochemical levels of PSA with prostatic tumour 
differentiation status. Since no consensus has been reached 
concerning the most suited histological grading system for 
prostatic cancer, immunohistochemical results were not 
correlated with grading scores. In addition to PSA expression 
we also studied prostate-specific acid phosphatase (PAP) 
expression in this material. 
MATERIALS AND METHODS 
Prostatic tissue 
Prostatic tissues used in this study were obtained from 
prostatectomy specimens. Fifty-five patients (randomly 
selected from a much larger series) with clinically staged 
localized prostatic carcinoma (Tl, T2 and T3) were treated by 
radical prostatectomy in the years 1980-1987 at the Department 
of Urology of Erasmus University Rotterdam. Patients did not 
receive any therapy prior to surgery. 
All immunohistochemical assays were performed on surgical 
prostatectomy specimens. These specimens were routinely fixed 
in 10% buffered formalin, sectioned perpendicular to the 
prostatic urethra and submitted completely for histological 
examination. Tissues were routinely handled and stained with 
haematoxilin-azofloxin. The number of sections per specimen 
varied from 24 to 43. Of each specimen two slides were 
selected in which equally distributed glandular benign 
prostatic hyperplasia (BPH) and tumour areas were present. In 
all slides different subtypes of prostatic carcinoma based 
predominantly upon histological features could be distinguis-
hed. Apart from well-, moderately-, and poorly-differentiated 
adenocarcinomas, a cribriform growth pattern, and an undiffer-
entiated (diffusely infiltrating variant without acinar 
formations) subtype were present in our material. In 
addition, a growth variant characterized by solid undiffer-
entiated tumour areas (medullary growth pattern) and the 
so-called hypernephroid or clear cell type (showing 
resemblance with adenocarcinoma renis) were discerned (see 
Table 1). Tumour patterns with typical endometrioid features 
were not present in our material. 
Primary Antibodies 
PSA specific antibodies: 
PSA purified from extracts of BPH tissue by affinity 
chromatography using the PSA-specific monoclonal antibody ER-
Pr 1 (12) was applied to generate mouse monoclonal antibodies 
and a rabbit polyclonal antiserum (PSA(pc)) using standard 
procedures. Details will be published elsewhere. In short, 
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Table 1. Distribution of different histological 
patterns of prostatic carcinoma and benign 
prostatic hyperplasia in prostatectomy 
specimens obtained from 55 patients with 
localized carcinoma. 
well differentiated adenocarcinoma (WDA) 
moderately differentiated adenocarcinoma (MDA) 
poorly differentiated adenocarcinoma (PDA) 
undifferentiated carcinoma (UC) 
clear cell carcinoma (CCC) 
solid tumour areas (STA) 
cribriform carcinoma (CC) 
benign prostatic hyperplasia (BPH) 
N 
39 
43 
16 
10 
12 
8 
19 
55 
specificity of the antibodies was checked by immuno-(Western-) 
blotting and immunohistochemistry using extracts and tissue 
sections of malignant and non-malignant human tissues from 
different origins. Three monoclonal antibodies (ER-Pr 8, 12 
and 27) which showed the highest reactivity with formalin-
fixed paraffin-embedded prostate tissue were analyzed in 
detail. All antibodies were reactive with a 33-35 kD protein, 
recognized as PSA. Monoclonal antibodies were of the IgG1 
subclass. Ascites batches with high concentrations of 
monoclonal antibodies were used for further studies. The four 
monoclonal antibodies defined three unique antigenic 
determinants of PSA as established by competition ELISA 
assays. ER-Pr 8 and ER-Pr 27 were directed against the same 
PSA-epitope. Antibodies were titrated for optimalization of 
the most suitable dilution for immunohistochemistry. 
Dilutions of all antibodies were selected in such a manner 
that further lowering of the concentration resulted in a 
decrease of staining intensity of BPH control sections. 
PAP specific antibodies: 
A commercially available rabbit polyclonal antibody 
directed against PAP was obtained from Cambridge Research 
Laboratory, Cambridge, Massachusetts (Com-PAP(pc)). Addition-
ally, a rabbit polyclonal antiserum (PAP(pc)) was prepared in 
our own laboratory. PAP was purified from BPH tissue by 
affinity chromatography using a PAP-specific McAb, which was 
able to bind PAP but did not recognize PAP in formalin-fixed 
tissue. Specificity of this polyclonal antiserum was assessed 
by means of the Western blot technique and immunohisto-
chemistry. As cross-reactivity existed at immunohistochemical 
level, the rabbit anti-PAP serum was extensively adsorbed with 
acetone-dried human pancreatic and kidney tissue powder. The 
resulting purified antiserum (PAP(pc)) showed no reactivity 
with pancreatic island cells, kidney tubules, mast cells or 
granulocytes. 
140 
As described above for the PSA antibodies, PAP antibodies 
were used in such a dilution that further lowering of the 
concentration resulted into a decrease of staining intensity 
of BPH control tissue. 
Immunohistochemistry: 
Consecutive paraffin sections were cut at 5 ~m thickness. 
After rehydration of the deparaffinized sections, the sections 
were treated for 20 min with absolute methyl alcohol, 
containing 0.3% H2o2 to block endogenous peroxidase activity. Subsequently, sec~ions were rinsed in PBS. Primary antibodies 
were applied for 1 hr at 37°C. Subsequently, slides were 
incubated with peroxidase conjugated antisera (P-rabbit anti-
mouse or P-conjugated swine anti-rabbit; Dakopatts Denmark) 
for 1 hr at room temperature. Peroxidase activity was 
visualized by incubating the sections in Tris-HCl buffer 
(0.05 M, pH 7.4) containing 0.0125% 3,3'-diamino benzidine 
tetrahydrochloride (Fluka AG, Switserland) activated by 0.03% 
H o (10 min at room temperature). In all cases a brief 
n6cfear counter stain with Mayer's haematoxilin was performed. 
Finally, sections were dehydrated, mounted in malinol and 
examined microscopically. Appropriate positive (BPH) and 
negative control slides were processed in an identical manner. 
Intra-epithelial staining intensities were judged subjectively 
as o (absent), 1 (faint), 2 (moderate), or 3 (strong). For 
purpose of presentation 0 and 1 were considered as negative, 2 
and 3 as positive results. Since heterogeneity (variation in 
number of tumour cells that stain positively) even within the 
same histological subtype was often present, only areas with 
the highest staining intensity were judged in both BPH and 
prostatic carcinoma. 
RESULTS 
Histology of prostatectomy specimens 
It is well established that prostate tumours are very 
heterogeneous. In the prostatectomy specimens investigated in 
this study, adjacent to prostatic carcinoma, areas of proli-
ferative benign epithelial glandular structures (glandular-
BPH) were present in all sections. In some areas groups of 
hyperplastic glands were arranged in nodular formations. In 
the 55 cases examined, tumour heterogeneity was reflected by 
the large number of different growth patterns present in each 
sample. Although the subdivision of growth characteristics of 
prostatic carcinoma such as represented in Table 1 is somewhat 
arbitrary, in our set of tumours the whole range of histo-
logical subtypes in nearly every combination was detectable 
and varied from only 1 histological carcinoma type in 4 cases 
to 5 different patterns in 3 specimens. Adenocarcinomas with 
gland formation, irrespective their degree of differentiation, 
were most frequently observed. Tumours consisting of 
glandular structures were subdivided into well-, moderately-
and poorly-differentiated carcinomas based upon diameter of 
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tumour glands and their resemblance to normal prostatic 
glandular structures. A cribriform growth pattern was 
considered as a separate entity. A total lack of glandular 
formations in tumour tissue was only found in 5 specimens. 
Expression of PSA in various prostate tumour growth patterns 
and BPH present in prostatectomy specimens. 
The set of 55 prostatectomy preparations was analyzed for 
expression of PSA by immunohistochemical techniques using four 
different monoclonal antibodies directed against three differ-
ent epitopes and a polyclonal antiserum (PSA(pc)) (see 
Materials and Methods). In BPH tissue sections some hetero-
geneity in immunostaining patterns was observed with all 
antibody preparations used. This heterogeneity was most 
prominent when monoclonal antibody ER-Pr 1 was applied. 
Heterogeneity was rarely detected in epithelial cells lining 
the same gland, but was observed as a variation of staining of 
different glands. The heterogeneity observed with monoclonal 
antibody ER-Pr 1 could partially be due to a less stable 
appearance of the PSA antigenic site recognized by this 
antibody. In spite of the presence of some unstained glands, 
essentially all (91%-98%) BPH specimens examined were clearly 
stained with three out of four monoclonal antibodies and the 
polyclonal antiserum against PSA. ER-Pr 1 gave somewhat lower 
figures (Table 2 and Figure 1). 
We examined PSA expression in prostatic carcinoma in the 
same tissue slides as used for the study of PSA in BPH. 
Without subdividing the tumour regions into different growth 
patterns, the immunostaining for PSA was scored between 64% 
and 75% of the sections examined (Table 2). Similarly as 
noted in BPH tissue sections, ER-Pr 1 stained the smallest 
number of slides (35 out of 55), whereas the polyclonal 
antiserum (PSA(pc)) and the monoclonal antibody ER-Pr 27 
showed the highest percentage of positives (75%). Figure 2 
depicts four examples of lowered or even absent PSA staining 
in carcinoma areas as compared to the internal BPH control. 
If PSA expression was compared for the various tumour growth 
patterns as summarized in Table 1 an interesting distribution 
could be observed (Figure 1). Fifty to 70% of those tumour 
areas that consisted of glandular structures and designated as 
well- or moderately-differentiated adenocarcinomas stained 
positively for PSA. The variation of staining scored in our 
series of poorly-differentiated carcinoma is possibly due to 
some difficulties in determining the histological criteria for 
this subgroup. The same is true for the small group of solid 
undifferentiated tumours (Figure 1). In general, however, 
this growth pattern showed a low percentage of positives. The 
cribriform growing tumour areas also showed a low staining 
percentage (26 or less). 
The difference between PSA expression in tumour tissue and 
BPH tissue was most striking in the sections containing 
undifferentiated carcinoma. In the latter group almost none 
of the tumour areas could be stained. As stated in the method. 
section we used PSA antibodies at such a concentration that 
further dilution would cause a decrease in the staining 
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Schematic presentation of PSA·immunoreactivity (scored 2 and 3) in BPH areas 
and various gro~o~th patterns of prostatic carcinoma, determined by potyclonal 
(PSA(pc)) · and McAbs (ER·Pr 1, 8, 12, and 27). 1: PSA(pc); 2: ER·Pr 8; 3: ER-Pr 
12; 4: ER-Pr 27; 5: ER-Pr 1. Abbreviations of gro~o~th patterns_ are as described 
in Table 1. 
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intensity of BPH controls. Therefore, the results obtained 
reflect the maximal difference in PSA expression detectable 
with immunohistochemical techniques in the various tumour 
growth patterns and BPH. 
To investigate the effect of antibody concentration on 
detection of PSA expression the 10 slides containing 
undifferentiated carcinoma areas were re-examined with a ten-
fold higher PSA antibody concentration. Results are 
summarized in Table 3. All antibodies used showed essentially 
the same shift in staining intensity. At the low antibody 
titer staining could only be detected in a small number of the 
undifferentiated carcinomas, whereas application of high 
antibody titers resulted into staining of the majority of the 
undifferentiated prostate tumours. It is obvious from these 
results that differences in PSA expression level can only be 
clearly detected if carefully controlled experimental 
conditions are applied. 
Comparison of PSA and PAP expression in prostatic tumour 
sections 
Two different polyclonal antisera against PAP (Com-PAP 
(pc) and PAP (pc); see Materials and Methods section) were 
used for comparison of PAP expression with that of PSA in 
various prostate tumour growth patterns. Similarly as 
described for PSA antibodies, PAP antibodies were applied at 
such a concentration that further dilution would result in 
decreased staining of BPH tissue sections. Figure 3 shows an 
example of the immunostaining found with a PSA and a PAP 
antibody. In this particular tumour area PSA was absent using 
the initial antibody titer, whereas PAP could be readily 
demonstrated. Further results are presented in Figure 4. 
Identical to PSA, PAP expression assessed by either antiserum 
was found to be lower in tumour areas as compared to BPH. 
However, the differences observed were much less pronounced. 
Comparison of PSA and PAP expression in undifferentiated 
carcinoma and in cribriform carcinoma shows that the majority 
of sections examined were positively stained with PAP 
antibodies, whereas the PSA antibodies were in general 
negative (Figures 1 and 4). Both antisera against PAP gave 
Figure 2: 
Examples of diminished or absent (scored 1 or 0) ?SA-immunoreactivity in growth 
patterns of prostatic carcinoma. At the lower half of every photograph an area of 
BPH is present. Original magnification 150x. Selected antibody titers were based on 
maximum staining in BPH areas. 
A Solid tumour areas; section stained by the antibody ER-Pr 12 
B moderately differentiated adenocarcinoma; section stained by the antibody ER-Pr 
27. 
C cribriform carcinoma; section stained by the antibody ER-Pr 27. 
D moderately differentiated adenocarcinoma; section stained by the antibody ER-Pr 
27. 
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Tab1e 2. Number of prostatectomy specimens (%) with 
staining for PSA (scored 2 or 3)jtotal no. 
in benign prostatic hyperplasia {BPH) and 
carc1noma regardless its histological 
characteristics. 
indicated 
specimens 
prostatic 
growth 
Antibodies BPH Carcinoma 
PSA (pc) 53/55 {96%) 41/55 (75%) 
ER-Pr 1 48/55 (87%) 35/55 (64%) 
ER-Pr 8 50/55 {91%) 40/55 (73%) 
ER-Pr 12 52/55 {95%) 36/55 (65%) 
ER-Pr 27 54/55 {98%) 41/55 (75%) 
Tab1e 3. Distribution of immunostaining intensity scores 
(scores 0 and 1 are combined) of PSA within undif-
ferentiated carcinoma areas assessed by polyclonal 
{PSA{pc)) and monoclonal antibodies {ER-Pr 12; ER-
Pr 8) using two different concentrations of the 
primary antibody. 
------------------------------- ------------------------------
0,1 2 3 0,1 2 3 
PSA {pc) 1:6400 7 3 0 PSA {pc) 1:640 0 8 2 
ER-Pr 12 1:102.400 9 1 0 ER-Pr 12 1:10.240 3 4 3 
ER-Pr 8 1:51.200 9 1 0 ER-Pr 8 1:5.120 4 4 2 
essentially identical results. From these data we concluded 
that, in contrast to PSA, PAP expression is considerably less 
correlated with tumor-differentiation. 
DISCUSSION 
Although now accepted as a reliable marker for prostatic 
carc1noma both in serological and immunohistochemical assays 
the detailed possibilities of application of PSA expression as 
a too1 for characterization of neoplastic cells of prostatic 
origin and its precise correlation with tumour differentiation 
are still a matter of dispute. This especially concerns 
fluctuation in PSA expression in various tumours and the 
sensitivity of PSA as compared to PAP. In this study PSA 
expression was investigated in various growth patterns of 
prostatic carcinoma present in prostatectomy specimens. 
Prostatectomy was performed without prior therapy. In 
general, several different growth patterns could be 
distinguished in each prostatectomy specimen and were often 
even present in one single tissue slide. As an internal 
control all tissue sections examined contained, in addition to 
tumour regions, areas of BPH. By this approach fluctuations 
in the data due to experimental artefacts or differences in 
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Figure 3: 
Prostatectomy tissue section showing BPH and an area of 
moderately differentiated adenocarcinoma. Consecutive slides 
were stained by the anti-PSA antibody ER·Pr 12 (A) and the PAP 
(pc) antiserum (B). Chosen antibody titers were based on 
maximum staining in BPH areas. In the tumor area PSA could 
not be demonstrated, whereas PAP could be detected more 
readily. Original magnification 150x. 
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Figure 4: 
Schematic presentation of PSA- and PAP immunoreactivity (scored 
2 and 3) in BPH areas and various growth patterns of prostatic 
carcinoma, determined by polyclonal antibodies Com·PAP(pc)(1), 
PAP(pc) (2) and PSA(pc) (3). Abbreviations of growth patterns are 
as described in Table 1. 
the quality of the tissue slides could be reduced to a 
minimum. PSA expression was correlated to the differentiation 
status of a tumour area. Since consensus is lacking referring 
the most appropriate grading method for prostatic carcinoma no 
attempts were made to compare immunohistochemical findings 
with scores of one of the various grading systems described 
(13,15,19,20). 
The data obtained clearly show a difference in PSA 
expression in BPH and prostatic carcinoma irrespective of its 
histological features. Most pronounced differences were 
detected between undifferentiated tumours and the BPH control. 
Under well-defined conditions (low antibody concentration) the 
majority of undifferentiated tumour areas were negative when 
stained with five different PSA antibodies. In most studies 
described so far, a much higher percentage of PSA positive 
tumours has been reported (1,7,8,10,23), although in part of 
these less intense staining of less-differentiated tumours has 
been noticed. Two of the more recent studies mention the 
absence of PSA staining in (part of) undifferentiated tumours 
(9,16). Further experiments presented here clearly establish 
that the choice of the antibody titer for immunohistochemical 
detection of PSA in tumour material is of utmost importance. 
If higher concentrations of specific antibodies are used most 
of the undifferentiated tumour sections in prostatectomy 
specimens stain positively. 
These data confirm and extend earlier observations that 
PSA is a very good marker for prostate carcinoma. 
Furthermore, the data presented here indicate that at least 
those monoclonal antibodies which are directed against 
dominant epitopes of PSA (in this study ER-Pr 8 and ER-Pr 27) 
are very useful in diagnostic pathology and do not differ in 
sensitivity from polyclonal antibodies. Our results may lend 
support to the assumption that a decrease of PSA concentration 
in the sera of patients with prostatic carcinoma not always 
has to reflect a successful therapeutic intervention, but may 
also be the result of dominant progressive growth of 
undifferentiated prostatic carcinoma. More extensive studies 
correlating immunohistochemical data with PSA serum levels 
have to be initiated to gain better insight in this 
phenomenon. Moreover, it is our opinion that during monito-
ring of endocrine therapy special care must be taken in the 
accurate interpretation of a decrease of serum PSA 
concentration, especially since there are indications that PSA 
expression is influenced by hormones (14). 
In contrast to the results obtained on PSA a definite 
relationship between histopathological growth patterns and PAP 
expression was less apparent. Even at the experimental 
conditions chosen which were optimal for the visualization of 
differential expression, the differences in PAP expression 
level in the various tumour sections were small. From our 
data it can only be concluded that in tumour regions PAP 
expression is slightly reduced. Our data support those 
earlier observations showing that in undifferentiated 
prostatic tumours the presence of PAP can be more easily 
detected than PSA (4,5,9,14,16,17). However, our findings 
contradict the reports of others in which no difference or 
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even a better PSA staining was described in poorly- or 
undifferentiated prostatic carcinomas (1,2,7,8,31). Since the 
prostate specificity of PAP antibodies is sometimes questioned 
(25), we find it to be important to use both PAP and PSA as 
prostatic tumour markers. PAP expression might provide more 
information on the prostate origin of a tumour, whereas PSA 
expression (or its absence) seems to be better correlated with 
histological differentiation. 
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ABSTRACT 
The transplantable, hormone-dependent, human prostatic 
carcinoma PC-82 was used as an in vivo model for monitoring 
the proliferative fraction of tumor cells under the influence 
of androgen withdrawal and resubstitution. The number of 
cycling cells was assessed by means of an immunoperoxidase 
method and monoclonal antibody Ki-67. The number of Ki-67 
positive tumor cells dropped from an average of 17% in 
androgen-supplemented, tumor-bearing female BALB/c mice to 
approximately 1.0% within 10 days after removal of the 
testosterone (T) implant. A similar effect was noted after 
castration of tumor-bearing male BALBjc mice. Androgen 
resubstitution after a 10-day period of T deprivation resulted 
in a rise in the tumor cell proliferation index to 20% within 
4 days. The same pattern of response to androgen depletion 
and resubstitution was found when the number of cycling cells 
in s phase was assessed by the 5-bromo-2'deoxyuridine 
incorporation technique. Administration of supraphysiologic 
dosis of T in intact male mice did not lead to an increase in 
the number of Ki-67-stained nuclei. Androgen manipulation did 
not influence the immunohistochemically assessed expression of 
prostatic acid phosphatase and prostate-specific antigen. The 
rapid effect of hormone deprivation and resubstitution in the 
tumor cell proliferation fraction suggests that monoclonal 
antibody Ki-67 can be used for monitoring the short-term 
effects of hormonal treatment of prostatic cancer. 
INTRODUCTION 
Prostatic cancer is often treated by endocrine management, 
e.g. administration of estrogens, anti-androgens, luteinizing 
hormone releasing hormone agonists and antagonists, castration 
or other androgen-depriving procedures (1,2). In general, the 
therapeutic outcome can only be evaluated after a period of at 
least several weeks (1). In the majority of patients, the 
tumor becomes insensitive to further hormonal therapy as the 
disease progresses (1). To prevent unnecessary side effects 
due to hormonal treatment and to facilitate a timely change of 
the therapeutic regimen, early evaluation of the effects of 
hormonal manipulation of prostatic cancer could be of great 
value. 
The human prostatic carcinoma PC-82 is an androgen-
dependent cell line that can only be maintained by serial 
transplantation into intact male nude mice or into castrated 
male and intact female mice supplemented with androgen (3). 
Due to its androgen-dependent growth, its relatively slow 
growth rate in vivo, its moderately differentiated 
histological appearance (still resembling the original tumor) 
and the secretion of both PAP and PSA, the PC-82 tumor appears 
to be a suitable model for studying hormonal effects on human 
prostatic cancer growth (3-5). 
Recently, a monoclonal antibody, Ki-67, was described (7) 
that identifies a nuclear DNA-related antigen associated with 
proliferation. The presence of this antigen is not only 
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observed in cells in mitosis but also in cells during the G , 
s, and G2 phases (7,8). The antibody, used in an immunohistb-chemical technique, is a reliable tool for the quantification 
of the proliferative fraction of a human tumor. 
In an attempt to detect an early effect of hormonal 
treatment on hormone-responsive prostatic carcinoma, we 
performed an androgen depletion-androgen repletion protocol to 
manipulate tumor cell kinetics in the human PC-82 prostate 
tumor model in nude mice. 
MATERIALS AND METHODS 
Tumor cell line 
The PC-82 prostatic carcinoma was maintained by serial 
transplantation of tumor tissue fragments into intact male or 
into T-supplemented female or castrated male nude mice of the 
BALB/c strain, as described earlier (3). Routinely tumor 
grafts were inoculated subcutaneously into both flanks of the 
host animals. Single- and double-take tumor samples were 
distri-buted equally among the experiments described later in 
this paper. Administration of T in female mice was performed 
by using subcutaneous T-containing Silastic implants (10 mg T; 
average plasma T value, 25 nM/liter) (9). Castration was 
performed via the scrotal route under total anesthesia with 
the use of tribromoethanol (Janssen Pharmaceutica, Beerse, 
Belgium). 
Experimental protocol 
The effects of androgen withdrawal were ~etermined by 
castration of PC-82-carrying intact male nude m1ce. Animals 
were sacrificed at 2, 7, and 10 days after bilateral orchidec-
tomy. 
An androgen depletion-androgen repletion protocol, used to 
manipulate tumor cell kinetics, was applied to PC-82-
transplanted female mice that received at the same time a 
T implant (length, 1.0 em). Androgen withdrawal (i.e., remo-
val of the T implant) was performed when tumors were in the 
exponential phase of growth. The animals were sacrificed at 
different time points after androgen withdrawal or after 
reimplantation with T. This protocol was followed in 4 
separate experiments with the use of different (overlapping) 
time frames. In each study, the duration of the androgen-free 
period was limited to 10 days. In experiment 4 tumor-bearing 
mice also were given ip injections of 10 mg BrdUrdjkg 1 hour 
before they were killed. This procedure was performed to 
attain simultaneous results with different techniques for 
measuring proliferation (10). 
Some tumor-bearing, intact male mice were treated with a 
high dose (100 ~g) of T for 5 days (resulting in high plasma 
levels of T) to examine the effect of supraphysiologic plasma 
T levels on the PC-82 tumor. After sacrifice of the animals, 
tumor nodules were excised, and a representative part of each 
tumor was immediately frozen in liquid nitrogen and stored at 
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-80°C until further use. 
Immunohistochemistry 
All immunohistochemical assays were performed on cryostat 
sections of 5 MID thick. Sections were fixed in acetone for 
10 minutes. Rabbit antibodies directed against secretory PAP 
and PSA were purchased from Ortho Diagnostic Systems, Inc., 
Raritan,NJ. The antigen-antibody binding was visualized with 
an indirect peroxidase-antiperoxidase procedure. 
The murine monoclonal antibody Ki-67, defining a human 
proliferation-associated nuclear antigen, was commercially 
obtained from DAKO, Immunoglobulins Ltd., Copenhagen, Denmark, 
and was applied in a dilution of 1:5 in PBS containing 0.01% 
gelatine and 0.1% sodium azide. To visualize incorporated 
BrdUrd, a murine monoclonal antibody (Becton Dickinson 
Monoclonal Center, Inc., Mountain View, CA), diluted 1:10 in 
PBS containing 0.01% gelatine and 0.1% sodium azide, was used. 
Pretreatment of slides before application of the monoclonal 
anti-BrdUrd antibody was performed in the same manner as 
described by Schutte et al. (10). Pronase treatment of frozen 
slides was, however, omitted. A peroxidase-conjugated 
polyclonal rabbit anti-mouse antibody (DAKO Immunoglobulins 
Ltd.) was used as second-step reagent in the indirect 
conjugated peroxidase assay for detection of Ki-67 and the 
monoclonal anti-BrdUrd antibody. 
In both methods, 0.05% 3.3'-diaminobenzidine tetrahydro-
chloride, in 0.2 M Tris-HCl buffer (pH 7.2) and activated by 
0.075% H2o2 , was employed as a substrate for the peroxidase 
enzyme. Arter the immunoperoxidase staining reaction, slides 
were rinsed in absolute ethanol containing 5% acetic acid and 
8% formaldehyde. Subsequently, the slides were rinsed in tap 
water and counterstained for 10 minutes in full-strength 
Mayer's hematoxilin. In each experiment, control PC-82 
sections were incubated with PBS instead of the primary 
antibody. 
Quantification of the number of cycling cells 
To obtain objective data, in each section 500 epithelial 
tumor cell nuclei were counted in nonadjacent, randomly chosen 
nonperipherally localized, high power fields (objective 100x). 
The mean percentage of immunopositive nuclei per section slide 
was calculated. Counting of nuclei was facilitated using a 
grid of measured dimensions inserted in one of the ocular 
tubes of the microscope. 
RESULTS 
Staining properties of the Ki-67 antibody in PC-82 tumor 
In all sections tested, 
(<30% in all cases) showed 
of immunopositive nuclei in 
and T-supplemented female 
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only a fraction 
immunoreactivity. 
tumor tissue grown 
mice are listed in 
of the nuclei 
The percentages 
in intact male 
table 1. There 
Table 1. Percentage of Ki-67-positive cells of 
PC-82 tumor tissue grown in intact male 
and in T-implanted female nude mice 
Mouse 
#1 
#2 
#3 
#4 
#5 
#6 
#7 
#8 
#9 
Ki-67 positive cells, % 
Males 
12.2 
18.8 
15.4 
18.0 
Females 
14.6 
8.8 
20.0 
21.8 
19.8 
Mean ± SD 
16.1±4.0 
17.0±4.1 
was no statistically significant difference in the proli-
feration index between male and T-supplemented female host 
animals. In the immunopositive fraction, some variation in 
intensity of nuclear staining was observed. Irrespective of 
the degree of nuclear staining, staining of nucleoli was 
always marked (fig. 1), with only slight variation. Prominent 
nucleoli, without staining of the surrounding nuclear content, 
were only sporadically observed. The latter also were regar-
ded as immunopositive nuclei. Independently of the gender of 
the host animal, most slides showed a slightly larger number 
of Ki-67-positive nuclei at the periphery of the tumor and in 
the perivascular region. 
Inasmuch as the vascular and stromal compartments in the 
PC-82 tumor are both of murine origin and as the second 
antibody used was a rabbit antibody directed against murine 
proteins (see "Materials and Methods"), an inevitable but 
moderate background staining of these areas was observed. 
Since the monoclonal antibody Ki-67 was raised against a crude 
nuclear fraction of L428 cells (a Hodgkin's disease-derived 
human cell line), immunoreactivity with nuclei of the murine 
compartment was not found within the human PC-82 tumor. 
Effect of hormonal manipulation on Ki-67 expression in PC-82 
tissue grown in male mice. 
Androgen deprivation by means of bilateral orchidectomy 
resulted in a decline in the percentage of Ki-67-positive 
nuclei (from an average of 16.1% for control mice (table 1) to 
10.7% within 2 days (table 2)). This percentage decreased 
further to 1.5% at 7 days and to 0.2% at 10 days after 
castration. At this time point, changes in the tumor volumes 
or tumor weights were not yet demonstrable. 
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Table 3. Effects of androgen manipulation on proliferative 
activity in PC-82 tumor tissue assayed in 4 kinetic 
studies in female mice. 
Mouse 
#1 
#2 
#3 
#4 
#1 
#2 
#3 
#4 
#5 
#6 
#7 
#8 
#1 
#2 
#3 
#4 
#5 
#6 
#1 
#2 
#3 
R 
L 
R 
L 
L 
R 
L 
R 
L 
R 
L 
R 
R 
L 
R 
L 
Rc 
L 
L 
Rc 
L 
L 
R 
Rc 
L 
R 
L 
R 
L 
R 
EndocriBe 
state 
Ki-67-positive 
cells, % 
(BrdUrd labeling index, %) 
Experiment 1 
To 
T 
T010-
T 10-/2+ 
T 10-/10 
Experiment 2 
T 
T01-
T 2-
T 2-
T 3-
T 4-
T 10-
T 10-/1+ 
T 10-/2+ 
Experiment 3 
To 
T 
T010-
T 10-
T 10-/1+ 
T 10-/2+ 
T 10-/2+ 
T 10-/4+ 
T 10-/4+ 
T 10-/7+ 
Experiment 4 
To 
T 
T010-
T 10-
T 10-/4+ 
T 10-/4+ 
14.6 
14.6 
0.2 
14.3 
17.9 
3.9 
2.7 
2.3 
0.2 
1.5 
0.2 
0.2 
0.8 
0.0 
21.8 
19.8 
1.4 
1.9 
6.2 
5.7 
2.8 
18.8 
21.1 
30.9 
16.3 
18.6 
1.0 
1.0 
19.3 
27.6 
(11. 2) 
(7.4) 
(0.4) 
(0.4) 
(10.4) 
(16.0) 
aR = right; L = Left 
bT0= starting point (time 0);- =duration, days, of T withdrawal; + = duration, days, of T resubstitution 
csections were photographed and are shown in fig. 2. 
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Table 2. Effect of castration on percentage of Ki-67 
positive cells in PC-82 tumor grown in male mice 
Mouse 
#1 
#2 
#3 
Fisure1: 
Duration of 
castration, days 
2 
7 
10 
Ki-67-positive 
cells, % 
10.7 
1.5 
0.2 
Section of the PC-82 tumor, grown subcutaneously in intact male 
mice, and incubated by the monoclonal antibody Ki-67 (150x). 
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Figure 2: 
PC-82 sections derived from tumors grown in female mice at three 
different time points during androgen manipulation (expt 3): at 
10 days after androgen withdrawal (2A), and at 2 days (28) and 
7 days (2C) after reimplantation of T (150x). 
Histologically, no areas of necrosis were found in either 
tumor in this series. 
Administration of high doses of T 
intact male mice did not lead to a 
percentage of Ki-67-positive nuclei 
percentage for control mice. 
(100 ~g) for 5 days in 
further rise in the 
when compared to the 
As judged by the staining intensity in the immunohisto-
chemical assay, androgen deprivation did not affect the 
expression of PAP and PSA. 
Effect of androgen withdrawal and resubstitution on no. of 
cycling tumor cells in PC-82 tissue grown in female mice. 
The results of 4 separate experiments, performed according 
to the depletion-repletion protocol (as described in 
"Materials and Methods"), are shown in table 3. Experiment 2 
showed very low percentages of Ki-67 positive cells on 
day 1,2, and 4 after removal of the T implant, although an 
exceptionally low proliferation index (< 5% positive nuclei) 
was found in the control (TO) tumor at the start of the 
experiment (T ). The other 3 experiments also indicated a 
drastic declin2 in the Ki-67-determined proliferative fraction 
on day 10 after removal of the T implant. A complete return 
of the number of Ki-67-positive tumor cells to the control 
value was attained in the first, third and fourth experiments 
2-4 days after replacement of T (table 3; fig. 2) In the third 
experiment, prolonged resubstitution of T led to a further 
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increase in the proliferative fraction (~ 30% at 7 days). 
Results obtained by the BrdUrd assay for quantification of the 
number of cycling cells in the S phase (table 3, expt 4) were 
in agreement with those obtained by the Ki-67-determined 
proliferative fraction. At 10 days T withdrawal and 7 days 
resubstitution (time point T 10-/7+), the preferential 
perivascular localization of Ki-67-positive cells, noted at 
earlier time points was no longer detectable (fig. 3). 
In all samples listed in table 3, no T-related variations 
in intensity of staining were noticed in the expression of PAP 
and PSA assessed in cryostat sections. 
DISCUSSION 
In this report we describe the early effect of hormonal 
manipulation on the proliferative activity of human prostatic 
tumor cells using the human hormone-dependent tumor model 
PC-82, which is serially transplantable in nude mice (3). 
The sporadic occurrence of mitotic figures in human 
prostatic cancer (11), including the PC-82 tumor, precludes 
the use of this feature for the assessment of the tumor cell 
proliferative fraction. Compared to other malignant 
neoplasms, the low thymidine labeling indices for prostatic 
cancer, as reported by Meyer et al. (12) indicate that a large 
proportion of cells present are either quiescent with respect 
to cell cycle or are progressing through it very slowly with 
long intermitotic intervals. 
Androgen withdrawal in PC-82 tumor-bearing mice leads to a 
complete inhibition of tumor growth but not to a drastic 
regression of tumor volume, whereas resubstitution of T (even 
after longer periods of time) results in a rapid onset of the 
growth rate (4). Therefore, we assumed that during androgen 
deprivation, the cells enter the G0 phase of the cell cycle 
and remain in a quiescent state. 
Although the precise nature of the human nuclear 
proliferative antigen, which is recognized by monoclonal 
antibody Ki-67, is still unknown, Gerdes et al. (8), 
demonstrated that it is expressed in the G , S, G2 , and M phases of all human continuously cycling eells but is absent 
in G phase. Thus application of this antibody in the PC-82 
mode£ might discriminate between resting and cycling cells. 
The present study shows that in PC-82 tumors, expression 
of the Ki-67-defined proliferation antigen declined within 
4 days after removal of the T implant from PC-82 tumor-bearing 
female mice (table 3). A similar decline of cycling cells 
also was observed in castrated PC-82 tumor-bearing male mice 
(table 2). 
In the PC-82 model, a rapid recovery of proliferation 
within 4 days (expts 3 and 4) after T-resubstitution was 
observed (table 3). The 30% of positively stained nuclei at 
7 days after T-replacement (table 3, expt 3) may suggest a 
rebound effect of PC-82 cell proliferation. Further 
experiments covering the traject of 1-10 days after androgen 
replacement need to be performed to verify this phenomenon. 
Controversely, no rise in the percentage of cycling cells, as 
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Figure 3: 
Resubstitution effect as observed at time point T 10-/2+ (3A) in 
expt 3_ Note the preferential localization of Ki-67 positive 
PC-82 tumor cell nuclei surrounding the medium-sized blood 
vessels (3A)- This preferential localization was lost at time 
point T 10-/7+ (36) (70x)_ 
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compared to control values, was achieved after administration 
of high doses of T administration in PC-82 tumor-bearing, 
intact, male nude mice. With the use of the BrdUrd incorpora-
tion technique, only cells in the S phase were detected {10}, 
and as a consequence the percentages of BrdUrd-positive cells 
should be lower as compared to the Ki-67-determined proli-
feration indices. The effects of androgen withdrawal and 
repletion on the BrdUrd labeling indices (table 3, expt 4} 
provided further evidence for the assumption that the changes 
in Ki-67 labeling percentages reflected a decrease or an 
increase of proliferating cells rather than increases or 
decreases in numbers of tumor cells in the G phase. 
Rijnders et al. {13} recently showed th!t the expression 
of the oncogene fos in the PC-82 tumor is similarly regulated 
by androgen withdrawal and resubstitution as is the expression 
of the Ki-67 defined antigen. Analogous to this observation, 
a transient expression of fos-encoded proteins was induced in 
benign fibroblasts very early after growth stimulation by 
platelet-derived growth factor (14). Thus far, one might 
speculate that a deregulated constitutive express1on of the 
fos oncogene can lead to unlimited cell proliferation and 
transformation {15}. 
Contrary to these findings, no T-related changes of the 
immunohistochemically determined expression of PAP and PSA 
were found in our study. Quantitative experiments related to 
the PAP concentration in PC-82 tumor samples, as reported 
earlier {16} are in agreement with these findings. A decline 
in PAP and PSA in the serum of patients under hormone treat-
ment might thus reflect a decrease in tumor volume instead of 
a decline in secretory activity in the individual tumor cells. 
Recently, comparable effects of hormone manipulation on 
proliferative activity were reported from similar experiments, 
in which the rat ventral prostate (17) and the Dunning rat 
prostate adenocarcinoma (18) were used. In the hormone-
dependent Dunning R 3327H tumor it was shown that after a 
postcastration period of 12 days, androgen repletion resulted 
into a rapid increase (from 2 to 10%) of cells in S phase. A 
peak of reactivity exceeding the precastration value was 
reached at 72 hours after androgen administration, after which 
a decline to control levels was observed. 
Further experiments, applying a fluorochrome-labeled Ki-67 
antibody coupled to flow cytometric DNA analysis, may provide 
additional information on the distribution of PC-82 tumor 
cells over the G0 and G phases of the cell cycle at different hormonal stages of the ~ost animal. Since both withdrawal and 
resubstitution of androgens have a profound effect on the 
Ki-67 determined proliferative activity of the PC-82 tumor, 
this technique might be useful for evaluation of the effects 
of hormonal therapy of patients with prostatic cancer. 
Inasmuch as it is possible to perform the here-described 
assay on cytologic smears, the technique of sequential (fine-
needle) aspiration biopsies of (PC-82} tumors might yield 
additional information on proliferative response during 
hormonal manipulation of individual tumors. The application 
of this technique to patients with prostatic cancer thus may 
contribute to the early identification of responders and 
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nonresponders to endocrine therapy. 
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SUMMARY 
Growth fractions were assessed immunohistochemically in 
prostatic tissues with benign glandular hyperplasia (BPH) and 
in specimens of prostatic cancer using the monoclonal antibody 
Ki-67. This antibody is specific for a proliferation-associa-
ted nuclear antigen. In BPH tissues about 0.3% of nuclei of 
epithelial cells was reactive with Ki-67. The Ki-67 positive 
nuclei were distributed equally among the basal and luminal 
cells of the hyperplastic prostatic acini. In prostatic 
cancer the Ki-67 defined growth fraction ranged from 0.4% to 
9.1% (mean value 2.9%). cancers with a cribriform growth 
pattern and tumors composed of solid areas of undifferentiated 
cancer cells showed the highest growth fraction (average 
values 4.0%, respectively 7.6%). The investigated 4 tumors 
composed of undifferentiated solitary tumor cells with diffuse 
infiltration of the stroma demonstrated an unexpectedly low 
growth activity (average 1.2%). In cancers with a glandular 
growth pattern the Ki-67 defined growth fraction of tumor 
cells varied from 2.2% to 5%. Compared with other epithelial 
tumors these values are low, but they are in agreement with 
~he earlier findings on prostatic cancer obtained with 
H-thymidine labeling and bromodeoxyuridine incorporation. 
The observed variation in the level of Ki-67 defined growth 
activity partly related to the histological tumor pattern 
suggests that Ki-67 labeling may serve as a prognostic factor 
additional to the current histopathological grading criteria 
of prostatic cancer. 
INTRODUCTION 
The production and characterization of the murine 
monoclonal antibody Ki-67 directed against a human nuclear 
antigen associated with cell growth has enabled the 
immunocytochemical assessment of growth fractions in frozen 
sections (1-4) and on fine needle aspiration smears (5). The 
Ki-67 defined antigen is present throughout the cell-cycle 
except during GO and early G1 (1,2). Recent studies 
demonstrated that the Ki-67 score correlates well both with 
mitotic index and with S-phase fractions determined either by 
DNA precursor incorporation techniques or by DNA-flowcytometry 
(6-12). Since only a minor fraction of growing cells is in 
mitosis or present in S-phase it can be expected that counting 
of mitotic figures and determination of S-phase fractions by 
tedious methods yield an incomplete reflection of the actual 
growth activity of a given tumor. The latter disadvantages 
are surpassed by the application of the Ki-67 antibody. 
Prostatic cancers pursue a highly variable course. The 
predictive value of current histological grading systems for 
prostatic cancer is hampered by the lack of inter- and intra-
observer reproducibility (13). In contrast with grading 
systems developed for other types of cancer (e.g. breast 
tumors; 14), most grading methods for prostatic cancer do not 
imply the mitotic rate in the criteria for grading. The use 
of this parameter as a prognostic criterium in prostate cancer 
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has probably been impeded due to the extremely low number of 
mitotic figures in these tumors. Meyer et al. (15} and Nemoto 
et al. (16} have confirmed this low proliferative activity in 
normal prostate, BPH and prostatic cancer by determination of 
s-phase fractions. 
In this study we investigated the Ki-67 defined growth 
fractions in human prostatic cancer and BPH and we sought to 
establish a possible relationship between Ki-67 assessed 
growth rates and histopathologic characteristics of prostatic 
carcinoma. 
MATERIALS AND METHODS 
Prostatic tissue 
Prostatic tissue was obtained from 33 patients with 
localized prostatic cancer, randomly selected from a much 
larger series. These patients underwent in the years 1983-
1988 a suprapubic total prostatectomy. Prior to surgery no 
other therapy, especially no hormonal treatment was given. 
Immediately after surgery, prostatectomy specimens were 
sectioned in a step-wise fashion perpendicular to the 
prostatic urethra. Tumor areas were macroscopically localized 
and proven by means of histologic examination of cryostat 
sections routinely stained with eosin-Mayer's haematoxilin. 
Subsequently, samples of tumor areas were snap frozen in 
isopentane and stored in liquid nitrogen until further use. 
The remainder of the specimen was fixed in buffered 10% 
formaldehyde solution and submitted in toto for routine 
histopathologic examination. Similarly, 6 samples of 
transurethral specimens of patients with benign prostatic 
hyperplasia were snap frozen. Again, none of these patients 
received hormonal treatment prior to endoscopic resection. 
Immunohistochemistry 
The murine monoclonal antibody, Ki-67, was purchased from 
Dako Immunoglobulins Ltd., Copenhagen, Denmark. As second 
step reagent a peroxidase-conjugated polyclonal rabbit anti-
mouse immunoglobulin serum was applied (Dakopatts, Denmark). 
In brief: 6 ~m cryostat sections were cut from each sample, 
air dried and fixed for 10' in acetone. Afterwards, slides 
were rinsed in phosphate buffered saline (PBS; pH 7.4) and 
incubated with the Ki-67 monoclonal antibody for 60' at room 
temperature at a dilution of 1:5 in PBS containing 0.01% 
gelatine and 0.1% sodium azide. Subsequently, sections were 
rinsed in PBS to remove the excess of unbound antibody, 
followed by incubation with the second reagent. After a final 
thorough washing in PBS, antigen-antibody binding was 
visualized by incubating the sections in TRIS-HCl buffer 
(0.05 M, pH 7.4) containing 0.0125% 3,3'-diamino benzidine 
tetrahydrochloride (Fluka AG, Switserland) activated by 
0.03% H~o2 (10' at room temperature). Sections were lightly counter~tained with Mayer's haematoxilin for exactly 
15 seconds to obtain a discrete nuclear staining pattern 
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without obscuring the Ki-67 reactivity. Replacement of the 
primary antibody by PBS served as a negative control whereas 
frozen sections of the prostatic cancer cell line PC-82 (grown 
in the presence of androgens) were considered as positive 
controls (17). Of all samples analyzed immunohistochemically 
with the Ki-67 antibody (human prostatic tumor; BPH and PC-82) 
consecutive sections were stained routinely with haematoxilin 
and eosin for optimal microscopic examination in order to 
evaluate the different histologic growth patterns. No attempt 
was made to determine the mitotic rate. 
Assessment of the Ki-67 defined growth activity 
Tissue sections stained with the antibody Ki-67 were 
examined by light-microscopy. Counting of negative and 
positive nuclei was performed at a magnification of 400x. For 
enumeration a number of high-power fields were randomly 
selected. To facilitate the counting procedure a grid of 
measured dimensions was inserted in one of the ocular tubes. 
The number of nuclei observed in every case ranged from 500 to 
1000. Regardless of its intensity and distribution within the 
nucleus, cell nuclei were considered as positive if there was 
any nuclear staining present. As proposed by others (18) the 
Ki-67 growth fraction or Ki-67 score was determined by the 
quotient of Ki-67 positive cells and total number of cells. 
In those specimens showing more than one architectural tumor 
growth pattern counting was performed for each histologic 
growth pattern separately. 
Statistical analysis 
To investigate a possible relationship between the Ki-67 
score and diverse histologic growth patterns of prostatic 
cancer the Mann-Whitney U test was used (19). One-tailed 
probabilities were determined. 
RESULTS 
Histology 
The 6 cases of BPH investigated in this study were 
exclusively characterized by proliferation of the epithelial 
fraction resulting in hyperplastic glands showing intraluminal 
papillary folding of the lining epithelium. Apart from 
arrangement of hyperplastic glands in (often enlarged) lobular 
formations, a nodular appearance of proliferating glands was 
observed. No other types of prostatic hyperplasia such as 
fibromuscular proliferation or exclusive proliferation of the 
basal cell layer of prostatic acini were included in this 
survey. Nor was squamous metaplasia present in those sections 
used for assessment of the Ki-67 defined growth fraction. 
Instead of grading, prostatic tumors were categorized into 
several growth characteristics according to generally accepted 
features. Apart from tumors consisting of glands and designa-
ted as well-, moderately, or poorly differentiated adenocarci-
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nomas (respectively WDA, MDA, PDA), also undifferentiated 
cancers (UC), tumors with cribriform growth patterns (CF) and 
tumors composed of undifferentiated neoplastic cells arranged 
in well circumscribed islets (considered as solid tumor areas: 
STA) were discerned. The latter growth characteristic is by 
other investigators designated as a medullary pattern (16). 
Heterogeneity of prostatic cancer was reflected by the 
fact that in the 33 cryostat sections derived from 
33 different prostatectomy specimens a total of 40 growth 
patterns could be recognized (Table 1). Two growth patterns 
were present in 5 cases. In one case even 3 growth patterns 
could be detected. The human androgen-dependent prostatic 
cancer cell-line PC-82 shows an exclusive cribriform growth 
pattern. 
Ki-67 defined growth fractions in glandular BPH 
The number of cells that showed nuclear immunoreactivity 
for the ·Ki-67 antibody in BPH tissue sections was low. Data 
are presented in Table 1 and Fig. 1. Immunopositive nuclei 
were equally distributed amongst basal cells and inner 
cylindric cells (Fig. 2A}. In the 6 cases of BPH studied a 
mean value of 0.3% Ki-67 positive cells was found. In some 
hyperplastic glands cytoplasmic immunostaining was present in 
basal cells; nuclei in these cells lacked immuno-reactivity 
(Fig 2B}. A similar cytoplasmic staining pattern was 
recognized by others in breast and cervical epithelium 
(12,20), but this reactivity seems not to be correlated with 
proliferative activity. Background staining was fully absent. 
Sporadically, nuclei of stromal cells showed Ki-67 reactivity. 
Table 1. Ki-67 defined growth fractions 
in various histologic growth 
prostatic carcinoma, in BPH 
cancer cell line PC-82. 
(or Ki-67 scores) (%) 
patterns of human 
and in the prostatic 
N 
benign prostatic hyperplasia 6 
human prostatic cancer cell line (PC-82) 9 
well differentiated adenocarcinoma 4 
moderately differentiated adenocarcinoma 15 
poorly differentiated adenocarcinoma 8 
undifferentiated carcinoma 4 
cribriform carcinoma 7 
solid tumor areas 2 
* see reference 17 
range 
0.2-0.4 
8.8-21.8 
0.7-4.0 
0.4-4.8 
0.6-7.1 
0.6-2.5 
1.7-7.5 
6.2-9.1 
mean 
value 
0.3 
16.6* 
2.9 
2.5 
2.5 
1.2 
4.0 
7.6 
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Figure1: 
Ki-67 defined growth fractions in glandular benign prostatic 
hyperplasia (BPH), and in the various growth patterns of 
prostatic cancer i.e. adenocarcinomas (AC): well differentiated 
adenocarcinoma; moderately differentiated adenocarcinoma; poorly 
differentiated adenocarcinoma (\IDA: .A. , MDA:@, PDA: ,.- ), and 
cribriform cancer (CF), undifferentiated cancer (UC), and solid 
tumor areas (STA) (all latter tumor patterns including BPH are 
depicted in the figure ase). 
Figure 2: 
Immunolabeling of glandular BPH with Ki-67. A: Immunopositive 
nucleus within the inner cylindric cell-layer of hyperplastic 
acinus (magnification 600x). B: Cytoplasmatic expression of 
Ki-67 in the basal cell layer of hyperplastic gland without 
nuclear immuno-reactivity (magnification 380x). Nuclear 
counterstaining with haematoxylin. 
173 
Ki-67 defined growth fractions in prostatic carcinoma 
In general, staining was most prominent in the nucleoli of 
neoplastic cells. In some tumor cells only nucleoli were 
stained, whereas the remainder nuclear area was negative. 
Results of the Ki-67 defined growth fractions related to the 
different histopathologic growth patterns of prostatic cancer 
are summarized in Table 1 and Fig. 1. Comparatively high Ki-67 
scores were obtained in CF and in STA tumors. The highest 
growth activity was observed in the PC-82 tissue sections 
(16.6%). In the 4 UC cases the Ki-67 values tended to be 
lower in comparison with those obtained in cancers with 
glandular differentiation regardless of their differentiation 
grade, but no statistical significance was reached (p = 0.07). 
The growth fractions of CF were significantly higher than 
those of UC cancers. Similarly, the CF cancers had higher 
Ki-67 values than cancers with glandular differentiation 
irrespespective of their differentiation grade (p = 0.05). 
When CF cancer combined with STA were compared with 
adenocarcinomas regardless their grade of differentiation 
statistical significance was obtained (p = 0.01). Examples of 
Ki-67 labeling in different growth patterns of prostatic 
cancer are presented in Fig. 3. In all tumor samples 
heterogeneity of the Ki-67 nuclear staining pattern was 
considerable and often clustering of immunopositive nuclei was 
observed. By counting at least 500 nuclei a bias in the 
selection of tumor areas was avoided as much as possible. 
Contrary to basal cells in BPH, tumor cells did not display 
cytoplasmic Ki-67 immunoreactivity. In morphologically 
heterogenous prostatic tumors it appeared that the Ki-67 score 
was identical in each of the growth patterns within the same 
tumor. For example, in the case characterized by the presence 
of WDA, MDA and CF tumor areas, the Ki-67 defined growth 
fraction was assessed at 3.8%, 3.5% and 3.5% respectively. 
DISCUSSION 
Since a close correlation between Ki-67 labeling on the 
one hand and mitotic rate or s-phase fraction on the other 
hand has been demonstrated in various tumor types, the 
immunocytochemical assessment of the Ki-67 defined antigen may 
be regarded as a reliable technique to measure cell-kinetics 
(8,10,11). A relative disadvantage is that the antibody is 
exclusively applicable on either fresh frozen tissue sections 
or fine needle aspiration smears (5,8). 
In normal and diseased prostatic tissues mitotic figures 
are rarely encountered. The latter is reflected in this study 
by the very low Ki-67 defined growth fraction in glandular 
BPH. Our average value measured in BPH (0.3%; see Table 1 and 
Fig. 1) is consistent with the previously repo3ted S-phase 
fraction (0.31%) assessed by in vitro uptake of H-thymidine 
(15). The thymidine labeling index of stromal cells in 
prostatic hyperplasia was even considerably lower (15). 
The low Ki-67 scores found in BPH hardly overlapped with 
the values obtained in prostatic cancer (Fig. 1). The 
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Figure 3: 
Four examples of Ki-67 immunostaining reactions 
growth patterns of prostatic cancer. Magnification 
A: Well differentiated adenocarcinoma 
B: Perineural arrangement of a cribriform cancer 
C: Solid tumor area 
0: Poorly differentiated adenocarcinoma 
in different 
380x. 
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observed distribution of Ki-67 immunoreactive nuclei among the 
inner cylindric and the outer basal cell layer of the 
hyperplastic prostatic glands supports the hypothesis that the 
basal cells do not solely account for the regenerative 
potential of glandular prostatic epithelium (22). 
Occasionally, the Ki-67 antibody reacted with the 
cytoplasm of the outer basal cell layer (Fig. 2B). The nuclei 
of these cells remained unstained. Cytoplasmic 
immunoreactivity was not observed in the inner cylindric cell 
layer, nor in the cytoplasm of neoplastic epithelial cells or 
in the cytoplasm of stromal cells. To our knowledge 
cytoplasmic Ki-67 staining is not directly related with 
proliferative activity. 
Prostatic carcinomas displayed a rather low growth 
fraction (mean value 2.9%); mitotic figures are scarcely found 
and the Ki-67 score is low especially when compared with 
epithelial benign and malignant lesions of other origin (see 
Table 2; ref. 5,7,8,10,12,17,20,21,23-28). With reference to 
other human epithelial tumors for as yet the highest Ki-67 
scores are reported for high grade lung cancers (26), breast 
cancers (23), carcinomas of the cervix uteri (20) and high 
grade adenocarcinomas of the large bowel (27) (Table 2). In 
comparison with prostatic cancer these tumors display even at 
routine histological examination a much larger number of 
mitotic figures. 
Similar observations concerning the relatively low growth 
rate in prostatic cancer were made by Meyer et al. (15). The 
average fract~on of prostate tumor cells in S-phase assessed 
by in vitro H-thymidine labeling measured 0.90% (15). After 
intravenous injection of BrdUrd in patients with prostatic 
cancer, Nemoto et al. recently found an average S-phase 
fraction of 2.86% (16). These latter authors selected well-
labeled tumor areas for counting. In contrast to these low 
proliferation scores, Raymond and coworkers reported a mean 
Ki-67 score of 16.3% in human prostatic cancer samples (21). 
Their discrepant data might be explained by a different 
immunohistochemical method. We feel, however, that our 
results are more compatible with those obtained by the afore-
mentioned authors who used in vitro or in vivo DNA-precursor 
incorporation techniques. 
In human and rat prostatic cancer cell lines proliferative 
activity appeared to be considerably higher than 1n the 
patient material. Ki-67 defined growth fractions in the human 
prostatic carcinoma model PC-82 (cribriform growth pattern) 
ranged between 8.8% to 21.8% (17). In the androgen dependent 
Dunning R3327H rat model of prostatic adenocarcinoma flow-
cytometry studies revealed 4.02% cells in S-phase (29). 
Synchronization of cell-kinetics by means of short-term 
castration subsequently followed by renewed administration of 
androgens resulted into a maximum increase in s-phase cells 
till 9.72% (30). In the human PC-82 model using Ki-67 as 
proliferation marker we found a similar rebound effect (17). 
In this study we hav8 avoided to include patients who were 
treated by hormones prior to surgery. 
The precise relationship of cell kinetic data and 
histologic growth patterns of prostatic cancer remains 
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Tab1e 2. Comparison of Ki-67 defined growth fractions in 
benign and malignant epithelial lesions of various 
organs as reported in literature. 
percentual Ki-67 score 
mean values 
Benign Lesions 
benign breast disease 3 
mammary fibro-adenoma 1.0 
mammary fibro-adenoma 1.1* 
benign prostatic hyperplasia 0.3 
Malignant Lesions 
breast cancer 14.3 
breast cancer 16.7 
breast cancer 10.5* 
breast cancer 22.0 
breast cancer 16.0 
breast cancer 20.7 
breast cancer 16.2 
cervix carcinoma 30.7 
small cell cancer of lung 65 
colorectal cancer 43.8 
adenocarcinoma of lung 24.6 
prostatic cancer 16.3 
prostatic cancer 2.9 
prostatic cancer cell-line 
PC-82 16.6 
metastases of breast carcinomas 
in brain 47.6 
Lit ref (no.) 
23 
24 
5 
this study 
8 
23 
5 
10 
12 
7 
25 
20 
26 
27 
26 
21 
this study 
17 
28 
* Ki-67 rate was assessed in fine needle aspiration (FNA) 
smears. In stead of the mean values, the median figures are 
given 
unclear. Our results indicate that CF (including STA) 
prostatic cancers strongly tend to have higher Ki-67 
proliferative rates compared with cancers consisting exclusi-
vely of glandular formations (p = 0.01). In contrast, the 
4 UC displayed an unexpectedly low proliferative activity as 
judged from Ki-67 labeling. These findings suggest that the 
level of Ki-67 labeling is partly dependent on the tumor 
growth pattern. On the other hand, we found that within the 
investigated 6 morphologically heterogenous tumors the same 
Ki-67 score was obtained for each of the composing growth 
patterns. The latter observations indicate that Ki-67 
labeling is - to some extent - independent of growth pattern 
and seems to be a more characteristic feature for the 
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individual tumor. A possible trend of increasing S-phase 
fraction and Ki-67 defined growth fraction with increasing 
Gleason score was also reported by others (15,16,21). 
Unfortunately, these studies were performed largely on biopsy 
samples and the precise value of histopathological grading 
upon small tissue samples is often questioned (31,32). 
Moreover, the reproducibility of the rather complex Gleason 
grading system is still controversial (13,33). Of utmost 
interest was the observation that metastatic prostatic cancer 
tended to have a higher fraction of tumor cells in s-phase 
compared with primary tumor deposits (15). 
Since a reliable, reproducible, and generally accepted 
grading system based on histopathologic features in prostatic 
cancer is not available as yet, the assessment of tumor cell 
kinetic data may provide additional information refering the 
prognosis of prostatic cancer. Of those methods currently in 
use (DNA precursor uptake and DNA flow cytometry) the Ki-67 
technique can be considered as the most simple assay, which 
has proven its significance in many other tumors and is 
regarded as a reliable marker in the immunologic armamentarium 
of the routine pathologist. The precise elucidation of the 
prognostic value of Ki-67 labeling in prostatic cancer will, 
however, require extensive prospective studies, encompassing 
large numbers of patients. These studies should give insight 
whether Ki-67 labeling has to be regarded as a strongly 
independent prognostic factor or dependent on other variables 
such as histologic growth pattern. 
ACKNOWLEDGMENTS 
The authors wish 
statistic evaluation 
skilful photographic 
excellent secretarial 
manuscript. 
178 
to thank Dr. P.G.H. Mulder for advice on 
of the material, Mrs P. Delfos for 
assistance and Mrs. M. Hanegraaff for 
help in the final preparation of the 
1. Gerdes, J., SchwabL~!!:!.... Lemke, H.,. arrl Stein, H.: ,Production. of a 
~ monoclol191 am::.~y react1ve Wlth a human ant1gen assocaated 
Wlth cell prollferat1on. Int. J. cancer, 31: 13, 1983. 
2. Gerdes, J., Lemke, H., Baisch, H., Wacker, H.H., Schwab, U. arrl 
stein, H.: Cell cycle analysis of a cell proliferation associated 
human nuclear antigen defined by the monoclonal antibody Ki -67. J. 
Immunol. 133: 1710 1984. 
3. Gerdes, J., Da.llenbach, F., Lermert, K., Lemke, H. arrl Stein H.: 
GrcMth fractions in malignant non-Hbdgkin's lymi:itlomas as determined 
in situ with the monoclonal antibody Ki-67. Hematol. oncol., 2: 365, 
1984. 
4. Baisch, H. arrl Gerdes, J.: Simultaneous sta~ of exponentially 
~jng versus plateau~ cells with the proliferation-associatea. 
antjJ::x:x;ty Ki-67 arrl propidimn iodide: analysis by flow cyt.orretry. 
Cell T1sssue Kinet. 2D: 387, 1987. 
5. Kuenen-Botnneester, v., Blank, D.I.i arrl Van der Kwast, 'lh.H.: Inununo-
cytc;x::hemical staining of pro iferat.:!ng cells 1n fine needle 
aspiration smears of prillary ana metastatic breast tumours. Br. J. 
CafiCer, 57: 509, 1988. . . 
6. Schrape, s., Jones, D. B., W:nQht, D.H.: A c;:orrpcq:1son of three methods 
for t.he detennination of the qrowth fraction in non-Hodgkin' s 
lynphoma. Br.J.cancer.t. 55: 283, ,19S7. . . 
7. Barnard, M.J., Hall, :r-.A., Iemo1ne, N.R. arrl Kadar, N.: Prol1ferat1ve 
index in breast carcinoma determined in situ by Ki-67 immunostain4!g 
arrl its relationship to clinical arrl pathological variables. J. 
Patho+. 152: 287, 1987. .. . . . 
8. Sasaki, K., Matsumura, K., '1'9UJ~, T., Shinozakit. F., Takahashi,~ M.: 
Rel~tionship between labellng ina.ices of Ki -67 ana Bi:'dUrd in numan 
rnall9J:I'ffit tumors. ~, 62: 989, 1988. . 
9. SasaJq., K., Murakami, T., J.<awasaki, 1:1·, Takahashi, M,: '!he cell cycle 
assoc1ated ~e of the Ki -67 react1ve nuclear ant1gen express1on. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
J. Cell. Phys1ol., 133: 579, 1987. 
M<:::Gu;:rin,~_,J.F.J. Doria, M.I., Dawson, P.J., Karrisonf. T., Stein, H.O. 
arrl rraruu.in, w.A.: Assessment of tumour cell kine ics by :imnuno-
histoch~st.:IT in carcinoma of t:!fe breast. cancer..,_ 59: 1744.c. 1~87. 
Schwartll1Cf, R., Gerdes, J. 1- N1ehus, J. , JaescnKe, L. , :::>teln, H.: 
Detenninat10n of the grc::IW!:h rraction in cell suspensions by flow 
cvtorne1:J::y using the monoclonal antibody Ki -67. J. Immunol.MetlJ.. , 90: 
65. 1986. 
waiker, R.A. arrl camplejohnt. R.S.: Comparison of monoclonal antibody 
Ki-67 reactivity with graae arrl rnA flow cytorneb:y of breast 
carc1nomas. :&. J. cancer, 57: 281, 1988. 
Ten Kate, F.J.W., Gallet?, M.P.W . .t. Schrnitzi P.I.M., Joebsisi A.C:, 
Van der Heul, R.O. L Prlns, M.E.r·. arrl B om, J .H.M.: Prob ems 1n 
g:t:ading of prostadc carcinoma: interobserver variability of five 
different graaing §YSterns. World J. Ural., 4: 147, 1986. 
Ba.ak, J.P.A.L_~an DOp, H:, KUIVer, :r.H.J. ~ Hennans, J.: '!he value 
of mo:rphorne~.,L.y to class1c prognost1cators 1n breast cancer. cancer, 
56: 374 1985. 
Meyer, J.S., SUfrin, G. arrl Martin, S.A.: Proliferative activity of 
befrign hu!nan PX'Q9~te, prQ9tatic adenocarcinoma arrl seminal ves1ele 
evaluated by tllynq.d1ne labelP.19'. J .. Ural. , 128: 13!?3, 1982. . 
Nemoto, R., lTchi~....._~:L Shima.ZUl, T., Hattor1, K_:L_ __ Ko1soi K., 
Harada, M.: Inununl:.'l:'yl...u .. :uemical demonstration of S pru:t= eel s by 
anti -b:i:'ornc;x:leoxytl!"idine monoclonal antibody in h\.nnan prostate 
adenocarc1noma. J. Ural., 141: 337 .c. 1989. 
Gallee, M.P.W.t. Van Steenbr1.1gge, (,j.J., Ten Kate, F.J.W., Schroeder, 
F .H. and Van aer Kwasti '!h. H.: Detennination of the proliferatieve 
fraction of a t:;ransp antable ho:nnone dependent, h\.nnan prostatic 
carcinoma {PC-82) by mol).ocl9nal ant~ Ki -"67: potential application 
for ho:nnone therapy mon1tonng. J. Natl. cane. illst. , 79: 1333 J. ,1987. 
Hall, P.A • .c. Richaros, M.A., G~o:ry, W.M., D'Ardenne, A.J • ..c. Lister, 
T.A. arrl ::;tansfeld, A.G.: '!he prognostic value of Ki-6t :imnuno-
stai.ni!B in non-Hcx;lqkin's lvmohoma. J. Pathol. 154: 223, 1988. 
Mann, H.B. arrl Whitney, D.f{.": On a test of whether one of two random 
vari<;lbles is stochastlcally larger than the other. Ann. Math. 
stat1st., 18: 52, 1947. 
Brown, D.C., COle, D., GatterL K.C. arrl Mason, D.Y.: carcinoma of the 
cervix uteri: an assessment:. of tumour proliferation using the 
monoclonal antil::>ody Ki-67. Br. J. cancer 57:.178, 1988. 
Rayrnondr.. W.A:, I.e<;mg.., A. S-Y., Bo+t, J.W., Mil1os, J. ~Jose, J:S.: 
9r0wt:h rrac;:t~ons 1n numan prostatlC carc1noma determined by Ki -67 
J..IlUllUl10 sta1nrng. J. Pathol. , 156: 161, 1988. 
179 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
31. 
32. 
33. 
180 
Al.Blllleller, G.: Morphologic and endocrine aspects of prostatic 
function. The Prostate 4: 195 1983. 
Gerdes, J., Lelle, R.J., Piekartz, H., J:Ieidenreich, W., S<::lJ.w¥ting, 
R. , KUrtsJ.efer, L. r, • Stal,lchr, G. and St:elll, H. : GrOwth fractJ.Ons m 
breast carcinomas ae1:eilllinea. in situ with monoclonal antibody Ki -67. 
J. Clm. Bathol., 39: 977L_1986. 
Gerdes, J. : An ilmnunohisOJ19C;Jical method for estiJnating cell ~ 
fractions in rapid hist::opathological diagnosis during sm:gery. Int. 
J. cancer~ 35: 1o9r. 1985. 
Lelle .( R. oJ • , Heiaenreich, W. , Sta~<;:h r G. and Gerdes r. J. : '!he 
corre.Lation of grcMt:h fract:i9ns with nis"t:Oloqic qradinq an::1 lytniimode 
status m human~ carcl.l10llla. cancer, 59; s~J- 1987. 
Gatter, K.C., Dillmill, M.D., Gerdes, J., Stem, .t1. and Masoni D.Y.: 
New approach to assessJ..ll:3" lung tumors in man. J. Clin. Patho • 39: 
590, 1986. . . . 
ShePherd, N.A., Riclnnan, P.r. and England, J.: Ki-67 derJ.ved 
prolif~tive activicy in colorectal adenocarcinoma with prognostic 
correlatJ.ons. J. ~thol."- 155: 2:p, 1988. 
~~er P.C., Shiba~J T., Kleihues, P.: '!he use of the monoclonal 
ant . . Ki-67 in. =e J.dentificatJ.On of proliferating cells: 
appll.ca J.On to sm:gJ.cal neuropathology. Am. oT. surg. Bathol. , 10: 
611 1986. 
English, H.F.i Drago, J.R. and Santen, R.J.: Cellular ~nse to 
an;:trogen dep etion and repletion in the rat ventral prostate: 
autoradiography and moxph~tric analysis~ The Prostate, 7: ~1, 1985. 
~ll.sh, H.~, Kloszewskil- E.D., ValentmeJ. E.G. and Santen, R.J.: 
PrOliferative resp::Jnse or the D.mning R33z7H experimental mOdel of 
prostate adenocarcmoma to conditions of anC!rcqen depletion and 
repletJ.on. cancer Res., 46: 839i 1986. 
Mi119, S.E. and Fowlt?r, J.E.: G ea59n histologic qra~ of prQ9tatic 
carcl.l10llla; correlatJ.ons between bl.Opsy and prostatectllmy specJ.mens. 
cancer 57: 346, 1986. 
Garnett, J.E., Oyasu, R. and Grayhack, J.T.: '!he accuracy of 
diagnost:ic bJ.Opsy ~imens in predlcting tumor grades bv Gleason's 
classification orracfical prostatectomy specimens. J. "IJrol.' 131: 
690, 1984. . Hara9a, M., Most9f1, F.K . .,,Corle, .D.K., Byar, D.~. and Trumpl- B.F.: 
Prelll111IlarY studJ.es of !ll.StoloqJ.c proqnoses m cancer or the 
prostate. Cancer Treat Rep., 61: 223, 1977. 
CHAPTER VIII 
GENERAL DISCUSSION 
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In the papers presented in this thesis, we have searched 
for parameters of prognostic relevance for PC. In general our 
survey encompasses the study of three putative parameters 
linked with the biological behavior of PC. 
Initially we have examined the reproducibility of five 
conventional histological grading systems currently in use for 
PC. Histological grading was performed by 5 pathologists with 
varying experience in both general pathology and pathological 
aspects of male urogenital oncology. All participants in the 
study received prior to histological grading the original 
papers in which the grading methods were explained. None of 
the grading methods displayed a good interobserver agreement 
such as measured by statistical evaluation. A reasonable 
interobserver consensus was reached in the methods based 
primarily on histological (architectural) criteria in simple 
grading methods as those designed by Broders and Brawn. 
Though inconsistent with several reports from the United 
states, the complex Gleason system showed only a poor 
consensus among the 5 observers. 
The prognostic performance of the 5 grading methods ~as 
described in a subsequent paper. Extended data concern1ng 
time relapse to recurrence (progression) and time relapse to 
death were available. Results indicated that the methods of 
Broders and that described by Mostofi-Schroeder displayed the 
highest predictive value especially regarding the end point 
"recurrence". Of special interest was the observation that 
the application of more than one histological grading system 
on the same tumor may enhance the predictive value of grading. 
In our study this appeared to be the case with the afore 
mentioned two systems. summarizing our data obtained with 
histological grading several conclusions and comments can be 
made. ~ Reproducibility of results derived from histological 
grading seems poor. ~ Experience of the observers will 
undoubtedly influence results positively. ~ Simple grading 
methods are preferable since some of these show at least a 
reasonable agreement. 
A general drawback of histological grading is that the 
majority of grading methods designed for PC allow only the 
morphological judgment of one growth pattern. However, it is 
generally accepted that many tumors including PC are composed 
of several areas differing in morphological appearance (and 
also in immunophenotypical make up). On the other hand the 
only method investigated in our survey that permitted to grade 
two growth patterns (Gleason technique) showed even less 
interobserver agreement. The latter problems especially occur 
when large specimens are available for histological grading. 
'Though theoretically the accuracy of grading has to increase 
when a large number of slides of each tumor is available, in 
practice the interobserver agreement will be hindered. For as 
yet there is, particularly in the case of PC, no consensus 
upon which type of specimen histological grading has to be 
performed. 
Our survey regarding the prognostic accuracy of 
histological grading has to be evaluated with some 
restrictions. At first, the performance of a total 
prostatectomy has undoubtedly influenced the prognostic end 
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points studied. Secondly, our data set was derived from the 
same tissue slides that were previously used to set up the 
recently described new grading method by Schroeder and 
Mostofi. And thirdly, we have utilized for statistical 
calculations the average (or mean) values of grading data 
obtained from 5 observers. In spite of these restrictions, of 
interest might be our observation that the simultaneous use of 
more than one system on the same tumor may improve the 
predictive value of histological grading. As far as we know 
this has not been suggested previously for PC. One can 
imagine especially for PC, for which tumor diverse 
histological grading techniques have been developed, that one 
method supplies additional prognostic information to another. 
Preliminary results presented here have to be regarded as a 
challenge to combine other grading systems than the one 
described, not only for prostatic tumors but also for 
malignancies of other origin. 
Subsequently, immunological aspects of PC have been 
studied. In the beginning we have attempted to generate TAAs 
or TSAs using the well-characterized human PC model PC-82. 
However, our attempts have been without success in this 
regard. Numerous McAb's produced by hybrid cell lines were 
generated. Though interesting cross-reactivity immunocytochem-
ical profiles with human malignant and non-malignant tissues 
were encountered, none of the McAb's showed an exclusive 
binding for prostatic cancer cells. As was known already, the 
PC-82 cell line maintained PAP expression. Therefore, it was 
not surprising that some of the antibodies were directed 
against PAP. PA expression was also retained in the PC-82 
cells as some of the antibodies were directed against 
antigenic sites of PA. McAb's prepared against PAP and PA 
enabled the further purification of both prostatic tissue-
specific markers and resulted in the generation of sets of 
monoclonals and monospecific polyclonal rabbit antisera. At 
least three different epitopes of PA could be recognized by 
our set of monoclonal antibodies. As some of the monoclonal 
antibodies were applicable on formalin-fixed sections further 
immunocytochemical elucidation of especially PA expression was 
examined in human PC tissue sections and the relation was 
studied with histological tumor differentiation. Since the 
reliability of assignment of grading scores was questioned, no 
correlation was performed with data derived from grading 
systems. Our studies indicate that though the sensitivity of 
PAP is higher than that of PA as prostate-specific tumor 
marker, there are indications that especially PA expression is 
lost in undifferentiated prostatic tumors. Our results 
suggest that PA expression is correlated with tumor different-
iation status. Therefore, PA expression interpreted quantita-
tively may be of help in forecasting the biological behavior 
of PC. The selection of antibodies and the concentration of 
the antibodies used seem of utmost importance and will have a 
large impact on the outcome. Since controversial data exist 
concerning the precise specificity of PAP, PA is to date the 
prostatic tissue-associated marker with the highest specifi-
city. Our preliminary data are of further importance for the 
use of PA to monitor patients with PC. To date a fall in 
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serum PA level after a presumed curative prostatectomy for 
localized cancer is unequivocally linked with a total absence 
of remaining PC cells. However our data suggest that lack of 
detectable levels of serum PA may also be accompanied with the 
persistence of undifferentiated (FA-lacking) prostatic tumor 
cell clones. For these reasons further studies correlating 
serum PA levels in patients with histologically proven 
undifferentiated PC have to be carried out. Moreover one has 
to realize that in the course of human PC an initially 
differentiated tumor may become less differentiated or even 
undifferentiated. Time-related changes in the histomorpho-
logical appearance of PC are presumably associated with time 
related alterations in PA serum levels. Therefore, the 
precise interpretation of the serum PA level remains for as 
yet equivocal. 
Not only several cDNAs for PA have been identified but 
also the structure of the PA gene has been elucidated. PA 
seems to belong to the human kallikreine-like gene family. 
These genes are located on chromosome 19. Of this group of 
genes the human glandular kallikreine 1 (hGK-1) gene appears 
also to be expressed exclusively in human prostatic tissue. 
This is of particular interest since the homology between the 
protein structures of the PA and the hGK-1 genes is high 
(79%). The latter implies that probably some of the 
antibodies described in literature (especially the polyclonal 
antisera) and presumed to be reactive against PA might be 
directed against antigenic sites of the hGK-1 protein. Recent 
experiments in our laboratory have demonstrated that at least 
the McAb ER-Pr 8 (and ER-Pr 27) is not reactive with hGK. 
The tremendous interest during the recent years for PA has 
obscured the precise value of PAP as prostatic tumor marker. 
Both markers are shed in the blood circulation. Precise 
insight in the specificity of the numerous antibodies 
recognizing epitopes of PAP is difficult to obtain. The 
antigenic overlap of the so-called prostate-specific acid 
phosphatase with acid phosphatases originating from other 
sites remains for as yet unclear. All investigators in this 
field recommend the use of both markers for all studies of PC, 
whereas PA is generally accepted as the marker with the 
highest specificity. 
The use of labeled antibodies against these PTSAs for in 
vivo immune-imaging of primary and secondary prostatic tumor 
deposits has to be further investigated. Incidental articles 
report a limited success of visualizing retroperitoneal lymph 
node metastases in patients with widespread PC using Fab 
fragments of a polyclonal antiserum against PAP. The 
secretory features and the absence of PAP along the cell 
membrane are presumably the main reasons for the lack of 
success. Although PA is also a secretory protein, there is 
evidence available obtained by immuno-electronmicroscopy, that 
PA is somewhat more concentrated along the cell membrane of 
prostatic epithelial cells than PAP. Therefore immune-imaging 
with PA antibodies might be more successful!. 
Cell kinetic aspects are often associated 
malignant potential of neoplasms. However, 
characterized by a relatively low growth rate. 
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with the 
PC is 
Mitotic 
figures are rarely encountered. other approaches than simply 
counting of mitotic figures to gain insight into the 
proliferative capacity of PC are DNA flowcytometry, DNA 
precursor uptake methodes and application of the Ki-67 
antibody. Of these methods the DNA precursor uptake can only 
be performed in vivo. The availability of antibodies against 
BrdU has facilitated the visualization of the in vivo exposure 
of the tumor to BrdU. The monoclonal antibody Ki-67 is 
directed against a for as yet unknown antigen that is 
expressed in the nucleus of cycling cells. In the PC-82 model 
the Ki-67 defined growth rate responded quickly upon androgen 
depletion and repletion. As this technique is also applicable 
on fine needle aspiration smears of human prostatic cancers, 
the Ki-67 method might be of help in the judgment of the 
effects of hormonal treatment in patient with PC. A fall in 
Ki-67 defined growth fraction after initiation of treatment 
has to be interpreted as a success of therapy, whereas an 
absence of such a decline in Ki-67 defined PC growth fraction 
provides evidence for a lack of success of the endocrine 
therapeutic regimen. Further studies in patients have to be 
carried out for more precise elucidation of this relationship 
and for more accurate determination of the time interval after 
which these growth fraction changes occur. If the 
observations made by us can be repeated in patient material, 
the timely interruption of an unsuccessful endocrine therapy 
will circumvent the occurrence of unpleasant side effects 
associated with this therapy and will lead to a rapid 
transition to another hopefully more successfull therapeutic 
modality. The relationship of Ki-67 defined growth rate and 
tumor growth pattern is described in Chapter VII. Relatively 
high growth fractions were found in medullary cancers (solid 
tumors) and cribriform tumors. A correlation with histo-
logical grading scores was avoided for previously mentioned 
reasons. The precise prognostic value of the Ki-67 antibody 
has to be further investigated in large prospective studies 
with a long-term follow-up. Such studies will elucidate 
whether the Ki-67 defined growth fraction has to be considered 
as an independent (prognostic) parameter or is linked with 
histological grade. 
Of the other functional markers which will become easily 
detectable in prostatic tissue, the AR (Androgen Receptor) has 
to be mentioned. The primary structure of the AR has been 
elucidated and the production of antibodies against the 
purified AR and synthetic oligopeptides of the AR has very 
recently been realized. Availability of a set of antibodies 
will enable structure-function analysis of the AR. In the 
case of PC the immunological visualization of the AR in tissue 
slides will enable detailed studies regarding the potential 
effects of hormonal treatment. Thusfar ligand binding studies 
were not able to demonstrate a relationship between AR 
concentration and responsiveness of the tumor to endocrine 
therapy. Immunocytochemistry will gain further insight into 
the variation of distribution of the AR in prostate malignant 
and non-malignant tissue. The prognostic value of the 
immunocytochemical demonstration of the AR can be investigated 
and related to architectural growth patterns or histological 
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grading scores of PC. 
Of more fundamental interest is the research referring the 
specific (onco)genes which might be involved in the 
pathogenesis of PC. To date, it still is completely unknown 
which (onco)genes might play a role in PC and whatever 
mechanisms might be involved. Especially when amplification 
andjor overexpression of a particular oncogene can be proven, 
immunocytochemistry with antibodies against the oncogene 
product might help in recognizing PC in an early stage (more 
precise identification of for as yet doubtfull histological 
preneoplastic lesions) and expression of the gene product 
might be related with clinical behavior. 
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SUMMARY 
Prostatic cancer is a highly frequent malignancy in the 
aging male population. When all clinical stages are 
considered it might even be the most frequent malignancy in 
men. As for most other malignancies the etiology of PC is not 
understood as yet. Epidemiological studies concerning PC have 
revealed interesting data. Whereas incidental (dormant) 
prostatic cancer figures are almost equal in each country, 
figures referring to clinically manifest tumors and mortality 
figures show a remarkable geographic distribution. Many 
studies have been performed to explain this phenomenon. 
Environmental factors, socio-cultural habits, endocrine status 
and genetic susceptibility have been investigated for their 
possible role in influencing the biological course of PC. 
However, the precise reasons for the large variation in 
clinical course remains unclear. Nevertheless one has 
attempted to predict the biological course by extracting 
parameters with presumed prognostic value of the malignant 
prostate tissue. out of these parameters the morphological 
appearance of the tumor can be considered to be the oldest 
method to gain information concerning the clinical course. 
For PC numerous histological grading techniques have been 
developed. Five of these systems have been studied in Chapter 
II. The reproducibility of the grading data, when applied by 
several pathologists, was investigated. With exception of the 
methods using histological criteria, reproducibility was poor. 
In Chapter III a correlation of grading results and follow-up 
data was performed. The methods using predominantly 
histological criteria reached the largest prognostic impact. 
Of interest was the observation that two methods provided 
additional prognostic information when applied on the same 
tumor. 
In Chapter IV an attempt was made to discover other 
parameters (antigens) linked to PC. The PC-82 model was used 
to generate monoclonal antibodies. None of the antibodies 
reacted with an exclusive PC-associated antigen. Among the 
antibodies prepared several recognized at least three 
different epitopes of PA. Moreover some antibodies 
identifying PAP were isolated. Those antibodies that were 
applicable on routinely handled tissue were used to examine 
the relationship between tumor differentiation status and PA 
and PAP expression respectively (Chapter V). Retention of PAP 
in PC was slightly higher than that of PA. Therefore the 
sensitivity of antibodies recognizing PAP in PC is higher. On 
the other hand, contrary to PAP, PA expression seems to be 
related to tumor differentiation. Diminished PA expression 
was noticed in undifferentiated prostatic cancers. 
Cell kinetic studies related to PC are described in 
Chapters VI and VII. The monoclonal antibody Ki-67 was used 
to measure growth fractions in PC. In Chapter VI a relatively 
high Ki-67 defined growth fraction was assessed in the 
cribriform tumor model PC-82. Results obtained with the Ki-67 
method paralelled those reached with the BrdU technique. 
Interesting was the observation that rapid fluctuations of 
proliferative acivity were found in androgen repletion and 
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depletion protocols. The use of this parameter in forecasting 
the effects of hormonal treatment are discussed. The 
relationship of cell kinetics and growth pattern of PC is 
described 1n Chapter VII. There seems to be a correlation 
between Ki-67 score and architectural growth pattern of PC. 
In less differentiated cancers higher proliferation scores 
were observed. The question whether the Ki-67 score has to be 
considered as an independent prognostic parameter for PC 
remains to be resolved. 
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SAMENVATTING 
Prostaatcarcinoom is een zeer frequent voorkomende 
maligniteit. Wanneer de incidentiecijfers van alle klinische 
stadia van prostaatcarcinoom tesamen worden genomen, is het 
prostaatcarcinoom hoogst waarschijnlijk de meest frequente 
maligne aandoening bij de mens. Echter in tegenstelling tot 
deze hoge incidentie is de morbiditeit en mortaliteit veel 
lager. Zeals voor bijna elke maligne tumor is er nog maar 
weinig bekend over de oorzaak en ontstaanswijze van prostaat-
carcinoom. Epidemiologisch onderzoek heeft interessante 
feiten aan het licht gebracht. Het voorkomen van incidenteel 
prostaatcarcinoom is voorzover onderzocht in elk land en 
iedere bevolkingsgroep gelijk. In tegenstelling hiermee is de 
waarneming dat het voorkomen van het klinisch manifeste 
prostaatcarcinoom grate verschillen toont van land tot land en 
ook van ras tot ras. Een goede verklaring hiervoor heeft men 
tot op de dag van vandaag niet kunnen vinden. Onderzoek is 
verricht naar tal van factoren gerelateerd aan socio-culturele 
status, genetische predispositie, hormonale status en factoren 
betreffende het milieu. Desalniettemin tracht men steeds 
opnieuw parameters te zoeken en toe te passen die het 
biologisch gedrag van prostaattumoren in een vroeg stadium 
kunnen voorspellen. Van al deze potentiele parameters meet de 
microscopisch morfologische bestudering van tumoren als een 
van de oudste worden beschouwd. Voor het prostaatcarcinoom 
zijn een groat aantal van histologische graderingssystemen 
beschreven. Steeds wordt aan een tumor op basis van histolo-
gische en of cytologische kenmerken een score toegekend die 
zou overeenstemmen met een bepaald te verwachten biologisch 
gedrag. In hoofdstuk II en III wordt een aantal van deze 
graderingssystemen veer prostaatcarcinoom nader bestudeerd. 
In hoofdstuk II wordt de reproduceerbaarheid van een 5-tal 
methoden vergeleken na toepassing op een serie van 50 tumoren 
door 5 beoordelaars. De reproduceerbaarheid van de systemen 
gebaseerd op hoofdzakelijk histologische criteria bleek 
redelijk, terwijl de methoden waarin ook gebruik werd gemaakt 
van vaak slecht gedefinieerde cytologische kenmerken een 
slechte reproduceerbaarheid toonden. In hoofdstuk III werd de 
prognostische waarde van de histologische graderingssystemen 
onderzocht. Ook hier bezaten de systemen gebaseerd op 
histologische kenmerken de hoogste prognostische relevantie. 
Opvallend en voorzover bekend nooit eerder beschreven was de 
waarneming dat twee graderingssystemen indien toegepast op 
eenzelfde tumor ten opzichte van elkaar additioneel 
prognostische waarde bleken te bezitten. 
In hoofdstuk IV wordt een overzicht gegeven van de 
productie van antistoffen gebruik makend van de humane 
prostaatcarcinoom cellijn PC-82. Het bleek niet mogelijk 
antistoffen te isoleren met een exclusieve binding voor humaan 
prostaatcarcinoom weefsel. Wel werden antistoffen geisoleerd 
die gericht bleken tegen PA en PAP. Tenminste 3 verschillende 
antigene determinanten van PA konden worden herkend. In 
hoofdstuk V wordt een immunohistochemische studie beschreven 
waarbij de relatie PA en PAP expressie met tumordifferentiatie 
wordt onderzocht. Zowel monoclonale als polyclonale 
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antistoffen werden hiervoor toegepast op prostaatcarcinoom-
weefsel in prostatectomiepreparaten. PAP bleek aanwezig in 
iets meer tumoren dan PA. Echter in tegenstelling tot PAP, 
bleek de PA expressie gerelateerd aan de differentiatie-status 
van het carcinoom. De PA expressie was aanzienlijk verlaagd 
in ongedifferentieerde tumoren. 
Celkinetische aspecten van prostaattumoren worden 
beschreven in de hoofdstukken VI en VII. De monoclonale 
antistof Ki-67 werd gebruikt voor het bepalen van de groei-
fracties in prostaatcarcinoom. In de humane prostaatcarcinoom 
cellijn PC-82 met een cribriforme groeiwijze werd een relatief 
hoge groeifractie bepaald. De resultaten verkregen met de Ki-
67 methode liepen parallel met die bepaald met de BrdU 
incorporatie-techniek. In het algemeen liggen de waarden 
bereikt met de Ki-67 techniek hoger. In het PC-82 model bleek 
dat de Ki-67 bepaalde groeifractie snel reageerde op depletie 
van androgeen en hernieuwde toediening van androgenen na 10 
dagen onttrekking. Het potentiele gebruik van de Ki-67 
techniek voor het beoordelen van het effect van hormonale 
therapie bij patienten met PC werd besproken. De relatie Ki-
67 score en histologisch groeipatroon van prostaatcarcinoom 
wordt besproken in hoofdstuk VII. Deze correlatie bleek 
aanwezig. In het algemeen geldt dat medullaire carcinomen 
(solide ongedifferentieerde carcinomen) een hogere groei-
fractie tonen dan buisvormende carcinomen. Vooralsnog zal 
moeten blijken in hoeverre de Ki-67 score rechtstreeks 
gerelateerd is aan groeipatroon dan wel beschouwd moet worden 
als onafhankelijke parameter met (potentieel) prognostische 
waarde. 
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Mevr. Monique Hanegraaff. 
Tot slot heb ik de prettige en 
met medewerkers van de afdeling 
Schroeder, Dr. J.C. Romijn en Dr. 
Biostatistiek (Dr. P.I.M. Schmitz en 
gewaardeerd. 
stimulerende samenwerking 
Urologie (Prof.Dr. F.H. 
G.J. van Steenbrugge) en 
Dr. P.G.H. Mulder) zeer 
Ook al diegenen die ik hier, door ruimtegebrek 
genoodzaakt, niet heb kunnen noemen en mij met raad en daad, 
in meer en in mindere mate, zowel op de voor-, maar ook op de 
achtergrond ter zijde hebben gestaan, dank ik. 
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CURRICULUM VITAE 
Schrijver dezes werd geboren in 1957. De gymnasium-~ 
opleiding werd gevolgd aan het St. Ignatius College te 
Amsterdam en afgerond in 1975. In aansluiting hierop werd 
aangevangen met de studie geneeskunde aan de Vrije 
Universiteit eveneens te Amsterdam. Na het behalen van het 
doctoraal examen in februari 1981 werd de studie onderbroken 
voor een assistentschap aan het pathologisch instituut der 
Vrije Universiteit (hoofd destijds Prof.Dr. R. Donner). Het 
artsexamen werd behaald in januari 1983. Vanaf februari 1983 
tot mei 1989 was de schrijver verbonden aan de afdeling 
Pathologische Anatomie I van de Erasmus Universiteit te 
Rotterdam (hoofd Prof.Dr. R.O. van der Heul) alwaar het hier 
beschreven onderzoek werd verricht en de opleiding tot 
patholoog-anatoom werd gevolgd. Sedert 1 juni 1989 is de 
schrijver weer terug in de hoofdstad en verbonden als 
patholoog-anatoom aan het Nederlands Kanker Instituut (Antoni 
van Leeuwenhoek Ziekenhuis). 
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ABBREVIATIONS 
AC 
AFIP 
Ag 
AP 
AR 
BGA 
BGrAg 
BPH 
BrdU 
BrdUrd 
cc 
CCC 
CEA 
CF 
DES 
DHT 
DNA 
EGF 
EGF-R 
EIA 
ELISA 
EORTC 
HLA 
Ig 
.B-Inhibin 
LH-RH 
LNCaP 
MAGIC 
McAb 
MDA 
MDAH 
MNU 
MSP 
NPCP 
PA 
PAP 
PBS 
PC 
PC-82 
PDA 
PDGF 
PHI 
PSA 
PSAP 
PSP94 
PTSA 
RIA 
SA 
Adenocarcinoma 
Armed Forces Institute of Pathology (Washington) 
Antigen 
Alkaline Phosphatase 
Androgen Receptor 
Blood Group Antigens 
Blood Group-Related Antigens 
Benign Prostatic Hyperplasia 
BromodesoxyUridine 
Bromodesoxyuridine 
Cribriform Carcinoma (=CF) 
Clear cell Carcinoma (hypernephroid carcinoma) 
Carcino-Embryonic Antigen 
Cribriform carcinoma (=CC) 
Diethylstilbestrol 
DiHydroTestosterone 
Deoxyribonucleic Acid 
Epidermal Growth Factor 
Epidermal Growth Factor Receptor 
Enzyme ImmunoAssay 
Enzyme-Linked Immunosorbent Assay 
European Organization on Research and Treatment of 
Cancer 
Human Leukocyte Antigen 
Immunoglobulin 
,8-MSP 
Luteinizing Hormone Releasing Hormone 
Prostatic cancer cell-line; Lymph Node Carcinoma of 
Prostatic origin 
Mixed AGgregation Immunocytochemical technique 
Monoclonal Antibody 
Moderately Differentiated Adenocarcinoma 
M.D. Anderson Hospital grading system designed by 
Brawn ( 1982) 
N-methyl-N-nitrosurea 
.B-microseminoprotein = .B-inhibin 
National Prostatic Cancer Project 
Prostatic Antigen (= PSA) 
Prostatic Acid Phosphatase (= PSAP); secretory 
subtype (iso-enzyme) of acid phosphatases in the 
prostatic gland 
Phosphate Buffered Saline (pH 7.2) 
Prostatic Cancer; Prostatic Carcinoma 
(human) Prostatic Carcinoma cell-line 82 
Poorly Differentiated Adenocarcinoma 
Platelet-Derived Growth Factor. 
Phosphohexose Isomerase 
Prostate-Specific Antigen (= PA) 
Prostate-Specific Acid Phosphatase (=PAP) 
Prostatic Secretory Protein consisting of 94 amino 
acids = .B-MSP 
Prostatic Tissue-Specific Antigen 
Radio Immuno-Assay 
Secretory Antigen 
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SHBG 
STA 
T 
TAA 
Tc 
TGF 
TNM 
TPA 
TSA 
TUR 
uc 
UEA-1 
VACURG 
WDA 
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Sex Hormone-Binding Globulin 
Solid Tumor Areas (medullary growth pattern) 
Testosterone 
Tumor Associated Antigen 
Technetium (radio-nucleide) 
Transforming Growth Factor 
Tumor, Node, Metastasis; classification of malig-
nant tumours 
Tissue Polypeptide Antigen 
Tumor Specific Antigen 
Transurethral Resection 
Undifferentiated Carcinoma 
Ulex Europaeus Agglutin 1 (lectin) 
Veterans Administration Cooperative Urologenital 
Research Group 
Well Differentiated Adenocarcinoma 
OMNIA VANITAS EST 
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